#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Connectome-Wide Analysis Reveals Common Dimensional Reward Deficits Across Mood and Psychotic Disorders
#Text=Objective
#Text=Anhedonia is central to multiple psychiatric disorders and causes substantial disability.
1-1	0-15	Connectome-Wide	_	
1-2	16-24	Analysis	_	
1-3	25-32	Reveals	_	
1-4	33-39	Common	_	
1-5	40-51	Dimensional	_	
1-6	52-58	Reward	_	
1-7	59-67	Deficits	_	
1-8	68-74	Across	_	
1-9	75-79	Mood	_	
1-10	80-83	and	_	
1-11	84-93	Psychotic	_	
1-12	94-103	Disorders	_	
1-13	104-113	Objective	_	
1-14	114-123	Anhedonia	_	
1-15	124-126	is	_	
1-16	127-134	central	_	
1-17	135-137	to	_	
1-18	138-146	multiple	_	
1-19	147-158	psychiatric	_	
1-20	159-168	disorders	_	
1-21	169-172	and	_	
1-22	173-179	causes	_	
1-23	180-191	substantial	_	
1-24	192-202	disability	_	
1-25	202-203	.	_	

#Text=A dimensional conceptualization posits that anhedonia severity relates to a trans-diagnostic continuum of reward deficits in specific neural networks.
2-1	204-205	A	_	
2-2	206-217	dimensional	_	
2-3	218-235	conceptualization	_	
2-4	236-242	posits	_	
2-5	243-247	that	_	
2-6	248-257	anhedonia	_	
2-7	258-266	severity	_	
2-8	267-274	relates	_	
2-9	275-277	to	_	
2-10	278-279	a	_	
2-11	280-296	trans-diagnostic	_	
2-12	297-306	continuum	_	
2-13	307-309	of	_	
2-14	310-316	reward	_	
2-15	317-325	deficits	_	
2-16	326-328	in	_	
2-17	329-337	specific	_	
2-18	338-344	neural	_	
2-19	345-353	networks	_	
2-20	353-354	.	_	

#Text=Prior investigations of functional connectivity related to anhedonia have focused on case-control comparisons in specific disorders, using region-specific seed-based analyses.
3-1	355-360	Prior	_	
3-2	361-375	investigations	_	
3-3	376-378	of	_	
3-4	379-389	functional	_	
3-5	390-402	connectivity	_	
3-6	403-410	related	_	
3-7	411-413	to	_	
3-8	414-423	anhedonia	_	
3-9	424-428	have	_	
3-10	429-436	focused	_	
3-11	437-439	on	_	
3-12	440-452	case-control	_	
3-13	453-464	comparisons	_	
3-14	465-467	in	_	
3-15	468-476	specific	_	
3-16	477-486	disorders	_	
3-17	486-487	,	_	
3-18	488-493	using	_	
3-19	494-509	region-specific	_	
3-20	510-520	seed-based	_	
3-21	521-529	analyses	_	
3-22	529-530	.	_	

#Text=Here, the authors explore the entire functional connectome in relation to reward responsivity across a population of adults with hetereogenous psychopathology.
4-1	531-535	Here	_	
4-2	535-536	,	_	
4-3	537-540	the	_	
4-4	541-548	authors	_	
4-5	549-556	explore	_	
4-6	557-560	the	_	
4-7	561-567	entire	_	
4-8	568-578	functional	_	
4-9	579-589	connectome	_	
4-10	590-592	in	_	
4-11	593-601	relation	_	
4-12	602-604	to	_	
4-13	605-611	reward	_	
4-14	612-624	responsivity	_	
4-15	625-631	across	_	
4-16	632-633	a	_	
4-17	634-644	population	_	
4-18	645-647	of	_	
4-19	648-654	adults	_	
4-20	655-659	with	_	
4-21	660-673	hetereogenous	_	
4-22	674-689	psychopathology	_	
4-23	689-690	.	_	

#Text=Method
#Text=In a sample of 225 adults from five diagnostic groups (major depressive disorder, n=32; bipolar disorder, n=50; schizophrenia, n=51, psychosis risk, n=39; and healthy controls, n=53), the authors conducted a connectome-wide analysis examining the relationship between a dimensional measure of reward responsivity (reward sensitivity subscale of the Behavioral Activation Scale) and resting-state functional connectivity using multivariate distance-based matrix regression.
5-1	691-697	Method	_	
5-2	698-700	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-3	701-702	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-4	703-709	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-5	710-712	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-6	713-716	225	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-7	717-723	adults	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-8	724-728	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-9	729-733	five	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-10	734-744	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-11	745-751	groups	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-12	752-753	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-13	753-758	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]	
5-14	759-769	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]	
5-15	770-778	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[2]	
5-16	778-779	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-17	780-781	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-18	781-782	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-19	782-784	32	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-20	784-785	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-21	786-793	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[3]	
5-22	794-802	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[3]	
5-23	802-803	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-24	804-805	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-25	805-806	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-26	806-808	50	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-27	808-809	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-28	810-823	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[4]	
5-29	823-824	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-30	825-826	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-31	826-827	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-32	827-829	51	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-33	829-830	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-34	831-840	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-35	841-845	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-36	845-846	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-37	847-848	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-38	848-849	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-39	849-851	39	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-40	851-852	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-41	853-856	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-42	857-864	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-43	865-873	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[6]	
5-44	873-874	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-45	875-876	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-46	876-877	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-47	877-879	53	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-48	879-880	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[1]	
5-49	880-881	,	_	
5-50	882-885	the	_	
5-51	886-893	authors	_	
5-52	894-903	conducted	_	
5-53	904-905	a	_	
5-54	906-921	connectome-wide	_	
5-55	922-930	analysis	_	
5-56	931-940	examining	_	
5-57	941-944	the	_	
5-58	945-957	relationship	_	
5-59	958-965	between	_	
5-60	966-967	a	_	
5-61	968-979	dimensional	_	
5-62	980-987	measure	_	
5-63	988-990	of	_	
5-64	991-997	reward	_	
5-65	998-1010	responsivity	_	
5-66	1011-1012	(	_	
5-67	1012-1018	reward	_	
5-68	1019-1030	sensitivity	_	
5-69	1031-1039	subscale	_	
5-70	1040-1042	of	_	
5-71	1043-1046	the	_	
5-72	1047-1057	Behavioral	_	
5-73	1058-1068	Activation	_	
5-74	1069-1074	Scale	_	
5-75	1074-1075	)	_	
5-76	1076-1079	and	_	
5-77	1080-1093	resting-state	_	
5-78	1094-1104	functional	_	
5-79	1105-1117	connectivity	_	
5-80	1118-1123	using	_	
5-81	1124-1136	multivariate	_	
5-82	1137-1151	distance-based	_	
5-83	1152-1158	matrix	_	
5-84	1159-1169	regression	_	
5-85	1169-1170	.	_	

#Text=Results
#Text=This connectome-wide analysis identified foci of dysconnectivity associated with reward responsivity in the nucleus accumbens (NAc), default mode network (DMN) and cingulo-opercular network (CON).
6-1	1171-1178	Results	_	
6-2	1179-1183	This	_	
6-3	1184-1199	connectome-wide	_	
6-4	1200-1208	analysis	_	
6-5	1209-1219	identified	_	
6-6	1220-1224	foci	_	
6-7	1225-1227	of	_	
6-8	1228-1243	dysconnectivity	_	
6-9	1244-1254	associated	_	
6-10	1255-1259	with	_	
6-11	1260-1266	reward	_	
6-12	1267-1279	responsivity	_	
6-13	1280-1282	in	_	
6-14	1283-1286	the	_	
6-15	1287-1294	nucleus	_	
6-16	1295-1304	accumbens	_	
6-17	1305-1306	(	_	
6-18	1306-1309	NAc	_	
6-19	1309-1310	)	_	
6-20	1310-1311	,	_	
6-21	1312-1319	default	_	
6-22	1320-1324	mode	_	
6-23	1325-1332	network	_	
6-24	1333-1334	(	_	
6-25	1334-1337	DMN	_	
6-26	1337-1338	)	_	
6-27	1339-1342	and	_	
6-28	1343-1360	cingulo-opercular	_	
6-29	1361-1368	network	_	
6-30	1369-1370	(	_	
6-31	1370-1373	CON	_	
6-32	1373-1374	)	_	
6-33	1374-1375	.	_	

#Text=Follow-up analyses revealed dysconnectivity among specific large-scale functional networks and their connectivity with the NAc.
7-1	1376-1385	Follow-up	_	
7-2	1386-1394	analyses	_	
7-3	1395-1403	revealed	_	
7-4	1404-1419	dysconnectivity	_	
7-5	1420-1425	among	_	
7-6	1426-1434	specific	_	
7-7	1435-1446	large-scale	_	
7-8	1447-1457	functional	_	
7-9	1458-1466	networks	_	
7-10	1467-1470	and	_	
7-11	1471-1476	their	_	
7-12	1477-1489	connectivity	_	
7-13	1490-1494	with	_	
7-14	1495-1498	the	_	
7-15	1499-1502	NAc	_	
7-16	1502-1503	.	_	

#Text=Reward deficits were associated with decreased connectivity between the NAc and DMN and increased connectivity between the NAc and CON.
8-1	1504-1510	Reward	_	
8-2	1511-1519	deficits	_	
8-3	1520-1524	were	_	
8-4	1525-1535	associated	_	
8-5	1536-1540	with	_	
8-6	1541-1550	decreased	_	
8-7	1551-1563	connectivity	_	
8-8	1564-1571	between	_	
8-9	1572-1575	the	_	
8-10	1576-1579	NAc	_	
8-11	1580-1583	and	_	
8-12	1584-1587	DMN	_	
8-13	1588-1591	and	_	
8-14	1592-1601	increased	_	
8-15	1602-1614	connectivity	_	
8-16	1615-1622	between	_	
8-17	1623-1626	the	_	
8-18	1627-1630	NAc	_	
8-19	1631-1634	and	_	
8-20	1635-1638	CON	_	
8-21	1638-1639	.	_	

#Text=In addition, impaired reward responsivity was associated with DMN hyper-connectivity and diminished connectivity between DMN and CON.
9-1	1640-1642	In	_	
9-2	1643-1651	addition	_	
9-3	1651-1652	,	_	
9-4	1653-1661	impaired	_	
9-5	1662-1668	reward	_	
9-6	1669-1681	responsivity	_	
9-7	1682-1685	was	_	
9-8	1686-1696	associated	_	
9-9	1697-1701	with	_	
9-10	1702-1705	DMN	_	
9-11	1706-1724	hyper-connectivity	_	
9-12	1725-1728	and	_	
9-13	1729-1739	diminished	_	
9-14	1740-1752	connectivity	_	
9-15	1753-1760	between	_	
9-16	1761-1764	DMN	_	
9-17	1765-1768	and	_	
9-18	1769-1772	CON	_	
9-19	1772-1773	.	_	

#Text=Conclusions
#Text=These results emphasize the centrality of the nucleus accumbens in the pathophysiology of reward deficits and suggest that dissociable patterns of connectivity among large-scale networks are critical to the neurobiology of reward dysfunction across clinical diagnostic categories.
10-1	1774-1785	Conclusions	_	
10-2	1786-1791	These	_	
10-3	1792-1799	results	_	
10-4	1800-1809	emphasize	_	
10-5	1810-1813	the	_	
10-6	1814-1824	centrality	_	
10-7	1825-1827	of	_	
10-8	1828-1831	the	_	
10-9	1832-1839	nucleus	_	
10-10	1840-1849	accumbens	_	
10-11	1850-1852	in	_	
10-12	1853-1856	the	_	
10-13	1857-1872	pathophysiology	_	
10-14	1873-1875	of	_	
10-15	1876-1882	reward	_	
10-16	1883-1891	deficits	_	
10-17	1892-1895	and	_	
10-18	1896-1903	suggest	_	
10-19	1904-1908	that	_	
10-20	1909-1920	dissociable	_	
10-21	1921-1929	patterns	_	
10-22	1930-1932	of	_	
10-23	1933-1945	connectivity	_	
10-24	1946-1951	among	_	
10-25	1952-1963	large-scale	_	
10-26	1964-1972	networks	_	
10-27	1973-1976	are	_	
10-28	1977-1985	critical	_	
10-29	1986-1988	to	_	
10-30	1989-1992	the	_	
10-31	1993-2005	neurobiology	_	
10-32	2006-2008	of	_	
10-33	2009-2015	reward	_	
10-34	2016-2027	dysfunction	_	
10-35	2028-2034	across	_	
10-36	2035-2043	clinical	_	
10-37	2044-2054	diagnostic	_	
10-38	2055-2065	categories	_	
10-39	2065-2066	.	_	

#Text=INTRODUCTION
#Text=Anhedonia, defined as diminished reward responsivity, is central to a wide range of psychiatric disorders.
11-1	2067-2079	INTRODUCTION	_	
11-2	2080-2089	Anhedonia	_	
11-3	2089-2090	,	_	
11-4	2091-2098	defined	_	
11-5	2099-2101	as	_	
11-6	2102-2112	diminished	_	
11-7	2113-2119	reward	_	
11-8	2120-2132	responsivity	_	
11-9	2132-2133	,	_	
11-10	2134-2136	is	_	
11-11	2137-2144	central	_	
11-12	2145-2147	to	_	
11-13	2148-2149	a	_	
11-14	2150-2154	wide	_	
11-15	2155-2160	range	_	
11-16	2161-2163	of	_	
11-17	2164-2175	psychiatric	_	
11-18	2176-2185	disorders	_	
11-19	2185-2186	.	_	

#Text=In mood disorders such as major depressive disorder (MDD) and bipolar disorder (BPD), depression is frequently associated with anhedonia, significantly impacting psychosocial function.
12-1	2187-2189	In	_	
12-2	2190-2194	mood	_	
12-3	2195-2204	disorders	_	
12-4	2205-2209	such	_	
12-5	2210-2212	as	_	
12-6	2213-2218	major	_	
12-7	2219-2229	depressive	_	
12-8	2230-2238	disorder	_	
12-9	2239-2240	(	_	
12-10	2240-2243	MDD	_	
12-11	2243-2244	)	_	
12-12	2245-2248	and	_	
12-13	2249-2256	bipolar	_	
12-14	2257-2265	disorder	_	
12-15	2266-2267	(	_	
12-16	2267-2270	BPD	_	
12-17	2270-2271	)	_	
12-18	2271-2272	,	_	
12-19	2273-2283	depression	_	
12-20	2284-2286	is	_	
12-21	2287-2297	frequently	_	
12-22	2298-2308	associated	_	
12-23	2309-2313	with	_	
12-24	2314-2323	anhedonia	_	
12-25	2323-2324	,	_	
12-26	2325-2338	significantly	_	
12-27	2339-2348	impacting	_	
12-28	2349-2361	psychosocial	_	
12-29	2362-2370	function	_	
12-30	2370-2371	.	_	

#Text=Similarly, in psychotic disorders such as schizophrenia (SCZ), anhedonia is one of the negative symptoms that lack effective treatments and cause substantial disability.
13-1	2372-2381	Similarly	_	
13-2	2381-2382	,	_	
13-3	2383-2385	in	_	
13-4	2386-2395	psychotic	_	
13-5	2396-2405	disorders	_	
13-6	2406-2410	such	_	
13-7	2411-2413	as	_	
13-8	2414-2427	schizophrenia	_	
13-9	2428-2429	(	_	
13-10	2429-2432	SCZ	_	
13-11	2432-2433	)	_	
13-12	2433-2434	,	_	
13-13	2435-2444	anhedonia	_	
13-14	2445-2447	is	_	
13-15	2448-2451	one	_	
13-16	2452-2454	of	_	
13-17	2455-2458	the	_	
13-18	2459-2467	negative	_	
13-19	2468-2476	symptoms	_	
13-20	2477-2481	that	_	
13-21	2482-2486	lack	_	
13-22	2487-2496	effective	_	
13-23	2497-2507	treatments	_	
13-24	2508-2511	and	_	
13-25	2512-2517	cause	_	
13-26	2518-2529	substantial	_	
13-27	2530-2540	disability	_	
13-28	2540-2541	.	_	

#Text=The presence of anhedonia across multiple psychiatric disorders suggests common underlying deficits in reward system function.
14-1	2542-2545	The	_	
14-2	2546-2554	presence	_	
14-3	2555-2557	of	_	
14-4	2558-2567	anhedonia	_	
14-5	2568-2574	across	_	
14-6	2575-2583	multiple	_	
14-7	2584-2595	psychiatric	_	
14-8	2596-2605	disorders	_	
14-9	2606-2614	suggests	_	
14-10	2615-2621	common	_	
14-11	2622-2632	underlying	_	
14-12	2633-2641	deficits	_	
14-13	2642-2644	in	_	
14-14	2645-2651	reward	_	
14-15	2652-2658	system	_	
14-16	2659-2667	function	_	
14-17	2667-2668	.	_	

#Text=Such a conceptualization accords with the NIMH Research Domain Criteria (RDoC) effort to map transdiagnostic (i.e. across disorder) dimensions of psychopathology, such as anhedonia, to abnormalities in specific brain circuitry.
15-1	2669-2673	Such	_	
15-2	2674-2675	a	_	
15-3	2676-2693	conceptualization	_	
15-4	2694-2701	accords	_	
15-5	2702-2706	with	_	
15-6	2707-2710	the	_	
15-7	2711-2715	NIMH	_	
15-8	2716-2724	Research	_	
15-9	2725-2731	Domain	_	
15-10	2732-2740	Criteria	_	
15-11	2741-2742	(	_	
15-12	2742-2746	RDoC	_	
15-13	2746-2747	)	_	
15-14	2748-2754	effort	_	
15-15	2755-2757	to	_	
15-16	2758-2761	map	_	
15-17	2762-2777	transdiagnostic	_	
15-18	2778-2779	(	_	
15-19	2779-2782	i.e	_	
15-20	2782-2783	.	_	
15-21	2784-2790	across	_	
15-22	2791-2799	disorder	_	
15-23	2799-2800	)	_	
15-24	2801-2811	dimensions	_	
15-25	2812-2814	of	_	
15-26	2815-2830	psychopathology	_	
15-27	2830-2831	,	_	
15-28	2832-2836	such	_	
15-29	2837-2839	as	_	
15-30	2840-2849	anhedonia	_	
15-31	2849-2850	,	_	
15-32	2851-2853	to	_	
15-33	2854-2867	abnormalities	_	
15-34	2868-2870	in	_	
15-35	2871-2879	specific	_	
15-36	2880-2885	brain	_	
15-37	2886-2895	circuitry	_	
15-38	2895-2896	.	_	

#Text=Both animal and human studies consistently implicate the mesolimbic reward system, particularly the ventral striatum (VS) and nucleus accumbens (NAc) in the neurobiology of anhedonia.
16-1	2897-2901	Both	_	
16-2	2902-2908	animal	_	
16-3	2909-2912	and	_	
16-4	2913-2918	human	_	
16-5	2919-2926	studies	_	
16-6	2927-2939	consistently	_	
16-7	2940-2949	implicate	_	
16-8	2950-2953	the	_	
16-9	2954-2964	mesolimbic	_	
16-10	2965-2971	reward	_	
16-11	2972-2978	system	_	
16-12	2978-2979	,	_	
16-13	2980-2992	particularly	_	
16-14	2993-2996	the	_	
16-15	2997-3004	ventral	_	
16-16	3005-3013	striatum	_	
16-17	3014-3015	(	_	
16-18	3015-3017	VS	_	
16-19	3017-3018	)	_	
16-20	3019-3022	and	_	
16-21	3023-3030	nucleus	_	
16-22	3031-3040	accumbens	_	
16-23	3041-3042	(	_	
16-24	3042-3045	NAc	_	
16-25	3045-3046	)	_	
16-26	3047-3049	in	_	
16-27	3050-3053	the	_	
16-28	3054-3066	neurobiology	_	
16-29	3067-3069	of	_	
16-30	3070-3079	anhedonia	_	
16-31	3079-3080	.	_	

#Text=Neuroimaging studies in unipolar depression report VS hypo-responsivity during reward-related tasks.
17-1	3081-3093	Neuroimaging	_	
17-2	3094-3101	studies	_	
17-3	3102-3104	in	_	
17-4	3105-3113	unipolar	_	
17-5	3114-3124	depression	_	
17-6	3125-3131	report	_	
17-7	3132-3134	VS	_	
17-8	3135-3152	hypo-responsivity	_	
17-9	3153-3159	during	_	
17-10	3160-3174	reward-related	_	
17-11	3175-3180	tasks	_	
17-12	3180-3181	.	_	

#Text=A similar blunting of striatal activation is seen in bipolar depression, schizophrenia and psychosis risk populations.
18-1	3182-3183	A	_	
18-2	3184-3191	similar	_	
18-3	3192-3200	blunting	_	
18-4	3201-3203	of	_	
18-5	3204-3212	striatal	_	
18-6	3213-3223	activation	_	
18-7	3224-3226	is	_	
18-8	3227-3231	seen	_	
18-9	3232-3234	in	_	
18-10	3235-3242	bipolar	_	
18-11	3243-3253	depression	_	
18-12	3253-3254	,	_	
18-13	3255-3268	schizophrenia	_	
18-14	3269-3272	and	_	
18-15	3273-3282	psychosis	_	
18-16	3283-3287	risk	_	
18-17	3288-3299	populations	_	
18-18	3299-3300	.	_	

#Text=Given that this system has been implicated in multiple disorders, dimensional paradigms have recently been employed to identify common reward valuation abnormalities across disorders.
19-1	3301-3306	Given	_	
19-2	3307-3311	that	_	
19-3	3312-3316	this	_	
19-4	3317-3323	system	_	
19-5	3324-3327	has	_	
19-6	3328-3332	been	_	
19-7	3333-3343	implicated	_	
19-8	3344-3346	in	_	
19-9	3347-3355	multiple	_	
19-10	3356-3365	disorders	_	
19-11	3365-3366	,	_	
19-12	3367-3378	dimensional	_	
19-13	3379-3388	paradigms	_	
19-14	3389-3393	have	_	
19-15	3394-3402	recently	_	
19-16	3403-3407	been	_	
19-17	3408-3416	employed	_	
19-18	3417-3419	to	_	
19-19	3420-3428	identify	_	
19-20	3429-3435	common	_	
19-21	3436-3442	reward	_	
19-22	3443-3452	valuation	_	
19-23	3453-3466	abnormalities	_	
19-24	3467-3473	across	_	
19-25	3474-3483	disorders	_	
19-26	3483-3484	.	_	

#Text=We recently demonstrated using task-based fMRI that depression severity is related to blunted VS responses to monetary rewards across unipolar and bipolar depression; others have reported similar results across a diverse group of patients with MDD, SCZ, alcohol dependence, ADHD and healthy controls.
20-1	3485-3487	We	_	
20-2	3488-3496	recently	_	
20-3	3497-3509	demonstrated	_	
20-4	3510-3515	using	_	
20-5	3516-3526	task-based	_	
20-6	3527-3531	fMRI	_	
20-7	3532-3536	that	_	
20-8	3537-3547	depression	_	
20-9	3548-3556	severity	_	
20-10	3557-3559	is	_	
20-11	3560-3567	related	_	
20-12	3568-3570	to	_	
20-13	3571-3578	blunted	_	
20-14	3579-3581	VS	_	
20-15	3582-3591	responses	_	
20-16	3592-3594	to	_	
20-17	3595-3603	monetary	_	
20-18	3604-3611	rewards	_	
20-19	3612-3618	across	_	
20-20	3619-3627	unipolar	_	
20-21	3628-3631	and	_	
20-22	3632-3639	bipolar	_	
20-23	3640-3650	depression	_	
20-24	3650-3651	;	_	
20-25	3652-3658	others	_	
20-26	3659-3663	have	_	
20-27	3664-3672	reported	_	
20-28	3673-3680	similar	_	
20-29	3681-3688	results	_	
20-30	3689-3695	across	_	
20-31	3696-3697	a	_	
20-32	3698-3705	diverse	_	
20-33	3706-3711	group	_	
20-34	3712-3714	of	_	
20-35	3715-3723	patients	_	
20-36	3724-3728	with	_	
20-37	3729-3732	MDD	_	
20-38	3732-3733	,	_	
20-39	3734-3737	SCZ	_	
20-40	3737-3738	,	_	
20-41	3739-3746	alcohol	_	
20-42	3747-3757	dependence	_	
20-43	3757-3758	,	_	
20-44	3759-3763	ADHD	_	
20-45	3764-3767	and	_	
20-46	3768-3775	healthy	_	
20-47	3776-3784	controls	_	
20-48	3784-3785	.	_	

#Text=These findings highlight the value of dimensional approaches in identifying common neurobehavioral brain abnormalities.
21-1	3786-3791	These	_	
21-2	3792-3800	findings	_	
21-3	3801-3810	highlight	_	
21-4	3811-3814	the	_	
21-5	3815-3820	value	_	
21-6	3821-3823	of	_	
21-7	3824-3835	dimensional	_	
21-8	3836-3846	approaches	_	
21-9	3847-3849	in	_	
21-10	3850-3861	identifying	_	
21-11	3862-3868	common	_	
21-12	3869-3884	neurobehavioral	_	
21-13	3885-3890	brain	_	
21-14	3891-3904	abnormalities	_	
21-15	3904-3905	.	_	

#Text=One approach increasingly utilized to investigate circuit-level abnormalities in psychiatric disorders is resting-state (intrinsic) functional connectivity, which examines correlations in activity across different regions and can be used to delineate large-scale functional networks.
22-1	3906-3909	One	_	
22-2	3910-3918	approach	_	
22-3	3919-3931	increasingly	_	
22-4	3932-3940	utilized	_	
22-5	3941-3943	to	_	
22-6	3944-3955	investigate	_	
22-7	3956-3969	circuit-level	_	
22-8	3970-3983	abnormalities	_	
22-9	3984-3986	in	_	
22-10	3987-3998	psychiatric	_	
22-11	3999-4008	disorders	_	
22-12	4009-4011	is	_	
22-13	4012-4025	resting-state	_	
22-14	4026-4027	(	_	
22-15	4027-4036	intrinsic	_	
22-16	4036-4037	)	_	
22-17	4038-4048	functional	_	
22-18	4049-4061	connectivity	_	
22-19	4061-4062	,	_	
22-20	4063-4068	which	_	
22-21	4069-4077	examines	_	
22-22	4078-4090	correlations	_	
22-23	4091-4093	in	_	
22-24	4094-4102	activity	_	
22-25	4103-4109	across	_	
22-26	4110-4119	different	_	
22-27	4120-4127	regions	_	
22-28	4128-4131	and	_	
22-29	4132-4135	can	_	
22-30	4136-4138	be	_	
22-31	4139-4143	used	_	
22-32	4144-4146	to	_	
22-33	4147-4156	delineate	_	
22-34	4157-4168	large-scale	_	
22-35	4169-4179	functional	_	
22-36	4180-4188	networks	_	
22-37	4188-4189	.	_	

#Text=Functional connectivity abnormalities are found in diverse psychiatric conditions, suggesting that psychiatric disorders can be studied as syndromes of dysconnectivity.
23-1	4190-4200	Functional	_	
23-2	4201-4213	connectivity	_	
23-3	4214-4227	abnormalities	_	
23-4	4228-4231	are	_	
23-5	4232-4237	found	_	
23-6	4238-4240	in	_	
23-7	4241-4248	diverse	_	
23-8	4249-4260	psychiatric	_	
23-9	4261-4271	conditions	_	
23-10	4271-4272	,	_	
23-11	4273-4283	suggesting	_	
23-12	4284-4288	that	_	
23-13	4289-4300	psychiatric	_	
23-14	4301-4310	disorders	_	
23-15	4311-4314	can	_	
23-16	4315-4317	be	_	
23-17	4318-4325	studied	_	
23-18	4326-4328	as	_	
23-19	4329-4338	syndromes	_	
23-20	4339-4341	of	_	
23-21	4342-4357	dysconnectivity	_	
23-22	4357-4358	.	_	

#Text=Utilizing resting-state fMRI, several studies in distinct psychiatric disorders have employed seed-based analyses, pre-selecting specific brain regions (seeds) and examining how their activity correlates with activity in the rest of the brain.
24-1	4359-4368	Utilizing	_	
24-2	4369-4382	resting-state	_	
24-3	4383-4387	fMRI	_	
24-4	4387-4388	,	_	
24-5	4389-4396	several	_	
24-6	4397-4404	studies	_	
24-7	4405-4407	in	_	
24-8	4408-4416	distinct	_	
24-9	4417-4428	psychiatric	_	
24-10	4429-4438	disorders	_	
24-11	4439-4443	have	_	
24-12	4444-4452	employed	_	
24-13	4453-4463	seed-based	_	
24-14	4464-4472	analyses	_	
24-15	4472-4473	,	_	
24-16	4474-4487	pre-selecting	_	
24-17	4488-4496	specific	_	
24-18	4497-4502	brain	_	
24-19	4503-4510	regions	_	
24-20	4511-4512	(	_	
24-21	4512-4517	seeds	_	
24-22	4517-4518	)	_	
24-23	4519-4522	and	_	
24-24	4523-4532	examining	_	
24-25	4533-4536	how	_	
24-26	4537-4542	their	_	
24-27	4543-4551	activity	_	
24-28	4552-4562	correlates	_	
24-29	4563-4567	with	_	
24-30	4568-4576	activity	_	
24-31	4577-4579	in	_	
24-32	4580-4583	the	_	
24-33	4584-4588	rest	_	
24-34	4589-4591	of	_	
24-35	4592-4595	the	_	
24-36	4596-4601	brain	_	
24-37	4601-4602	.	_	

#Text=These studies implicate corticostriatal abnormalities in reward-related symptomatology.
25-1	4603-4608	These	_	
25-2	4609-4616	studies	_	
25-3	4617-4626	implicate	_	
25-4	4627-4642	corticostriatal	_	
25-5	4643-4656	abnormalities	_	
25-6	4657-4659	in	_	
25-7	4660-4674	reward-related	_	
25-8	4675-4689	symptomatology	_	
25-9	4689-4690	.	_	

#Text=Studies investigating the relationship between reward-related deficits and functional network abnormalities have been limited, in part, by two factors.
26-1	4691-4698	Studies	_	
26-2	4699-4712	investigating	_	
26-3	4713-4716	the	_	
26-4	4717-4729	relationship	_	
26-5	4730-4737	between	_	
26-6	4738-4752	reward-related	_	
26-7	4753-4761	deficits	_	
26-8	4762-4765	and	_	
26-9	4766-4776	functional	_	
26-10	4777-4784	network	_	
26-11	4785-4798	abnormalities	_	
26-12	4799-4803	have	_	
26-13	4804-4808	been	_	
26-14	4809-4816	limited	_	
26-15	4816-4817	,	_	
26-16	4818-4820	in	_	
26-17	4821-4825	part	_	
26-18	4825-4826	,	_	
26-19	4827-4829	by	_	
26-20	4830-4833	two	_	
26-21	4834-4841	factors	_	
26-22	4841-4842	.	_	

#Text=First, only a few studies have evaluated these deficits across multiple psychiatric disorders.
27-1	4843-4848	First	_	
27-2	4848-4849	,	_	
27-3	4850-4854	only	_	
27-4	4855-4856	a	_	
27-5	4857-4860	few	_	
27-6	4861-4868	studies	_	
27-7	4869-4873	have	_	
27-8	4874-4883	evaluated	_	
27-9	4884-4889	these	_	
27-10	4890-4898	deficits	_	
27-11	4899-4905	across	_	
27-12	4906-4914	multiple	_	
27-13	4915-4926	psychiatric	_	
27-14	4927-4936	disorders	_	
27-15	4936-4937	.	_	

#Text=This diminishes the ability to identify common brain phenotypes underlying reward system deficits associated with anhedonia.
28-1	4938-4942	This	_	
28-2	4943-4953	diminishes	_	
28-3	4954-4957	the	_	
28-4	4958-4965	ability	_	
28-5	4966-4968	to	_	
28-6	4969-4977	identify	_	
28-7	4978-4984	common	_	
28-8	4985-4990	brain	_	
28-9	4991-5001	phenotypes	_	
28-10	5002-5012	underlying	_	
28-11	5013-5019	reward	_	
28-12	5020-5026	system	_	
28-13	5027-5035	deficits	_	
28-14	5036-5046	associated	_	
28-15	5047-5051	with	_	
28-16	5052-5061	anhedonia	_	
28-17	5061-5062	.	_	

#Text=Second, most studies have examined functional connectivity on a regional basis using traditional seed-based analyses restricted to a few brain regions.
29-1	5063-5069	Second	_	
29-2	5069-5070	,	_	
29-3	5071-5075	most	_	
29-4	5076-5083	studies	_	
29-5	5084-5088	have	_	
29-6	5089-5097	examined	_	
29-7	5098-5108	functional	_	
29-8	5109-5121	connectivity	_	
29-9	5122-5124	on	_	
29-10	5125-5126	a	_	
29-11	5127-5135	regional	_	
29-12	5136-5141	basis	_	
29-13	5142-5147	using	_	
29-14	5148-5159	traditional	_	
29-15	5160-5170	seed-based	_	
29-16	5171-5179	analyses	_	
29-17	5180-5190	restricted	_	
29-18	5191-5193	to	_	
29-19	5194-5195	a	_	
29-20	5196-5199	few	_	
29-21	5200-5205	brain	_	
29-22	5206-5213	regions	_	
29-23	5213-5214	.	_	

#Text=By definition, this approach cannot reveal potentially important effects in brain regions not included in the analysis.
30-1	5215-5217	By	_	
30-2	5218-5228	definition	_	
30-3	5228-5229	,	_	
30-4	5230-5234	this	_	
30-5	5235-5243	approach	_	
30-6	5244-5250	cannot	_	
30-7	5251-5257	reveal	_	
30-8	5258-5269	potentially	_	
30-9	5270-5279	important	_	
30-10	5280-5287	effects	_	
30-11	5288-5290	in	_	
30-12	5291-5296	brain	_	
30-13	5297-5304	regions	_	
30-14	5305-5308	not	_	
30-15	5309-5317	included	_	
30-16	5318-5320	in	_	
30-17	5321-5324	the	_	
30-18	5325-5333	analysis	_	
30-19	5333-5334	.	_	

#Text=In response to these limitations, here we evaluated a large and heterogeneous sample of adults with psychiatric conditions associated with reward abnormalities, including major depression, bipolar disorder, schizophrenia, genetic and clinical psychosis risk, as well as healthy individuals.
31-1	5335-5337	In	_	
31-2	5338-5346	response	_	
31-3	5347-5349	to	_	
31-4	5350-5355	these	_	
31-5	5356-5367	limitations	_	
31-6	5367-5368	,	_	
31-7	5369-5373	here	_	
31-8	5374-5376	we	_	
31-9	5377-5386	evaluated	_	
31-10	5387-5388	a	_	
31-11	5389-5394	large	_	
31-12	5395-5398	and	_	
31-13	5399-5412	heterogeneous	_	
31-14	5413-5419	sample	_	
31-15	5420-5422	of	_	
31-16	5423-5429	adults	_	
31-17	5430-5434	with	_	
31-18	5435-5446	psychiatric	_	
31-19	5447-5457	conditions	_	
31-20	5458-5468	associated	_	
31-21	5469-5473	with	_	
31-22	5474-5480	reward	_	
31-23	5481-5494	abnormalities	_	
31-24	5494-5495	,	_	
31-25	5496-5505	including	_	
31-26	5506-5511	major	_	
31-27	5512-5522	depression	_	
31-28	5522-5523	,	_	
31-29	5524-5531	bipolar	_	
31-30	5532-5540	disorder	_	
31-31	5540-5541	,	_	
31-32	5542-5555	schizophrenia	_	
31-33	5555-5556	,	_	
31-34	5557-5564	genetic	_	
31-35	5565-5568	and	_	
31-36	5569-5577	clinical	_	
31-37	5578-5587	psychosis	_	
31-38	5588-5592	risk	_	
31-39	5592-5593	,	_	
31-40	5594-5596	as	_	
31-41	5597-5601	well	_	
31-42	5602-5604	as	_	
31-43	5605-5612	healthy	_	
31-44	5613-5624	individuals	_	
31-45	5624-5625	.	_	

#Text=We conducted a connectome-wide association study (or CWAS), where alterations in functional connectivity are examined across all the inter-regional connections in the brain.
32-1	5626-5628	We	_	
32-2	5629-5638	conducted	_	
32-3	5639-5640	a	_	
32-4	5641-5656	connectome-wide	_	
32-5	5657-5668	association	_	
32-6	5669-5674	study	_	
32-7	5675-5676	(	_	
32-8	5676-5678	or	_	
32-9	5679-5683	CWAS	_	
32-10	5683-5684	)	_	
32-11	5684-5685	,	_	
32-12	5686-5691	where	_	
32-13	5692-5703	alterations	_	
32-14	5704-5706	in	_	
32-15	5707-5717	functional	_	
32-16	5718-5730	connectivity	_	
32-17	5731-5734	are	_	
32-18	5735-5743	examined	_	
32-19	5744-5750	across	_	
32-20	5751-5754	all	_	
32-21	5755-5758	the	_	
32-22	5759-5773	inter-regional	_	
32-23	5774-5785	connections	_	
32-24	5786-5788	in	_	
32-25	5789-5792	the	_	
32-26	5793-5798	brain	_	
32-27	5798-5799	.	_	

#Text=For this analysis, we used multivariate distance-based matrix regression (MDMR), a statistical procedure suited for analyzing complex neuroimaging data, where there are many biological variables (e.g. image voxels) per subject.
33-1	5800-5803	For	_	
33-2	5804-5808	this	_	
33-3	5809-5817	analysis	_	
33-4	5817-5818	,	_	
33-5	5819-5821	we	_	
33-6	5822-5826	used	_	
33-7	5827-5839	multivariate	_	
33-8	5840-5854	distance-based	_	
33-9	5855-5861	matrix	_	
33-10	5862-5872	regression	_	
33-11	5873-5874	(	_	
33-12	5874-5878	MDMR	_	
33-13	5878-5879	)	_	
33-14	5879-5880	,	_	
33-15	5881-5882	a	_	
33-16	5883-5894	statistical	_	
33-17	5895-5904	procedure	_	
33-18	5905-5911	suited	_	
33-19	5912-5915	for	_	
33-20	5916-5925	analyzing	_	
33-21	5926-5933	complex	_	
33-22	5934-5946	neuroimaging	_	
33-23	5947-5951	data	_	
33-24	5951-5952	,	_	
33-25	5953-5958	where	_	
33-26	5959-5964	there	_	
33-27	5965-5968	are	_	
33-28	5969-5973	many	_	
33-29	5974-5984	biological	_	
33-30	5985-5994	variables	_	
33-31	5995-5996	(	_	
33-32	5996-5999	e.g	_	
33-33	5999-6000	.	_	
33-34	6001-6006	image	_	
33-35	6007-6013	voxels	_	
33-36	6013-6014	)	_	
33-37	6015-6018	per	_	
33-38	6019-6026	subject	_	
33-39	6026-6027	.	_	

#Text=Specifically, MDMR examines the overall pattern of connectivity for each individual voxel with all other brain voxels, in relation to a clinical phenotype of interest such as dimensional reward responsiveness.
34-1	6028-6040	Specifically	_	
34-2	6040-6041	,	_	
34-3	6042-6046	MDMR	_	
34-4	6047-6055	examines	_	
34-5	6056-6059	the	_	
34-6	6060-6067	overall	_	
34-7	6068-6075	pattern	_	
34-8	6076-6078	of	_	
34-9	6079-6091	connectivity	_	
34-10	6092-6095	for	_	
34-11	6096-6100	each	_	
34-12	6101-6111	individual	_	
34-13	6112-6117	voxel	_	
34-14	6118-6122	with	_	
34-15	6123-6126	all	_	
34-16	6127-6132	other	_	
34-17	6133-6138	brain	_	
34-18	6139-6145	voxels	_	
34-19	6145-6146	,	_	
34-20	6147-6149	in	_	
34-21	6150-6158	relation	_	
34-22	6159-6161	to	_	
34-23	6162-6163	a	_	
34-24	6164-6172	clinical	_	
34-25	6173-6182	phenotype	_	
34-26	6183-6185	of	_	
34-27	6186-6194	interest	_	
34-28	6195-6199	such	_	
34-29	6200-6202	as	_	
34-30	6203-6214	dimensional	_	
34-31	6215-6221	reward	_	
34-32	6222-6236	responsiveness	_	
34-33	6236-6237	.	_	

#Text=As suggested by the NIMH RDoC initiative, we measured anhedonia as a reduction in reward responsivity, using the reward sensitivity subscale of the Behavioral Activation Scale (BAS Reward).
35-1	6238-6240	As	_	
35-2	6241-6250	suggested	_	
35-3	6251-6253	by	_	
35-4	6254-6257	the	_	
35-5	6258-6262	NIMH	_	
35-6	6263-6267	RDoC	_	
35-7	6268-6278	initiative	_	
35-8	6278-6279	,	_	
35-9	6280-6282	we	_	
35-10	6283-6291	measured	_	
35-11	6292-6301	anhedonia	_	
35-12	6302-6304	as	_	
35-13	6305-6306	a	_	
35-14	6307-6316	reduction	_	
35-15	6317-6319	in	_	
35-16	6320-6326	reward	_	
35-17	6327-6339	responsivity	_	
35-18	6339-6340	,	_	
35-19	6341-6346	using	_	
35-20	6347-6350	the	_	
35-21	6351-6357	reward	_	
35-22	6358-6369	sensitivity	_	
35-23	6370-6378	subscale	_	
35-24	6379-6381	of	_	
35-25	6382-6385	the	_	
35-26	6386-6396	Behavioral	_	
35-27	6397-6407	Activation	_	
35-28	6408-6413	Scale	_	
35-29	6414-6415	(	_	
35-30	6415-6418	BAS	_	
35-31	6419-6425	Reward	_	
35-32	6425-6426	)	_	
35-33	6426-6427	.	_	

#Text=We hypothesized that across the dimension of reward responsivity, this data-driven analysis would reveal common patterns of dysconnectivity involving key elements of the reward system such as the NAc.
36-1	6428-6430	We	_	
36-2	6431-6443	hypothesized	_	
36-3	6444-6448	that	_	
36-4	6449-6455	across	_	
36-5	6456-6459	the	_	
36-6	6460-6469	dimension	_	
36-7	6470-6472	of	_	
36-8	6473-6479	reward	_	
36-9	6480-6492	responsivity	_	
36-10	6492-6493	,	_	
36-11	6494-6498	this	_	
36-12	6499-6510	data-driven	_	
36-13	6511-6519	analysis	_	
36-14	6520-6525	would	_	
36-15	6526-6532	reveal	_	
36-16	6533-6539	common	_	
36-17	6540-6548	patterns	_	
36-18	6549-6551	of	_	
36-19	6552-6567	dysconnectivity	_	
36-20	6568-6577	involving	_	
36-21	6578-6581	key	_	
36-22	6582-6590	elements	_	
36-23	6591-6593	of	_	
36-24	6594-6597	the	_	
36-25	6598-6604	reward	_	
36-26	6605-6611	system	_	
36-27	6612-6616	such	_	
36-28	6617-6619	as	_	
36-29	6620-6623	the	_	
36-30	6624-6627	NAc	_	
36-31	6627-6628	.	_	

#Text=Our analytic approach was not biased by a priori network selection but rather explored the entire complexity of the functional connectome using MDMR.
37-1	6629-6632	Our	_	
37-2	6633-6641	analytic	_	
37-3	6642-6650	approach	_	
37-4	6651-6654	was	_	
37-5	6655-6658	not	_	
37-6	6659-6665	biased	_	
37-7	6666-6668	by	_	
37-8	6669-6670	a	_	
37-9	6671-6677	priori	_	
37-10	6678-6685	network	_	
37-11	6686-6695	selection	_	
37-12	6696-6699	but	_	
37-13	6700-6706	rather	_	
37-14	6707-6715	explored	_	
37-15	6716-6719	the	_	
37-16	6720-6726	entire	_	
37-17	6727-6737	complexity	_	
37-18	6738-6740	of	_	
37-19	6741-6744	the	_	
37-20	6745-6755	functional	_	
37-21	6756-6766	connectome	_	
37-22	6767-6772	using	_	
37-23	6773-6777	MDMR	_	
37-24	6777-6778	.	_	

#Text=This strategy was facilitated by a large sample of adults evaluated using a common imaging and phenotyping protocol.
38-1	6779-6783	This	_	
38-2	6784-6792	strategy	_	
38-3	6793-6796	was	_	
38-4	6797-6808	facilitated	_	
38-5	6809-6811	by	_	
38-6	6812-6813	a	_	
38-7	6814-6819	large	_	
38-8	6820-6826	sample	_	
38-9	6827-6829	of	_	
38-10	6830-6836	adults	_	
38-11	6837-6846	evaluated	_	
38-12	6847-6852	using	_	
38-13	6853-6854	a	_	
38-14	6855-6861	common	_	
38-15	6862-6869	imaging	_	
38-16	6870-6873	and	_	
38-17	6874-6885	phenotyping	_	
38-18	6886-6894	protocol	_	
38-19	6894-6895	.	_	

#Text=As described below, we offer novel evidence of functional network abnormalities associated with deficits in reward responsiveness across clinical diagnostic categories.
39-1	6896-6898	As	_	
39-2	6899-6908	described	_	
39-3	6909-6914	below	_	
39-4	6914-6915	,	_	
39-5	6916-6918	we	_	
39-6	6919-6924	offer	_	
39-7	6925-6930	novel	_	
39-8	6931-6939	evidence	_	
39-9	6940-6942	of	_	
39-10	6943-6953	functional	_	
39-11	6954-6961	network	_	
39-12	6962-6975	abnormalities	_	
39-13	6976-6986	associated	_	
39-14	6987-6991	with	_	
39-15	6992-7000	deficits	_	
39-16	7001-7003	in	_	
39-17	7004-7010	reward	_	
39-18	7011-7025	responsiveness	_	
39-19	7026-7032	across	_	
39-20	7033-7041	clinical	_	
39-21	7042-7052	diagnostic	_	
39-22	7053-7063	categories	_	
39-23	7063-7064	.	_	

#Text=METHODS
#Text=Participants
#Text=For this study, 244 subjects were assessed at two half-day visits using a common imaging and phenotyping protocol.
40-1	7065-7072	METHODS	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
40-2	7073-7085	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-3	7086-7089	For	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-4	7090-7094	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-5	7095-7100	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-6	7100-7101	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-7	7102-7105	244	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-8	7106-7114	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-9	7115-7119	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-10	7120-7128	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-11	7129-7131	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-12	7132-7135	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-13	7136-7144	half-day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-14	7145-7151	visits	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-15	7152-7157	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-16	7158-7159	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-17	7160-7166	common	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-18	7167-7174	imaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-19	7175-7178	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-20	7179-7190	phenotyping	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-21	7191-7199	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
40-22	7199-7200	.	_	

#Text=On the first visit, the Structured Clinical Interview for DSM-IV was conducted.
41-1	7201-7203	On	_	
41-2	7204-7207	the	_	
41-3	7208-7213	first	_	
41-4	7214-7219	visit	_	
41-5	7219-7220	,	_	
41-6	7221-7224	the	_	
41-7	7225-7235	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
41-8	7236-7244	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
41-9	7245-7254	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
41-10	7255-7258	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
41-11	7259-7265	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[8]	
41-12	7266-7269	was	_	
41-13	7270-7279	conducted	_	
41-14	7279-7280	.	_	

#Text=On the second visit, assessment of reward responsiveness and neuroimaging was conducted.
42-1	7281-7283	On	_	
42-2	7284-7287	the	_	
42-3	7288-7294	second	_	
42-4	7295-7300	visit	_	
42-5	7300-7301	,	_	
42-6	7302-7312	assessment	_	
42-7	7313-7315	of	_	
42-8	7316-7322	reward	_	
42-9	7323-7337	responsiveness	_	
42-10	7338-7341	and	_	
42-11	7342-7354	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#NeuroImagingProtocol	
42-12	7355-7358	was	_	
42-13	7359-7368	conducted	_	
42-14	7368-7369	.	_	

#Text=Subjects were enrolled if they met criteria for major depressive disorder, bipolar disorder, schizophrenia, were at genetic or clinical risk of psychosis (e.g., a first degree relative of an individual with a psychotic disorder or who met clinical high risk criteria for psychosis) or had no Axis I diagnosis (healthy controls).
43-1	7370-7378	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-2	7379-7383	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-3	7384-7392	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-4	7393-7395	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-5	7396-7400	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-6	7401-7404	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-7	7405-7413	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-8	7414-7417	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-9	7418-7423	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
43-10	7424-7434	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
43-11	7435-7443	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder[10]	
43-12	7443-7444	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-13	7445-7452	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[11]	
43-14	7453-7461	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder[11]	
43-15	7461-7462	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-16	7463-7476	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]	
43-17	7476-7477	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-18	7478-7482	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-19	7483-7485	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-20	7486-7493	genetic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-21	7494-7496	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-22	7497-7505	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-23	7506-7510	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-24	7511-7513	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-25	7514-7523	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#PsychoticDisorder[13]	
43-26	7524-7525	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-27	7525-7528	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-28	7528-7529	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-29	7529-7530	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-30	7531-7532	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-31	7533-7538	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-32	7539-7545	degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-33	7546-7554	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-34	7555-7557	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-35	7558-7560	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-36	7561-7571	individual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-37	7572-7576	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-38	7577-7578	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-39	7579-7588	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-40	7589-7597	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-41	7598-7600	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-42	7601-7604	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-43	7605-7608	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-44	7609-7617	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-45	7618-7622	high	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-46	7623-7627	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-47	7628-7636	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-48	7637-7640	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-49	7641-7650	psychosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-50	7650-7651	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-51	7652-7654	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-52	7655-7658	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
43-53	7659-7661	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-54	7662-7666	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-55	7667-7668	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-56	7669-7678	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-57	7679-7680	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-58	7680-7687	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-59	7688-7696	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-60	7696-7697	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]	
43-61	7697-7698	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Following quality assurance, the final sample included in the analysis comprised 225 subjects (Table 1).
44-1	7699-7708	Following	_	
44-2	7709-7716	quality	_	
44-3	7717-7726	assurance	_	
44-4	7726-7727	,	_	
44-5	7728-7731	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-6	7732-7737	final	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-7	7738-7744	sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-8	7745-7753	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-9	7754-7756	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-10	7757-7760	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-11	7761-7769	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-12	7770-7779	comprised	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-13	7780-7783	225	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-14	7784-7792	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
44-15	7793-7794	(	_	
44-16	7794-7799	Table	_	
44-17	7800-7801	1	_	
44-18	7801-7802	)	_	
44-19	7802-7803	.	_	

#Text=For a list of medications by class, see Table S1.
45-1	7804-7807	For	_	
45-2	7808-7809	a	_	
45-3	7810-7814	list	_	
45-4	7815-7817	of	_	
45-5	7818-7829	medications	_	
45-6	7830-7832	by	_	
45-7	7833-7838	class	_	
45-8	7838-7839	,	_	
45-9	7840-7843	see	_	
45-10	7844-7849	Table	_	
45-11	7850-7852	S1	_	
45-12	7852-7853	.	_	

#Text=The University of Pennsylvania Institutional Review Board approved all study procedures and all subjects gave informed consent in writing.
46-1	7854-7857	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-2	7858-7868	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-3	7869-7871	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-4	7872-7884	Pennsylvania	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-5	7885-7898	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-6	7899-7905	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-7	7906-7911	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-8	7912-7920	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-9	7921-7924	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-10	7925-7930	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-11	7931-7941	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-12	7942-7945	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-13	7946-7949	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-14	7950-7958	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-15	7959-7963	gave	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-16	7964-7972	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-17	7973-7980	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-18	7981-7983	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-19	7984-7991	writing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
46-20	7991-7992	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=See Supplementary Methods for additional details.
47-1	7993-7996	See	_	
47-2	7997-8010	Supplementary	_	
47-3	8011-8018	Methods	_	
47-4	8019-8022	for	_	
47-5	8023-8033	additional	_	
47-6	8034-8041	details	_	
47-7	8041-8042	.	_	

#Text=Dimensional assessment of reward responsiveness
#Text=To assess reward-related functioning, the Behavioral Activation Scale (BAS) including the reward sensitivity subscale (BAS Reward) was administered.
48-1	8043-8054	Dimensional	_	
48-2	8055-8065	assessment	_	
48-3	8066-8068	of	_	
48-4	8069-8075	reward	_	
48-5	8076-8090	responsiveness	_	
48-6	8091-8093	To	_	
48-7	8094-8100	assess	_	
48-8	8101-8115	reward-related	_	
48-9	8116-8127	functioning	_	
48-10	8127-8128	,	_	
48-11	8129-8132	the	_	
48-12	8133-8143	Behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-13	8144-8154	Activation	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-14	8155-8160	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-15	8161-8162	(	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-16	8162-8165	BAS	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-17	8165-8166	)	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale[17]	
48-18	8167-8176	including	_	
48-19	8177-8180	the	_	
48-20	8181-8187	reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-21	8188-8199	sensitivity	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-22	8200-8208	subscale	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-23	8209-8210	(	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-24	8210-8213	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-25	8214-8220	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-26	8220-8221	)	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[18]	
48-27	8222-8225	was	_	
48-28	8226-8238	administered	_	
48-29	8238-8239	.	_	

#Text=BAS Reward was chosen as it has been identified as a transdiagnostic measure of reward responsivity and used to index anhedonia.
49-1	8240-8243	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[19]	
49-2	8244-8250	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[19]	
49-3	8251-8254	was	_	
49-4	8255-8261	chosen	_	
49-5	8262-8264	as	_	
49-6	8265-8267	it	_	
49-7	8268-8271	has	_	
49-8	8272-8276	been	_	
49-9	8277-8287	identified	_	
49-10	8288-8290	as	_	
49-11	8291-8292	a	_	
49-12	8293-8308	transdiagnostic	_	
49-13	8309-8316	measure	_	
49-14	8317-8319	of	_	
49-15	8320-8326	reward	_	
49-16	8327-8339	responsivity	_	
49-17	8340-8343	and	_	
49-18	8344-8348	used	_	
49-19	8349-8351	to	_	
49-20	8352-8357	index	_	
49-21	8358-8367	anhedonia	_	
49-22	8367-8368	.	_	

#Text=The scale captures a broad range of reward functioning, and is useful for dimensional analyses across both clinical and non-clinical samples (Figure S1).
50-1	8369-8372	The	_	
50-2	8373-8378	scale	_	
50-3	8379-8387	captures	_	
50-4	8388-8389	a	_	
50-5	8390-8395	broad	_	
50-6	8396-8401	range	_	
50-7	8402-8404	of	_	
50-8	8405-8411	reward	_	
50-9	8412-8423	functioning	_	
50-10	8423-8424	,	_	
50-11	8425-8428	and	_	
50-12	8429-8431	is	_	
50-13	8432-8438	useful	_	
50-14	8439-8442	for	_	
50-15	8443-8454	dimensional	_	
50-16	8455-8463	analyses	_	
50-17	8464-8470	across	_	
50-18	8471-8475	both	_	
50-19	8476-8484	clinical	_	
50-20	8485-8488	and	_	
50-21	8489-8501	non-clinical	_	
50-22	8502-8509	samples	_	
50-23	8510-8511	(	_	
50-24	8511-8517	Figure	_	
50-25	8518-8520	S1	_	
50-26	8520-8521	)	_	
50-27	8521-8522	.	_	

#Text=As the initial descriptions of the BAS factor structure considered healthy young adults, we conducted a factor analysis on item-level data to confirm previously identified subfactors including BAS Reward in our clinical sample (Table S2).
51-1	8523-8525	As	_	
51-2	8526-8529	the	_	
51-3	8530-8537	initial	_	
51-4	8538-8550	descriptions	_	
51-5	8551-8553	of	_	
51-6	8554-8557	the	_	
51-7	8558-8561	BAS	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale	
51-8	8562-8568	factor	_	
51-9	8569-8578	structure	_	
51-10	8579-8589	considered	_	
51-11	8590-8597	healthy	_	
51-12	8598-8603	young	_	
51-13	8604-8610	adults	_	
51-14	8610-8611	,	_	
51-15	8612-8614	we	_	
51-16	8615-8624	conducted	_	
51-17	8625-8626	a	_	
51-18	8627-8633	factor	_	
51-19	8634-8642	analysis	_	
51-20	8643-8645	on	_	
51-21	8646-8656	item-level	_	
51-22	8657-8661	data	_	
51-23	8662-8664	to	_	
51-24	8665-8672	confirm	_	
51-25	8673-8683	previously	_	
51-26	8684-8694	identified	_	
51-27	8695-8705	subfactors	_	
51-28	8706-8715	including	_	
51-29	8716-8719	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[20]	
51-30	8720-8726	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[20]	
51-31	8727-8729	in	_	
51-32	8730-8733	our	_	
51-33	8734-8742	clinical	_	
51-34	8743-8749	sample	_	
51-35	8750-8751	(	_	
51-36	8751-8756	Table	_	
51-37	8757-8759	S2	_	
51-38	8759-8760	)	_	
51-39	8760-8761	.	_	

#Text=Image acquisition and processing
#Text=All magnetic resonance imaging data were acquired on the same Siemens 3T MRI scanner using the same imaging sequences, as detailed in Supplementary Methods.
52-1	8762-8767	Image	_	
52-2	8768-8779	acquisition	_	
52-3	8780-8783	and	_	
52-4	8784-8794	processing	_	
52-5	8795-8798	All	_	
52-6	8799-8807	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
52-7	8808-8817	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
52-8	8818-8825	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[21]	
52-9	8826-8830	data	_	
52-10	8831-8835	were	_	
52-11	8836-8844	acquired	_	
52-12	8845-8847	on	_	
52-13	8848-8851	the	_	
52-14	8852-8856	same	_	
52-15	8857-8864	Siemens	_	
52-16	8865-8867	3T	_	
52-17	8868-8871	MRI	_	
52-18	8872-8879	scanner	_	
52-19	8880-8885	using	_	
52-20	8886-8889	the	_	
52-21	8890-8894	same	_	
52-22	8895-8902	imaging	_	
52-23	8903-8912	sequences	_	
52-24	8912-8913	,	_	
52-25	8914-8916	as	_	
52-26	8917-8925	detailed	_	
52-27	8926-8928	in	_	
52-28	8929-8942	Supplementary	_	
52-29	8943-8950	Methods	_	
52-30	8950-8951	.	_	

#Text=Resting-state fMRI bold-oxygen-level dependent (BOLD) time series data were processed to correct image distortion and to minimize the influence of participant motion, transformed into a standard anatomical brain space (Montreal Neurological Institute, MNI) and downsampled to a lower spatial resolution prior to CWAS.
53-1	8952-8965	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
53-2	8966-8970	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
53-3	8971-8988	bold-oxygen-level	_	
53-4	8989-8998	dependent	_	
53-5	8999-9000	(	_	
53-6	9000-9004	BOLD	_	
53-7	9004-9005	)	_	
53-8	9006-9010	time	_	
53-9	9011-9017	series	_	
53-10	9018-9022	data	_	
53-11	9023-9027	were	_	
53-12	9028-9037	processed	_	
53-13	9038-9040	to	_	
53-14	9041-9048	correct	_	
53-15	9049-9054	image	_	
53-16	9055-9065	distortion	_	
53-17	9066-9069	and	_	
53-18	9070-9072	to	_	
53-19	9073-9081	minimize	_	
53-20	9082-9085	the	_	
53-21	9086-9095	influence	_	
53-22	9096-9098	of	_	
53-23	9099-9110	participant	_	
53-24	9111-9117	motion	_	
53-25	9117-9118	,	_	
53-26	9119-9130	transformed	_	
53-27	9131-9135	into	_	
53-28	9136-9137	a	_	
53-29	9138-9146	standard	_	
53-30	9147-9157	anatomical	_	
53-31	9158-9163	brain	_	
53-32	9164-9169	space	_	
53-33	9170-9171	(	_	
53-34	9171-9179	Montreal	_	
53-35	9180-9192	Neurological	_	
53-36	9193-9202	Institute	_	
53-37	9202-9203	,	_	
53-38	9204-9207	MNI	_	
53-39	9207-9208	)	_	
53-40	9209-9212	and	_	
53-41	9213-9224	downsampled	_	
53-42	9225-9227	to	_	
53-43	9228-9229	a	_	
53-44	9230-9235	lower	_	
53-45	9236-9243	spatial	_	
53-46	9244-9254	resolution	_	
53-47	9255-9260	prior	_	
53-48	9261-9263	to	_	
53-49	9264-9268	CWAS	_	
53-50	9268-9269	.	_	

#Text=Connectome-Wide Association Study (CWAS) using MDMR
#Text=MDMR relating reward sensitivity to whole-brain connectivity patterns was conducted in three steps (Figure 1).
54-1	9270-9285	Connectome-Wide	_	
54-2	9286-9297	Association	_	
54-3	9298-9303	Study	_	
54-4	9304-9305	(	_	
54-5	9305-9309	CWAS	_	
54-6	9309-9310	)	_	
54-7	9311-9316	using	_	
54-8	9317-9321	MDMR	_	
54-9	9322-9326	MDMR	_	
54-10	9327-9335	relating	_	
54-11	9336-9342	reward	_	
54-12	9343-9354	sensitivity	_	
54-13	9355-9357	to	_	
54-14	9358-9369	whole-brain	_	
54-15	9370-9382	connectivity	_	
54-16	9383-9391	patterns	_	
54-17	9392-9395	was	_	
54-18	9396-9405	conducted	_	
54-19	9406-9408	in	_	
54-20	9409-9414	three	_	
54-21	9415-9420	steps	_	
54-22	9421-9422	(	_	
54-23	9422-9428	Figure	_	
54-24	9429-9430	1	_	
54-25	9430-9431	)	_	
54-26	9431-9432	.	_	

#Text=In the first step, the processed voxelwise subject resting-state fMRI data were used to conduct a seed-based connectivity analysis at each gray matter voxel.
55-1	9433-9435	In	_	
55-2	9436-9439	the	_	
55-3	9440-9445	first	_	
55-4	9446-9450	step	_	
55-5	9450-9451	,	_	
55-6	9452-9455	the	_	
55-7	9456-9465	processed	_	
55-8	9466-9475	voxelwise	_	
55-9	9476-9483	subject	_	
55-10	9484-9497	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[23]	
55-11	9498-9502	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[23]	
55-12	9503-9507	data	_	
55-13	9508-9512	were	_	
55-14	9513-9517	used	_	
55-15	9518-9520	to	_	
55-16	9521-9528	conduct	_	
55-17	9529-9530	a	_	
55-18	9531-9541	seed-based	_	
55-19	9542-9554	connectivity	_	
55-20	9555-9563	analysis	_	
55-21	9564-9566	at	_	
55-22	9567-9571	each	_	
55-23	9572-9576	gray	_	
55-24	9577-9583	matter	_	
55-25	9584-9589	voxel	_	
55-26	9589-9590	.	_	

#Text=This step calculates the Pearsons correlation between each voxels BOLD time series and that of every other voxel within gray matter.
56-1	9591-9595	This	_	
56-2	9596-9600	step	_	
56-3	9601-9611	calculates	_	
56-4	9612-9615	the	_	
56-5	9616-9623	Pearson	_	
56-6	9623-9624		_	
56-7	9624-9625	s	_	
56-8	9626-9637	correlation	_	
56-9	9638-9645	between	_	
56-10	9646-9650	each	_	
56-11	9651-9656	voxel	_	
56-12	9656-9657		_	
56-13	9657-9658	s	_	
56-14	9659-9663	BOLD	_	
56-15	9664-9668	time	_	
56-16	9669-9675	series	_	
56-17	9676-9679	and	_	
56-18	9680-9684	that	_	
56-19	9685-9687	of	_	
56-20	9688-9693	every	_	
56-21	9694-9699	other	_	
56-22	9700-9705	voxel	_	
56-23	9706-9712	within	_	
56-24	9713-9717	gray	_	
56-25	9718-9724	matter	_	
56-26	9724-9725	.	_	

#Text=In the second step, the overall pattern of connectivity for each voxel was compared between the subjects using a distance metric.
57-1	9726-9728	In	_	
57-2	9729-9732	the	_	
57-3	9733-9739	second	_	
57-4	9740-9744	step	_	
57-5	9744-9745	,	_	
57-6	9746-9749	the	_	
57-7	9750-9757	overall	_	
57-8	9758-9765	pattern	_	
57-9	9766-9768	of	_	
57-10	9769-9781	connectivity	_	
57-11	9782-9785	for	_	
57-12	9786-9790	each	_	
57-13	9791-9796	voxel	_	
57-14	9797-9800	was	_	
57-15	9801-9809	compared	_	
57-16	9810-9817	between	_	
57-17	9818-9821	the	_	
57-18	9822-9830	subjects	_	
57-19	9831-9836	using	_	
57-20	9837-9838	a	_	
57-21	9839-9847	distance	_	
57-22	9848-9854	metric	_	
57-23	9854-9855	.	_	

#Text=The distance metric quantifies the similarity in the pattern of connectivity between each pair of subjects.
58-1	9856-9859	The	_	
58-2	9860-9868	distance	_	
58-3	9869-9875	metric	_	
58-4	9876-9886	quantifies	_	
58-5	9887-9890	the	_	
58-6	9891-9901	similarity	_	
58-7	9902-9904	in	_	
58-8	9905-9908	the	_	
58-9	9909-9916	pattern	_	
58-10	9917-9919	of	_	
58-11	9920-9932	connectivity	_	
58-12	9933-9940	between	_	
58-13	9941-9945	each	_	
58-14	9946-9950	pair	_	
58-15	9951-9953	of	_	
58-16	9954-9962	subjects	_	
58-17	9962-9963	.	_	

#Text=Finally, in the third step, MDMR was used to test how well the dimensional variable of interest (BAS Reward) explained the distances between each subjects pattern of connectivity at that seed voxel, while controlling for the effects of nuisance covariates such as clinical group status, age, sex, and in-scanner motion.
59-1	9964-9971	Finally	_	
59-2	9971-9972	,	_	
59-3	9973-9975	in	_	
59-4	9976-9979	the	_	
59-5	9980-9985	third	_	
59-6	9986-9990	step	_	
59-7	9990-9991	,	_	
59-8	9992-9996	MDMR	_	
59-9	9997-10000	was	_	
59-10	10001-10005	used	_	
59-11	10006-10008	to	_	
59-12	10009-10013	test	_	
59-13	10014-10017	how	_	
59-14	10018-10022	well	_	
59-15	10023-10026	the	_	
59-16	10027-10038	dimensional	_	
59-17	10039-10047	variable	_	
59-18	10048-10050	of	_	
59-19	10051-10059	interest	_	
59-20	10060-10061	(	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[24]	
59-21	10061-10064	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[24]	
59-22	10065-10071	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[24]	
59-23	10071-10072	)	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[24]	
59-24	10073-10082	explained	_	
59-25	10083-10086	the	_	
59-26	10087-10096	distances	_	
59-27	10097-10104	between	_	
59-28	10105-10109	each	_	
59-29	10110-10117	subject	_	
59-30	10117-10118		_	
59-31	10118-10119	s	_	
59-32	10120-10127	pattern	_	
59-33	10128-10130	of	_	
59-34	10131-10143	connectivity	_	
59-35	10144-10146	at	_	
59-36	10147-10151	that	_	
59-37	10152-10156	seed	_	
59-38	10157-10162	voxel	_	
59-39	10162-10163	,	_	
59-40	10164-10169	while	_	
59-41	10170-10181	controlling	_	
59-42	10182-10185	for	_	
59-43	10186-10189	the	_	
59-44	10190-10197	effects	_	
59-45	10198-10200	of	_	
59-46	10201-10209	nuisance	_	
59-47	10210-10220	covariates	_	
59-48	10221-10225	such	_	
59-49	10226-10228	as	_	
59-50	10229-10237	clinical	_	
59-51	10238-10243	group	_	
59-52	10244-10250	status	_	
59-53	10250-10251	,	_	
59-54	10252-10255	age	_	
59-55	10255-10256	,	_	
59-56	10257-10260	sex	_	
59-57	10260-10261	,	_	
59-58	10262-10265	and	_	
59-59	10266-10276	in-scanner	_	
59-60	10277-10283	motion	_	
59-61	10283-10284	.	_	

#Text=This MDMR procedure identified voxels where BAS Reward affected the overall pattern of connectivity.
60-1	10285-10289	This	_	
60-2	10290-10294	MDMR	_	
60-3	10295-10304	procedure	_	
60-4	10305-10315	identified	_	
60-5	10316-10322	voxels	_	
60-6	10323-10328	where	_	
60-7	10329-10332	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[25]	
60-8	10333-10339	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[25]	
60-9	10340-10348	affected	_	
60-10	10349-10352	the	_	
60-11	10353-10360	overall	_	
60-12	10361-10368	pattern	_	
60-13	10369-10371	of	_	
60-14	10372-10384	connectivity	_	
60-15	10384-10385	.	_	

#Text=As in Shehzad et al., the false positive error rate (type I error) of MDMR was controlled using cluster-correction with a voxel height of z>1.64, and utilized a cluster-extent probability threshold P<0.01.
61-1	10386-10388	As	_	
61-2	10389-10391	in	_	
61-3	10392-10399	Shehzad	_	
61-4	10400-10402	et	_	
61-5	10403-10405	al	_	
61-6	10405-10406	.	_	
61-7	10406-10407	,	_	
61-8	10408-10411	the	_	
61-9	10412-10417	false	_	
61-10	10418-10426	positive	_	
61-11	10427-10432	error	_	
61-12	10433-10437	rate	_	
61-13	10438-10439	(	_	
61-14	10439-10443	type	_	
61-15	10444-10445	I	_	
61-16	10446-10451	error	_	
61-17	10451-10452	)	_	
61-18	10453-10455	of	_	
61-19	10456-10460	MDMR	_	
61-20	10461-10464	was	_	
61-21	10465-10475	controlled	_	
61-22	10476-10481	using	_	
61-23	10482-10500	cluster-correction	_	
61-24	10501-10505	with	_	
61-25	10506-10507	a	_	
61-26	10508-10513	voxel	_	
61-27	10514-10520	height	_	
61-28	10521-10523	of	_	
61-29	10524-10525	z	_	
61-30	10525-10526	>	_	
61-31	10526-10530	1.64	_	
61-32	10530-10531	,	_	
61-33	10532-10535	and	_	
61-34	10536-10544	utilized	_	
61-35	10545-10546	a	_	
61-36	10547-10561	cluster-extent	_	
61-37	10562-10573	probability	_	
61-38	10574-10583	threshold	_	
61-39	10584-10585	P	_	
61-40	10585-10586	<	_	
61-41	10586-10590	0.01	_	
61-42	10590-10591	.	_	

#Text=Cortical projections of MDMR statistical maps were displayed using Caret.
62-1	10592-10600	Cortical	_	
62-2	10601-10612	projections	_	
62-3	10613-10615	of	_	
62-4	10616-10620	MDMR	_	
62-5	10621-10632	statistical	_	
62-6	10633-10637	maps	_	
62-7	10638-10642	were	_	
62-8	10643-10652	displayed	_	
62-9	10653-10658	using	_	
62-10	10659-10664	Caret	_	
62-11	10664-10665	.	_	

#Text=(See Supplementary Methods for additional details).
63-1	10666-10667	(	_	
63-2	10667-10670	See	_	
63-3	10671-10684	Supplementary	_	
63-4	10685-10692	Methods	_	
63-5	10693-10696	for	_	
63-6	10697-10707	additional	_	
63-7	10708-10715	details	_	
63-8	10715-10716	)	_	
63-9	10716-10717	.	_	

#Text=Follow up seed-based analyses
#Text=Although MDMR identifies clusters where the overall multivariate pattern of connectivity is dimensionally related to BAS Reward, it does not describe the specific pattern of connectivity that is driving the significant result.
64-1	10718-10724	Follow	_	
64-2	10725-10727	up	_	
64-3	10728-10738	seed-based	_	
64-4	10739-10747	analyses	_	
64-5	10748-10756	Although	_	
64-6	10757-10761	MDMR	_	
64-7	10762-10772	identifies	_	
64-8	10773-10781	clusters	_	
64-9	10782-10787	where	_	
64-10	10788-10791	the	_	
64-11	10792-10799	overall	_	
64-12	10800-10812	multivariate	_	
64-13	10813-10820	pattern	_	
64-14	10821-10823	of	_	
64-15	10824-10836	connectivity	_	
64-16	10837-10839	is	_	
64-17	10840-10853	dimensionally	_	
64-18	10854-10861	related	_	
64-19	10862-10864	to	_	
64-20	10865-10868	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[26]	
64-21	10869-10875	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[26]	
64-22	10875-10876	,	_	
64-23	10877-10879	it	_	
64-24	10880-10884	does	_	
64-25	10885-10888	not	_	
64-26	10889-10897	describe	_	
64-27	10898-10901	the	_	
64-28	10902-10910	specific	_	
64-29	10911-10918	pattern	_	
64-30	10919-10921	of	_	
64-31	10922-10934	connectivity	_	
64-32	10935-10939	that	_	
64-33	10940-10942	is	_	
64-34	10943-10950	driving	_	
64-35	10951-10954	the	_	
64-36	10955-10966	significant	_	
64-37	10967-10973	result	_	
64-38	10973-10974	.	_	

#Text=As in prior studies, we conducted post-hoc seed-based analyses from each cluster returned by MDMR, followed by network analyses of these regions (described below).
65-1	10975-10977	As	_	
65-2	10978-10980	in	_	
65-3	10981-10986	prior	_	
65-4	10987-10994	studies	_	
65-5	10994-10995	,	_	
65-6	10996-10998	we	_	
65-7	10999-11008	conducted	_	
65-8	11009-11017	post-hoc	_	
65-9	11018-11028	seed-based	_	
65-10	11029-11037	analyses	_	
65-11	11038-11042	from	_	
65-12	11043-11047	each	_	
65-13	11048-11055	cluster	_	
65-14	11056-11064	returned	_	
65-15	11065-11067	by	_	
65-16	11068-11072	MDMR	_	
65-17	11072-11073	,	_	
65-18	11074-11082	followed	_	
65-19	11083-11085	by	_	
65-20	11086-11093	network	_	
65-21	11094-11102	analyses	_	
65-22	11103-11105	of	_	
65-23	11106-11111	these	_	
65-24	11112-11119	regions	_	
65-25	11120-11121	(	_	
65-26	11121-11130	described	_	
65-27	11131-11136	below	_	
65-28	11136-11137	)	_	
65-29	11137-11138	.	_	

#Text=Group-level seed analyses included covariates as above.
66-1	11139-11150	Group-level	_	
66-2	11151-11155	seed	_	
66-3	11156-11164	analyses	_	
66-4	11165-11173	included	_	
66-5	11174-11184	covariates	_	
66-6	11185-11187	as	_	
66-7	11188-11193	above	_	
66-8	11193-11194	.	_	

#Text=These follow-up analyses subsequent to MDMR are applied descriptively, as the seeds were selected based on the significance of the MDMR result.
67-1	11195-11200	These	_	
67-2	11201-11210	follow-up	_	
67-3	11211-11219	analyses	_	
67-4	11220-11230	subsequent	_	
67-5	11231-11233	to	_	
67-6	11234-11238	MDMR	_	
67-7	11239-11242	are	_	
67-8	11243-11250	applied	_	
67-9	11251-11264	descriptively	_	
67-10	11264-11265	,	_	
67-11	11266-11268	as	_	
67-12	11269-11272	the	_	
67-13	11273-11278	seeds	_	
67-14	11279-11283	were	_	
67-15	11284-11292	selected	_	
67-16	11293-11298	based	_	
67-17	11299-11301	on	_	
67-18	11302-11305	the	_	
67-19	11306-11318	significance	_	
67-20	11319-11321	of	_	
67-21	11322-11325	the	_	
67-22	11326-11330	MDMR	_	
67-23	11331-11337	result	_	
67-24	11337-11338	.	_	

#Text=Further details are described in the Supplementary Methods.
68-1	11339-11346	Further	_	
68-2	11347-11354	details	_	
68-3	11355-11358	are	_	
68-4	11359-11368	described	_	
68-5	11369-11371	in	_	
68-6	11372-11375	the	_	
68-7	11376-11389	Supplementary	_	
68-8	11390-11397	Methods	_	
68-9	11397-11398	.	_	

#Text=Network construction and analysis
#Text=In order to summarize the observed pairwise interactions among the implicated brain regions, we evaluated the data within a network framework.
69-1	11399-11406	Network	_	
69-2	11407-11419	construction	_	
69-3	11420-11423	and	_	
69-4	11424-11432	analysis	_	
69-5	11433-11435	In	_	
69-6	11436-11441	order	_	
69-7	11442-11444	to	_	
69-8	11445-11454	summarize	_	
69-9	11455-11458	the	_	
69-10	11459-11467	observed	_	
69-11	11468-11476	pairwise	_	
69-12	11477-11489	interactions	_	
69-13	11490-11495	among	_	
69-14	11496-11499	the	_	
69-15	11500-11510	implicated	_	
69-16	11511-11516	brain	_	
69-17	11517-11524	regions	_	
69-18	11524-11525	,	_	
69-19	11526-11528	we	_	
69-20	11529-11538	evaluated	_	
69-21	11539-11542	the	_	
69-22	11543-11547	data	_	
69-23	11548-11554	within	_	
69-24	11555-11556	a	_	
69-25	11557-11564	network	_	
69-26	11565-11574	framework	_	
69-27	11574-11575	.	_	

#Text=We constructed a graph of cortical nodes consisting of clusters identified by MDMR.
70-1	11576-11578	We	_	
70-2	11579-11590	constructed	_	
70-3	11591-11592	a	_	
70-4	11593-11598	graph	_	
70-5	11599-11601	of	_	
70-6	11602-11610	cortical	_	
70-7	11611-11616	nodes	_	
70-8	11617-11627	consisting	_	
70-9	11628-11630	of	_	
70-10	11631-11639	clusters	_	
70-11	11640-11650	identified	_	
70-12	11651-11653	by	_	
70-13	11654-11658	MDMR	_	
70-14	11658-11659	.	_	

#Text=As in prior work, subcortical nodes such as the NAc were not included in detecting cortical modules.
71-1	11660-11662	As	_	
71-2	11663-11665	in	_	
71-3	11666-11671	prior	_	
71-4	11672-11676	work	_	
71-5	11676-11677	,	_	
71-6	11678-11689	subcortical	_	
71-7	11690-11695	nodes	_	
71-8	11696-11700	such	_	
71-9	11701-11703	as	_	
71-10	11704-11707	the	_	
71-11	11708-11711	NAc	_	
71-12	11712-11716	were	_	
71-13	11717-11720	not	_	
71-14	11721-11729	included	_	
71-15	11730-11732	in	_	
71-16	11733-11742	detecting	_	
71-17	11743-11751	cortical	_	
71-18	11752-11759	modules	_	
71-19	11759-11760	.	_	

#Text=The graph was separated into distinct network modules using community detection techniques (described in Supplementary Methods).
72-1	11761-11764	The	_	
72-2	11765-11770	graph	_	
72-3	11771-11774	was	_	
72-4	11775-11784	separated	_	
72-5	11785-11789	into	_	
72-6	11790-11798	distinct	_	
72-7	11799-11806	network	_	
72-8	11807-11814	modules	_	
72-9	11815-11820	using	_	
72-10	11821-11830	community	_	
72-11	11831-11840	detection	_	
72-12	11841-11851	techniques	_	
72-13	11852-11853	(	_	
72-14	11853-11862	described	_	
72-15	11863-11865	in	_	
72-16	11866-11879	Supplementary	_	
72-17	11880-11887	Methods	_	
72-18	11887-11888	)	_	
72-19	11888-11889	.	_	

#Text=Differences in connectivity among the cortical modules and with the NAc were investigated using measures of within-network and between network connectivity.
73-1	11890-11901	Differences	_	
73-2	11902-11904	in	_	
73-3	11905-11917	connectivity	_	
73-4	11918-11923	among	_	
73-5	11924-11927	the	_	
73-6	11928-11936	cortical	_	
73-7	11937-11944	modules	_	
73-8	11945-11948	and	_	
73-9	11949-11953	with	_	
73-10	11954-11957	the	_	
73-11	11958-11961	NAc	_	
73-12	11962-11966	were	_	
73-13	11967-11979	investigated	_	
73-14	11980-11985	using	_	
73-15	11986-11994	measures	_	
73-16	11995-11997	of	_	
73-17	11998-12012	within-network	_	
73-18	12013-12016	and	_	
73-19	12017-12024	between	_	
73-20	12025-12032	network	_	
73-21	12033-12045	connectivity	_	
73-22	12045-12046	.	_	

#Text=Within-network connectivity was defined as the mean correlation strength of all edges within a network module.
74-1	12047-12061	Within-network	_	
74-2	12062-12074	connectivity	_	
74-3	12075-12078	was	_	
74-4	12079-12086	defined	_	
74-5	12087-12089	as	_	
74-6	12090-12093	the	_	
74-7	12094-12098	mean	_	
74-8	12099-12110	correlation	_	
74-9	12111-12119	strength	_	
74-10	12120-12122	of	_	
74-11	12123-12126	all	_	
74-12	12127-12132	edges	_	
74-13	12133-12139	within	_	
74-14	12140-12141	a	_	
74-15	12142-12149	network	_	
74-16	12150-12156	module	_	
74-17	12156-12157	.	_	

#Text=In contrast, between-network connectivity was defined on a pairwise basis as the mean strength of edges between nodes within a network module and nodes outside the module.
75-1	12158-12160	In	_	
75-2	12161-12169	contrast	_	
75-3	12169-12170	,	_	
75-4	12171-12186	between-network	_	
75-5	12187-12199	connectivity	_	
75-6	12200-12203	was	_	
75-7	12204-12211	defined	_	
75-8	12212-12214	on	_	
75-9	12215-12216	a	_	
75-10	12217-12225	pairwise	_	
75-11	12226-12231	basis	_	
75-12	12232-12234	as	_	
75-13	12235-12238	the	_	
75-14	12239-12243	mean	_	
75-15	12244-12252	strength	_	
75-16	12253-12255	of	_	
75-17	12256-12261	edges	_	
75-18	12262-12269	between	_	
75-19	12270-12275	nodes	_	
75-20	12276-12282	within	_	
75-21	12283-12284	a	_	
75-22	12285-12292	network	_	
75-23	12293-12299	module	_	
75-24	12300-12303	and	_	
75-25	12304-12309	nodes	_	
75-26	12310-12317	outside	_	
75-27	12318-12321	the	_	
75-28	12322-12328	module	_	
75-29	12328-12329	.	_	

#Text=The relationship of BAS Reward to these connectivity measures was examined using linear regression, with covariates as detailed above.
76-1	12330-12333	The	_	
76-2	12334-12346	relationship	_	
76-3	12347-12349	of	_	
76-4	12350-12353	BAS	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[27]	
76-5	12354-12360	Reward	http://maven.renci.org/NeuroBridge/neurobridge#RewardSensitivitySubscale[27]	
76-6	12361-12363	to	_	
76-7	12364-12369	these	_	
76-8	12370-12382	connectivity	_	
76-9	12383-12391	measures	_	
76-10	12392-12395	was	_	
76-11	12396-12404	examined	_	
76-12	12405-12410	using	_	
76-13	12411-12417	linear	_	
76-14	12418-12428	regression	_	
76-15	12428-12429	,	_	
76-16	12430-12434	with	_	
76-17	12435-12445	covariates	_	
76-18	12446-12448	as	_	
76-19	12449-12457	detailed	_	
76-20	12458-12463	above	_	
76-21	12463-12464	.	_	

#Text=Supplementary analyses
#Text=To evaluate within-group dimensional effects, we conducted separate analyses examining network-level associations for each diagnostic group and specific sub-groups, as well as for a psychopathology-only sample that excluded healthy controls.
77-1	12465-12478	Supplementary	_	
77-2	12479-12487	analyses	_	
77-3	12488-12490	To	_	
77-4	12491-12499	evaluate	_	
77-5	12500-12512	within-group	_	
77-6	12513-12524	dimensional	_	
77-7	12525-12532	effects	_	
77-8	12532-12533	,	_	
77-9	12534-12536	we	_	
77-10	12537-12546	conducted	_	
77-11	12547-12555	separate	_	
77-12	12556-12564	analyses	_	
77-13	12565-12574	examining	_	
77-14	12575-12588	network-level	_	
77-15	12589-12601	associations	_	
77-16	12602-12605	for	_	
77-17	12606-12610	each	_	
77-18	12611-12621	diagnostic	_	
77-19	12622-12627	group	_	
77-20	12628-12631	and	_	
77-21	12632-12640	specific	_	
77-22	12641-12651	sub-groups	_	
77-23	12651-12652	,	_	
77-24	12653-12655	as	_	
77-25	12656-12660	well	_	
77-26	12661-12663	as	_	
77-27	12664-12667	for	_	
77-28	12668-12669	a	_	
77-29	12670-12690	psychopathology-only	_	
77-30	12691-12697	sample	_	
77-31	12698-12702	that	_	
77-32	12703-12711	excluded	_	
77-33	12712-12719	healthy	_	
77-34	12720-12728	controls	_	
77-35	12728-12729	.	_	

#Text=Additionally, we explored differences in network-level measures among categorical diagnostic groups.
78-1	12730-12742	Additionally	_	
78-2	12742-12743	,	_	
78-3	12744-12746	we	_	
78-4	12747-12755	explored	_	
78-5	12756-12767	differences	_	
78-6	12768-12770	in	_	
78-7	12771-12784	network-level	_	
78-8	12785-12793	measures	_	
78-9	12794-12799	among	_	
78-10	12800-12811	categorical	_	
78-11	12812-12822	diagnostic	_	
78-12	12823-12829	groups	_	
78-13	12829-12830	.	_	

#Text=Furthermore, to assess specificity for our clinical phenotype, we compared network associations among the BAS subscales and with diagnosis-specific disease severity measures (see Supplementary Methods).
79-1	12831-12842	Furthermore	_	
79-2	12842-12843	,	_	
79-3	12844-12846	to	_	
79-4	12847-12853	assess	_	
79-5	12854-12865	specificity	_	
79-6	12866-12869	for	_	
79-7	12870-12873	our	_	
79-8	12874-12882	clinical	_	
79-9	12883-12892	phenotype	_	
79-10	12892-12893	,	_	
79-11	12894-12896	we	_	
79-12	12897-12905	compared	_	
79-13	12906-12913	network	_	
79-14	12914-12926	associations	_	
79-15	12927-12932	among	_	
79-16	12933-12936	the	_	
79-17	12937-12940	BAS	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale	
79-18	12941-12950	subscales	_	
79-19	12951-12954	and	_	
79-20	12955-12959	with	_	
79-21	12960-12978	diagnosis-specific	_	
79-22	12979-12986	disease	_	
79-23	12987-12995	severity	_	
79-24	12996-13004	measures	_	
79-25	13005-13006	(	_	
79-26	13006-13009	see	_	
79-27	13010-13023	Supplementary	_	
79-28	13024-13031	Methods	_	
79-29	13031-13032	)	_	
79-30	13032-13033	.	_	

#Text=Although the above analyses accounted for variables including clinical group, age, sex and in-scanner motion, we also conducted additional analyses including smoking status as a covariate.
80-1	13034-13042	Although	_	
80-2	13043-13046	the	_	
80-3	13047-13052	above	_	
80-4	13053-13061	analyses	_	
80-5	13062-13071	accounted	_	
80-6	13072-13075	for	_	
80-7	13076-13085	variables	_	
80-8	13086-13095	including	_	
80-9	13096-13104	clinical	_	
80-10	13105-13110	group	_	
80-11	13110-13111	,	_	
80-12	13112-13115	age	_	
80-13	13115-13116	,	_	
80-14	13117-13120	sex	_	
80-15	13121-13124	and	_	
80-16	13125-13135	in-scanner	_	
80-17	13136-13142	motion	_	
80-18	13142-13143	,	_	
80-19	13144-13146	we	_	
80-20	13147-13151	also	_	
80-21	13152-13161	conducted	_	
80-22	13162-13172	additional	_	
80-23	13173-13181	analyses	_	
80-24	13182-13191	including	_	
80-25	13192-13199	smoking	_	
80-26	13200-13206	status	_	
80-27	13207-13209	as	_	
80-28	13210-13211	a	_	
80-29	13212-13221	covariate	_	
80-30	13221-13222	.	_	

#Text=Finally, we also included composite medication load as a confound variable in network analyses, based on a previously described method.
81-1	13223-13230	Finally	_	
81-2	13230-13231	,	_	
81-3	13232-13234	we	_	
81-4	13235-13239	also	_	
81-5	13240-13248	included	_	
81-6	13249-13258	composite	_	
81-7	13259-13269	medication	_	
81-8	13270-13274	load	_	
81-9	13275-13277	as	_	
81-10	13278-13279	a	_	
81-11	13280-13288	confound	_	
81-12	13289-13297	variable	_	
81-13	13298-13300	in	_	
81-14	13301-13308	network	_	
81-15	13309-13317	analyses	_	
81-16	13317-13318	,	_	
81-17	13319-13324	based	_	
81-18	13325-13327	on	_	
81-19	13328-13329	a	_	
81-20	13330-13340	previously	_	
81-21	13341-13350	described	_	
81-22	13351-13357	method	_	
81-23	13357-13358	.	_	

#Text=RESULTS
#Text=MDMR identifies multiple foci of connectivity related to reward responsivity
#Text=MDMR revealed multiple regions where the multivariate pattern of connectivity was dimensionally related to reward sensitivity across clinical diagnostic categories (Figure 2).
82-1	13359-13366	RESULTS	_	
82-2	13367-13371	MDMR	_	
82-3	13372-13382	identifies	_	
82-4	13383-13391	multiple	_	
82-5	13392-13396	foci	_	
82-6	13397-13399	of	_	
82-7	13400-13412	connectivity	_	
82-8	13413-13420	related	_	
82-9	13421-13423	to	_	
82-10	13424-13430	reward	_	
82-11	13431-13443	responsivity	_	
82-12	13444-13448	MDMR	_	
82-13	13449-13457	revealed	_	
82-14	13458-13466	multiple	_	
82-15	13467-13474	regions	_	
82-16	13475-13480	where	_	
82-17	13481-13484	the	_	
82-18	13485-13497	multivariate	_	
82-19	13498-13505	pattern	_	
82-20	13506-13508	of	_	
82-21	13509-13521	connectivity	_	
82-22	13522-13525	was	_	
82-23	13526-13539	dimensionally	_	
82-24	13540-13547	related	_	
82-25	13548-13550	to	_	
82-26	13551-13557	reward	_	
82-27	13558-13569	sensitivity	_	
82-28	13570-13576	across	_	
82-29	13577-13585	clinical	_	
82-30	13586-13596	diagnostic	_	
82-31	13597-13607	categories	_	
82-32	13608-13609	(	_	
82-33	13609-13615	Figure	_	
82-34	13616-13617	2	_	
82-35	13617-13618	)	_	
82-36	13618-13619	.	_	

#Text=These regions included bilateral NAc and a set of widely distributed cortical regions (bilateral temporoparietal junction, right insular cortex, right inferior and left superior lateral temporal cortex, left lateral orbitofrontal cortex and left dorsomedial frontal cortex) (Table S3).
83-1	13620-13625	These	_	
83-2	13626-13633	regions	_	
83-3	13634-13642	included	_	
83-4	13643-13652	bilateral	_	
83-5	13653-13656	NAc	_	
83-6	13657-13660	and	_	
83-7	13661-13662	a	_	
83-8	13663-13666	set	_	
83-9	13667-13669	of	_	
83-10	13670-13676	widely	_	
83-11	13677-13688	distributed	_	
83-12	13689-13697	cortical	_	
83-13	13698-13705	regions	_	
83-14	13706-13707	(	_	
83-15	13707-13716	bilateral	_	
83-16	13717-13732	temporoparietal	_	
83-17	13733-13741	junction	_	
83-18	13741-13742	,	_	
83-19	13743-13748	right	_	
83-20	13749-13756	insular	_	
83-21	13757-13763	cortex	_	
83-22	13763-13764	,	_	
83-23	13765-13770	right	_	
83-24	13771-13779	inferior	_	
83-25	13780-13783	and	_	
83-26	13784-13788	left	_	
83-27	13789-13797	superior	_	
83-28	13798-13805	lateral	_	
83-29	13806-13814	temporal	_	
83-30	13815-13821	cortex	_	
83-31	13821-13822	,	_	
83-32	13823-13827	left	_	
83-33	13828-13835	lateral	_	
83-34	13836-13849	orbitofrontal	_	
83-35	13850-13856	cortex	_	
83-36	13857-13860	and	_	
83-37	13861-13865	left	_	
83-38	13866-13877	dorsomedial	_	
83-39	13878-13885	frontal	_	
83-40	13886-13892	cortex	_	
83-41	13892-13893	)	_	
83-42	13894-13895	(	_	
83-43	13895-13900	Table	_	
83-44	13901-13903	S3	_	
83-45	13903-13904	)	_	
83-46	13904-13905	.	_	

#Text=As these results do not describe which specific connections form the basis for the observed multivariate results, each significant MDMR cluster was next evaluated using a standard seed-based connectivity analysis.
84-1	13906-13908	As	_	
84-2	13909-13914	these	_	
84-3	13915-13922	results	_	
84-4	13923-13925	do	_	
84-5	13926-13929	not	_	
84-6	13930-13938	describe	_	
84-7	13939-13944	which	_	
84-8	13945-13953	specific	_	
84-9	13954-13965	connections	_	
84-10	13966-13970	form	_	
84-11	13971-13974	the	_	
84-12	13975-13980	basis	_	
84-13	13981-13984	for	_	
84-14	13985-13988	the	_	
84-15	13989-13997	observed	_	
84-16	13998-14010	multivariate	_	
84-17	14011-14018	results	_	
84-18	14018-14019	,	_	
84-19	14020-14024	each	_	
84-20	14025-14036	significant	_	
84-21	14037-14041	MDMR	_	
84-22	14042-14049	cluster	_	
84-23	14050-14053	was	_	
84-24	14054-14058	next	_	
84-25	14059-14068	evaluated	_	
84-26	14069-14074	using	_	
84-27	14075-14076	a	_	
84-28	14077-14085	standard	_	
84-29	14086-14096	seed-based	_	
84-30	14097-14109	connectivity	_	
84-31	14110-14118	analysis	_	
84-32	14118-14119	.	_	

#Text=Seed-based connectivity analyses explain patterns of connectivity that drive MDMR results
#Text=Follow-up analyses used the regions identified by MDMR as the basis for seed-based connectivity analyses, which examined the connectivity from a given region with the rest of the brain on a voxelwise basis.
85-1	14120-14130	Seed-based	_	
85-2	14131-14143	connectivity	_	
85-3	14144-14152	analyses	_	
85-4	14153-14160	explain	_	
85-5	14161-14169	patterns	_	
85-6	14170-14172	of	_	
85-7	14173-14185	connectivity	_	
85-8	14186-14190	that	_	
85-9	14191-14196	drive	_	
85-10	14197-14201	MDMR	_	
85-11	14202-14209	results	_	
85-12	14210-14219	Follow-up	_	
85-13	14220-14228	analyses	_	
85-14	14229-14233	used	_	
85-15	14234-14237	the	_	
85-16	14238-14245	regions	_	
85-17	14246-14256	identified	_	
85-18	14257-14259	by	_	
85-19	14260-14264	MDMR	_	
85-20	14265-14267	as	_	
85-21	14268-14271	the	_	
85-22	14272-14277	basis	_	
85-23	14278-14281	for	_	
85-24	14282-14292	seed-based	_	
85-25	14293-14305	connectivity	_	
85-26	14306-14314	analyses	_	
85-27	14314-14315	,	_	
85-28	14316-14321	which	_	
85-29	14322-14330	examined	_	
85-30	14331-14334	the	_	
85-31	14335-14347	connectivity	_	
85-32	14348-14352	from	_	
85-33	14353-14354	a	_	
85-34	14355-14360	given	_	
85-35	14361-14367	region	_	
85-36	14368-14372	with	_	
85-37	14373-14376	the	_	
85-38	14377-14381	rest	_	
85-39	14382-14384	of	_	
85-40	14385-14388	the	_	
85-41	14389-14394	brain	_	
85-42	14395-14397	on	_	
85-43	14398-14399	a	_	
85-44	14400-14409	voxelwise	_	
85-45	14410-14415	basis	_	
85-46	14415-14416	.	_	

#Text=These analyses demonstrated that the multivariate results from MDMR were driven by altered patterns of connectivity impacting elements of the default mode network (DMN) and cingulo-opercular network (CON) (Figure 3).
86-1	14417-14422	These	_	
86-2	14423-14431	analyses	_	
86-3	14432-14444	demonstrated	_	
86-4	14445-14449	that	_	
86-5	14450-14453	the	_	
86-6	14454-14466	multivariate	_	
86-7	14467-14474	results	_	
86-8	14475-14479	from	_	
86-9	14480-14484	MDMR	_	
86-10	14485-14489	were	_	
86-11	14490-14496	driven	_	
86-12	14497-14499	by	_	
86-13	14500-14507	altered	_	
86-14	14508-14516	patterns	_	
86-15	14517-14519	of	_	
86-16	14520-14532	connectivity	_	
86-17	14533-14542	impacting	_	
86-18	14543-14551	elements	_	
86-19	14552-14554	of	_	
86-20	14555-14558	the	_	
86-21	14559-14566	default	_	
86-22	14567-14571	mode	_	
86-23	14572-14579	network	_	
86-24	14580-14581	(	_	
86-25	14581-14584	DMN	_	
86-26	14584-14585	)	_	
86-27	14586-14589	and	_	
86-28	14590-14607	cingulo-opercular	_	
86-29	14608-14615	network	_	
86-30	14616-14617	(	_	
86-31	14617-14620	CON	_	
86-32	14620-14621	)	_	
86-33	14622-14623	(	_	
86-34	14623-14629	Figure	_	
86-35	14630-14631	3	_	
86-36	14631-14632	)	_	
86-37	14632-14633	.	_	

#Text=With increasing BAS Reward, NAc connectivity increased with elements of the DMN, including the temporoparietal junction, lateral temporal cortex, anterior medial prefrontal cortex, and posterior cingulate cortex (Figure 3A).
87-1	14634-14638	With	_	
87-2	14639-14649	increasing	_	
87-3	14650-14653	BAS	_	
87-4	14654-14660	Reward	_	
87-5	14660-14661	,	_	
87-6	14662-14665	NAc	_	
87-7	14666-14678	connectivity	_	
87-8	14679-14688	increased	_	
87-9	14689-14693	with	_	
87-10	14694-14702	elements	_	
87-11	14703-14705	of	_	
87-12	14706-14709	the	_	
87-13	14710-14713	DMN	_	
87-14	14713-14714	,	_	
87-15	14715-14724	including	_	
87-16	14725-14728	the	_	
87-17	14729-14744	temporoparietal	_	
87-18	14745-14753	junction	_	
87-19	14753-14754	,	_	
87-20	14755-14762	lateral	_	
87-21	14763-14771	temporal	_	
87-22	14772-14778	cortex	_	
87-23	14778-14779	,	_	
87-24	14780-14788	anterior	_	
87-25	14789-14795	medial	_	
87-26	14796-14806	prefrontal	_	
87-27	14807-14813	cortex	_	
87-28	14813-14814	,	_	
87-29	14815-14818	and	_	
87-30	14819-14828	posterior	_	
87-31	14829-14838	cingulate	_	
87-32	14839-14845	cortex	_	
87-33	14846-14847	(	_	
87-34	14847-14853	Figure	_	
87-35	14854-14856	3A	_	
87-36	14856-14857	)	_	
87-37	14857-14858	.	_	

#Text=Conversely, NAc connectivity decreased with elements of the CON, including the insular cortex and dorsomedial frontal cortex (including supplementary motor regions).
88-1	14859-14869	Conversely	_	
88-2	14869-14870	,	_	
88-3	14871-14874	NAc	_	
88-4	14875-14887	connectivity	_	
88-5	14888-14897	decreased	_	
88-6	14898-14902	with	_	
88-7	14903-14911	elements	_	
88-8	14912-14914	of	_	
88-9	14915-14918	the	_	
88-10	14919-14922	CON	_	
88-11	14922-14923	,	_	
88-12	14924-14933	including	_	
88-13	14934-14937	the	_	
88-14	14938-14945	insular	_	
88-15	14946-14952	cortex	_	
88-16	14953-14956	and	_	
88-17	14957-14968	dorsomedial	_	
88-18	14969-14976	frontal	_	
88-19	14977-14983	cortex	_	
88-20	14984-14985	(	_	
88-21	14985-14994	including	_	
88-22	14995-15008	supplementary	_	
88-23	15009-15014	motor	_	
88-24	15015-15022	regions	_	
88-25	15022-15023	)	_	
88-26	15023-15024	.	_	

#Text=Within clusters in the DMN, higher BAS Reward was associated with a dissociable pattern of diminished connectivity with other elements of the DMN, as well as increased connectivity with CON regions (Figure 3B).
89-1	15025-15031	Within	_	
89-2	15032-15040	clusters	_	
89-3	15041-15043	in	_	
89-4	15044-15047	the	_	
89-5	15048-15051	DMN	_	
89-6	15051-15052	,	_	
89-7	15053-15059	higher	_	
89-8	15060-15063	BAS	_	
89-9	15064-15070	Reward	_	
89-10	15071-15074	was	_	
89-11	15075-15085	associated	_	
89-12	15086-15090	with	_	
89-13	15091-15092	a	_	
89-14	15093-15104	dissociable	_	
89-15	15105-15112	pattern	_	
89-16	15113-15115	of	_	
89-17	15116-15126	diminished	_	
89-18	15127-15139	connectivity	_	
89-19	15140-15144	with	_	
89-20	15145-15150	other	_	
89-21	15151-15159	elements	_	
89-22	15160-15162	of	_	
89-23	15163-15166	the	_	
89-24	15167-15170	DMN	_	
89-25	15170-15171	,	_	
89-26	15172-15174	as	_	
89-27	15175-15179	well	_	
89-28	15180-15182	as	_	
89-29	15183-15192	increased	_	
89-30	15193-15205	connectivity	_	
89-31	15206-15210	with	_	
89-32	15211-15214	CON	_	
89-33	15215-15222	regions	_	
89-34	15223-15224	(	_	
89-35	15224-15230	Figure	_	
89-36	15231-15233	3B	_	
89-37	15233-15234	)	_	
89-38	15234-15235	.	_	

#Text=Similarly, for clusters in the CON, higher BAS Reward was associated with decreased connectivity with other parts of the CON and increased connectivity with DMN regions (Figure 3C).
90-1	15236-15245	Similarly	_	
90-2	15245-15246	,	_	
90-3	15247-15250	for	_	
90-4	15251-15259	clusters	_	
90-5	15260-15262	in	_	
90-6	15263-15266	the	_	
90-7	15267-15270	CON	_	
90-8	15270-15271	,	_	
90-9	15272-15278	higher	_	
90-10	15279-15282	BAS	_	
90-11	15283-15289	Reward	_	
90-12	15290-15293	was	_	
90-13	15294-15304	associated	_	
90-14	15305-15309	with	_	
90-15	15310-15319	decreased	_	
90-16	15320-15332	connectivity	_	
90-17	15333-15337	with	_	
90-18	15338-15343	other	_	
90-19	15344-15349	parts	_	
90-20	15350-15352	of	_	
90-21	15353-15356	the	_	
90-22	15357-15360	CON	_	
90-23	15361-15364	and	_	
90-24	15365-15374	increased	_	
90-25	15375-15387	connectivity	_	
90-26	15388-15392	with	_	
90-27	15393-15396	DMN	_	
90-28	15397-15404	regions	_	
90-29	15405-15406	(	_	
90-30	15406-15412	Figure	_	
90-31	15413-15415	3C	_	
90-32	15415-15416	)	_	
90-33	15416-15417	.	_	

#Text=Reward deficits are associated with a dissociable pattern of within- and between-network connectivity
#Text=The results of the seed based analyses suggested common patterns of dysconnectivity involving the NAc, DMN, and CON.
91-1	15418-15424	Reward	_	
91-2	15425-15433	deficits	_	
91-3	15434-15437	are	_	
91-4	15438-15448	associated	_	
91-5	15449-15453	with	_	
91-6	15454-15455	a	_	
91-7	15456-15467	dissociable	_	
91-8	15468-15475	pattern	_	
91-9	15476-15478	of	_	
91-10	15479-15485	within	_	
91-11	15485-15486	-	_	
91-12	15487-15490	and	_	
91-13	15491-15506	between-network	_	
91-14	15507-15519	connectivity	_	
91-15	15520-15523	The	_	
91-16	15524-15531	results	_	
91-17	15532-15534	of	_	
91-18	15535-15538	the	_	
91-19	15539-15543	seed	_	
91-20	15544-15549	based	_	
91-21	15550-15558	analyses	_	
91-22	15559-15568	suggested	_	
91-23	15569-15575	common	_	
91-24	15576-15584	patterns	_	
91-25	15585-15587	of	_	
91-26	15588-15603	dysconnectivity	_	
91-27	15604-15613	involving	_	
91-28	15614-15617	the	_	
91-29	15618-15621	NAc	_	
91-30	15621-15622	,	_	
91-31	15623-15626	DMN	_	
91-32	15626-15627	,	_	
91-33	15628-15631	and	_	
91-34	15632-15635	CON	_	
91-35	15635-15636	.	_	

#Text=In order to concisely summarize these effects, we conducted network analyses where nodes were centered upon the clusters identified by MDMR (Figure 4).
92-1	15637-15639	In	_	
92-2	15640-15645	order	_	
92-3	15646-15648	to	_	
92-4	15649-15658	concisely	_	
92-5	15659-15668	summarize	_	
92-6	15669-15674	these	_	
92-7	15675-15682	effects	_	
92-8	15682-15683	,	_	
92-9	15684-15686	we	_	
92-10	15687-15696	conducted	_	
92-11	15697-15704	network	_	
92-12	15705-15713	analyses	_	
92-13	15714-15719	where	_	
92-14	15720-15725	nodes	_	
92-15	15726-15730	were	_	
92-16	15731-15739	centered	_	
92-17	15740-15744	upon	_	
92-18	15745-15748	the	_	
92-19	15749-15757	clusters	_	
92-20	15758-15768	identified	_	
92-21	15769-15771	by	_	
92-22	15772-15776	MDMR	_	
92-23	15777-15778	(	_	
92-24	15778-15784	Figure	_	
92-25	15785-15786	4	_	
92-26	15786-15787	)	_	
92-27	15787-15788	.	_	

#Text=Application of community detection procedures to the cortical regions identified by MDMR revealed two network modules: a DMN module (blue in Figure 3A) and a CON module (red).
93-1	15789-15800	Application	_	
93-2	15801-15803	of	_	
93-3	15804-15813	community	_	
93-4	15814-15823	detection	_	
93-5	15824-15834	procedures	_	
93-6	15835-15837	to	_	
93-7	15838-15841	the	_	
93-8	15842-15850	cortical	_	
93-9	15851-15858	regions	_	
93-10	15859-15869	identified	_	
93-11	15870-15872	by	_	
93-12	15873-15877	MDMR	_	
93-13	15878-15886	revealed	_	
93-14	15887-15890	two	_	
93-15	15891-15898	network	_	
93-16	15899-15906	modules	_	
93-17	15906-15907	:	_	
93-18	15908-15909	a	_	
93-19	15910-15913	DMN	_	
93-20	15914-15920	module	_	
93-21	15921-15922	(	_	
93-22	15922-15926	blue	_	
93-23	15927-15929	in	_	
93-24	15930-15936	Figure	_	
93-25	15937-15939	3A	_	
93-26	15939-15940	)	_	
93-27	15941-15944	and	_	
93-28	15945-15946	a	_	
93-29	15947-15950	CON	_	
93-30	15951-15957	module	_	
93-31	15958-15959	(	_	
93-32	15959-15962	red	_	
93-33	15962-15963	)	_	
93-34	15963-15964	.	_	

#Text=The integrity of these modules was confirmed through permutation testing (DMN: P=1.95  104; CON: P=2.39104).
94-1	15965-15968	The	_	
94-2	15969-15978	integrity	_	
94-3	15979-15981	of	_	
94-4	15982-15987	these	_	
94-5	15988-15995	modules	_	
94-6	15996-15999	was	_	
94-7	16000-16009	confirmed	_	
94-8	16010-16017	through	_	
94-9	16018-16029	permutation	_	
94-10	16030-16037	testing	_	
94-11	16038-16039	(	_	
94-12	16039-16042	DMN	_	
94-13	16042-16043	:	_	
94-14	16044-16045	P	_	
94-15	16045-16046	=	_	
94-16	16046-16050	1.95	_	
94-17	16051-16052		_	
94-18	16053-16055	10	_	
94-19	16055-16056		_	
94-20	16056-16057	4	_	
94-21	16057-16058	;	_	
94-22	16059-16062	CON	_	
94-23	16062-16063	:	_	
94-24	16064-16065	P	_	
94-25	16065-16066	=	_	
94-26	16066-16070	2.39	_	
94-27	16070-16071		_	
94-28	16071-16073	10	_	
94-29	16073-16074		_	
94-30	16074-16075	4	_	
94-31	16075-16076	)	_	
94-32	16076-16077	.	_	

#Text=These network modules were used to derive summary measures of within-network and between-network connectivity for each cortical network as well as the NAc.
95-1	16078-16083	These	_	
95-2	16084-16091	network	_	
95-3	16092-16099	modules	_	
95-4	16100-16104	were	_	
95-5	16105-16109	used	_	
95-6	16110-16112	to	_	
95-7	16113-16119	derive	_	
95-8	16120-16127	summary	_	
95-9	16128-16136	measures	_	
95-10	16137-16139	of	_	
95-11	16140-16154	within-network	_	
95-12	16155-16158	and	_	
95-13	16159-16174	between-network	_	
95-14	16175-16187	connectivity	_	
95-15	16188-16191	for	_	
95-16	16192-16196	each	_	
95-17	16197-16205	cortical	_	
95-18	16206-16213	network	_	
95-19	16214-16216	as	_	
95-20	16217-16221	well	_	
95-21	16222-16224	as	_	
95-22	16225-16228	the	_	
95-23	16229-16232	NAc	_	
95-24	16232-16233	.	_	

#Text=This approach demonstrated that deficits in reward responsivity were associated with DMN hyperconnectivity (t=3.75, P=2.3  104) and decreased integration between DMN and CON networks (t=5.17, P=5.3  107).
96-1	16234-16238	This	_	
96-2	16239-16247	approach	_	
96-3	16248-16260	demonstrated	_	
96-4	16261-16265	that	_	
96-5	16266-16274	deficits	_	
96-6	16275-16277	in	_	
96-7	16278-16284	reward	_	
96-8	16285-16297	responsivity	_	
96-9	16298-16302	were	_	
96-10	16303-16313	associated	_	
96-11	16314-16318	with	_	
96-12	16319-16322	DMN	_	
96-13	16323-16340	hyperconnectivity	_	
96-14	16341-16342	(	_	
96-15	16342-16343	t	_	
96-16	16343-16344	=	_	
96-17	16344-16348	3.75	_	
96-18	16348-16349	,	_	
96-19	16350-16351	P	_	
96-20	16351-16352	=	_	
96-21	16352-16355	2.3	_	
96-22	16356-16357		_	
96-23	16358-16360	10	_	
96-24	16360-16361		_	
96-25	16361-16362	4	_	
96-26	16362-16363	)	_	
96-27	16364-16367	and	_	
96-28	16368-16377	decreased	_	
96-29	16378-16389	integration	_	
96-30	16390-16397	between	_	
96-31	16398-16401	DMN	_	
96-32	16402-16405	and	_	
96-33	16406-16409	CON	_	
96-34	16410-16418	networks	_	
96-35	16419-16420	(	_	
96-36	16420-16421	t	_	
96-37	16421-16422	=	_	
96-38	16422-16423		_	
96-39	16423-16427	5.17	_	
96-40	16427-16428	,	_	
96-41	16429-16430	P	_	
96-42	16430-16431	=	_	
96-43	16431-16434	5.3	_	
96-44	16435-16436		_	
96-45	16437-16439	10	_	
96-46	16439-16440		_	
96-47	16440-16441	7	_	
96-48	16441-16442	)	_	
96-49	16442-16443	.	_	

#Text=In addition, reward deficits were associated with decreased connectivity between NAc and DMN (t=2.45, P=1.5  102) and increased connectivity between NAc and CON (t=3.35, P=9.4  104).
97-1	16444-16446	In	_	
97-2	16447-16455	addition	_	
97-3	16455-16456	,	_	
97-4	16457-16463	reward	_	
97-5	16464-16472	deficits	_	
97-6	16473-16477	were	_	
97-7	16478-16488	associated	_	
97-8	16489-16493	with	_	
97-9	16494-16503	decreased	_	
97-10	16504-16516	connectivity	_	
97-11	16517-16524	between	_	
97-12	16525-16528	NAc	_	
97-13	16529-16532	and	_	
97-14	16533-16536	DMN	_	
97-15	16537-16538	(	_	
97-16	16538-16539	t	_	
97-17	16539-16540	=	_	
97-18	16540-16541		_	
97-19	16541-16545	2.45	_	
97-20	16545-16546	,	_	
97-21	16547-16548	P	_	
97-22	16548-16549	=	_	
97-23	16549-16552	1.5	_	
97-24	16553-16554		_	
97-25	16555-16557	10	_	
97-26	16557-16558		_	
97-27	16558-16559	2	_	
97-28	16559-16560	)	_	
97-29	16561-16564	and	_	
97-30	16565-16574	increased	_	
97-31	16575-16587	connectivity	_	
97-32	16588-16595	between	_	
97-33	16596-16599	NAc	_	
97-34	16600-16603	and	_	
97-35	16604-16607	CON	_	
97-36	16608-16609	(	_	
97-37	16609-16610	t	_	
97-38	16610-16611	=	_	
97-39	16611-16615	3.35	_	
97-40	16615-16616	,	_	
97-41	16617-16618	P	_	
97-42	16618-16619	=	_	
97-43	16619-16622	9.4	_	
97-44	16623-16624		_	
97-45	16625-16627	10	_	
97-46	16627-16628		_	
97-47	16628-16629	4	_	
97-48	16629-16630	)	_	
97-49	16630-16631	.	_	

#Text=An MDMR analysis evaluating for effects of clinical diagnosis did not identify hubs of the reward system such as the NAc (Table S4).
98-1	16632-16634	An	_	
98-2	16635-16639	MDMR	_	
98-3	16640-16648	analysis	_	
98-4	16649-16659	evaluating	_	
98-5	16660-16663	for	_	
98-6	16664-16671	effects	_	
98-7	16672-16674	of	_	
98-8	16675-16683	clinical	_	
98-9	16684-16693	diagnosis	_	
98-10	16694-16697	did	_	
98-11	16698-16701	not	_	
98-12	16702-16710	identify	_	
98-13	16711-16715	hubs	_	
98-14	16716-16718	of	_	
98-15	16719-16722	the	_	
98-16	16723-16729	reward	_	
98-17	16730-16736	system	_	
98-18	16737-16741	such	_	
98-19	16742-16744	as	_	
98-20	16745-16748	the	_	
98-21	16749-16752	NAc	_	
98-22	16753-16754	(	_	
98-23	16754-16759	Table	_	
98-24	16760-16762	S4	_	
98-25	16762-16763	)	_	
98-26	16763-16764	.	_	

#Text=Notably, observed dimensional effects with BAS Reward were present within each clinical diagnostic category (Table S5).
99-1	16765-16772	Notably	_	
99-2	16772-16773	,	_	
99-3	16774-16782	observed	_	
99-4	16783-16794	dimensional	_	
99-5	16795-16802	effects	_	
99-6	16803-16807	with	_	
99-7	16808-16811	BAS	_	
99-8	16812-16818	Reward	_	
99-9	16819-16823	were	_	
99-10	16824-16831	present	_	
99-11	16832-16838	within	_	
99-12	16839-16843	each	_	
99-13	16844-16852	clinical	_	
99-14	16853-16863	diagnostic	_	
99-15	16864-16872	category	_	
99-16	16873-16874	(	_	
99-17	16874-16879	Table	_	
99-18	16880-16882	S5	_	
99-19	16882-16883	)	_	
99-20	16883-16884	.	_	

#Text=In controls, most effects were in the same direction but were attenuated in magnitude; exclusion of controls from the sample strengthened all associations.
100-1	16885-16887	In	_	
100-2	16888-16896	controls	_	
100-3	16896-16897	,	_	
100-4	16898-16902	most	_	
100-5	16903-16910	effects	_	
100-6	16911-16915	were	_	
100-7	16916-16918	in	_	
100-8	16919-16922	the	_	
100-9	16923-16927	same	_	
100-10	16928-16937	direction	_	
100-11	16938-16941	but	_	
100-12	16942-16946	were	_	
100-13	16947-16957	attenuated	_	
100-14	16958-16960	in	_	
100-15	16961-16970	magnitude	_	
100-16	16970-16971	;	_	
100-17	16972-16981	exclusion	_	
100-18	16982-16984	of	_	
100-19	16985-16993	controls	_	
100-20	16994-16998	from	_	
100-21	16999-17002	the	_	
100-22	17003-17009	sample	_	
100-23	17010-17022	strengthened	_	
100-24	17023-17026	all	_	
100-25	17027-17039	associations	_	
100-26	17039-17040	.	_	

#Text=Differences in BAS subfactor scores were present between groups (Table S6), however there were no group differences in network-level summary measures.
101-1	17041-17052	Differences	_	
101-2	17053-17055	in	_	
101-3	17056-17059	BAS	_	
101-4	17060-17069	subfactor	_	
101-5	17070-17076	scores	_	
101-6	17077-17081	were	_	
101-7	17082-17089	present	_	
101-8	17090-17097	between	_	
101-9	17098-17104	groups	_	
101-10	17105-17106	(	_	
101-11	17106-17111	Table	_	
101-12	17112-17114	S6	_	
101-13	17114-17115	)	_	
101-14	17115-17116	,	_	
101-15	17117-17124	however	_	
101-16	17125-17130	there	_	
101-17	17131-17135	were	_	
101-18	17136-17138	no	_	
101-19	17139-17144	group	_	
101-20	17145-17156	differences	_	
101-21	17157-17159	in	_	
101-22	17160-17173	network-level	_	
101-23	17174-17181	summary	_	
101-24	17182-17190	measures	_	
101-25	17190-17191	.	_	

#Text=Inclusion of smoking status or composite medication load did not impact results (Table S7).
102-1	17192-17201	Inclusion	_	
102-2	17202-17204	of	_	
102-3	17205-17212	smoking	_	
102-4	17213-17219	status	_	
102-5	17220-17222	or	_	
102-6	17223-17232	composite	_	
102-7	17233-17243	medication	_	
102-8	17244-17248	load	_	
102-9	17249-17252	did	_	
102-10	17253-17256	not	_	
102-11	17257-17263	impact	_	
102-12	17264-17271	results	_	
102-13	17272-17273	(	_	
102-14	17273-17278	Table	_	
102-15	17279-17281	S7	_	
102-16	17281-17282	)	_	
102-17	17282-17283	.	_	

#Text=Network-level associations were directionally similar for other BAS subscales but reduced in magnitude (Table S8).
103-1	17284-17297	Network-level	_	
103-2	17298-17310	associations	_	
103-3	17311-17315	were	_	
103-4	17316-17329	directionally	_	
103-5	17330-17337	similar	_	
103-6	17338-17341	for	_	
103-7	17342-17347	other	_	
103-8	17348-17351	BAS	_	
103-9	17352-17361	subscales	_	
103-10	17362-17365	but	_	
103-11	17366-17373	reduced	_	
103-12	17374-17376	in	_	
103-13	17377-17386	magnitude	_	
103-14	17387-17388	(	_	
103-15	17388-17393	Table	_	
103-16	17394-17396	S8	_	
103-17	17396-17397	)	_	
103-18	17397-17398	.	_	

#Text=The network associations did not relate to other disorder-specific, disease severity measures (Table S9).
104-1	17399-17402	The	_	
104-2	17403-17410	network	_	
104-3	17411-17423	associations	_	
104-4	17424-17427	did	_	
104-5	17428-17431	not	_	
104-6	17432-17438	relate	_	
104-7	17439-17441	to	_	
104-8	17442-17447	other	_	
104-9	17448-17465	disorder-specific	_	
104-10	17465-17466	,	_	
104-11	17467-17474	disease	_	
104-12	17475-17483	severity	_	
104-13	17484-17492	measures	_	
104-14	17493-17494	(	_	
104-15	17494-17499	Table	_	
104-16	17500-17502	S9	_	
104-17	17502-17503	)	_	
104-18	17503-17504	.	_	

#Text=DISCUSSION
#Text=We used a fully data-driven survey of the functional connectome to identify regions where the multivariate pattern of brain connectivity was dimensionally related to reward responsivity across a large, heterogeneous population of adults with psychiatric disorders.
105-1	17505-17515	DISCUSSION	_	
105-2	17516-17518	We	_	
105-3	17519-17523	used	_	
105-4	17524-17525	a	_	
105-5	17526-17531	fully	_	
105-6	17532-17543	data-driven	_	
105-7	17544-17550	survey	_	
105-8	17551-17553	of	_	
105-9	17554-17557	the	_	
105-10	17558-17568	functional	_	
105-11	17569-17579	connectome	_	
105-12	17580-17582	to	_	
105-13	17583-17591	identify	_	
105-14	17592-17599	regions	_	
105-15	17600-17605	where	_	
105-16	17606-17609	the	_	
105-17	17610-17622	multivariate	_	
105-18	17623-17630	pattern	_	
105-19	17631-17633	of	_	
105-20	17634-17639	brain	_	
105-21	17640-17652	connectivity	_	
105-22	17653-17656	was	_	
105-23	17657-17670	dimensionally	_	
105-24	17671-17678	related	_	
105-25	17679-17681	to	_	
105-26	17682-17688	reward	_	
105-27	17689-17701	responsivity	_	
105-28	17702-17708	across	_	
105-29	17709-17710	a	_	
105-30	17711-17716	large	_	
105-31	17716-17717	,	_	
105-32	17718-17731	heterogeneous	_	
105-33	17732-17742	population	_	
105-34	17743-17745	of	_	
105-35	17746-17752	adults	_	
105-36	17753-17757	with	_	
105-37	17758-17769	psychiatric	_	
105-38	17770-17779	disorders	_	
105-39	17779-17780	.	_	

#Text=This approach identified multivariate patterns of connectivity centered on regions within the DMN, CON and the NAc.
106-1	17781-17785	This	_	
106-2	17786-17794	approach	_	
106-3	17795-17805	identified	_	
106-4	17806-17818	multivariate	_	
106-5	17819-17827	patterns	_	
106-6	17828-17830	of	_	
106-7	17831-17843	connectivity	_	
106-8	17844-17852	centered	_	
106-9	17853-17855	on	_	
106-10	17856-17863	regions	_	
106-11	17864-17870	within	_	
106-12	17871-17874	the	_	
106-13	17875-17878	DMN	_	
106-14	17878-17879	,	_	
106-15	17880-17883	CON	_	
106-16	17884-17887	and	_	
106-17	17888-17891	the	_	
106-18	17892-17895	NAc	_	
106-19	17895-17896	.	_	

#Text=Network-based analyses revealed that reward deficits were associated with hyper-connectivity within the DMN and diminished connectivity between DMN and CON regions.
107-1	17897-17910	Network-based	_	
107-2	17911-17919	analyses	_	
107-3	17920-17928	revealed	_	
107-4	17929-17933	that	_	
107-5	17934-17940	reward	_	
107-6	17941-17949	deficits	_	
107-7	17950-17954	were	_	
107-8	17955-17965	associated	_	
107-9	17966-17970	with	_	
107-10	17971-17989	hyper-connectivity	_	
107-11	17990-17996	within	_	
107-12	17997-18000	the	_	
107-13	18001-18004	DMN	_	
107-14	18005-18008	and	_	
107-15	18009-18019	diminished	_	
107-16	18020-18032	connectivity	_	
107-17	18033-18040	between	_	
107-18	18041-18044	DMN	_	
107-19	18045-18048	and	_	
107-20	18049-18052	CON	_	
107-21	18053-18060	regions	_	
107-22	18060-18061	.	_	

#Text=Furthermore, NAc connectivity was de-coupled from DMN regions and showed increased connectivity with CON regions.
108-1	18062-18073	Furthermore	_	
108-2	18073-18074	,	_	
108-3	18075-18078	NAc	_	
108-4	18079-18091	connectivity	_	
108-5	18092-18095	was	_	
108-6	18096-18106	de-coupled	_	
108-7	18107-18111	from	_	
108-8	18112-18115	DMN	_	
108-9	18116-18123	regions	_	
108-10	18124-18127	and	_	
108-11	18128-18134	showed	_	
108-12	18135-18144	increased	_	
108-13	18145-18157	connectivity	_	
108-14	18158-18162	with	_	
108-15	18163-18166	CON	_	
108-16	18167-18174	regions	_	
108-17	18174-18175	.	_	

#Text=Taken together, these findings delineate a common pattern of large-scale network dysconnectivity associated with reward deficits across clinical diagnostic categories.
109-1	18176-18181	Taken	_	
109-2	18182-18190	together	_	
109-3	18190-18191	,	_	
109-4	18192-18197	these	_	
109-5	18198-18206	findings	_	
109-6	18207-18216	delineate	_	
109-7	18217-18218	a	_	
109-8	18219-18225	common	_	
109-9	18226-18233	pattern	_	
109-10	18234-18236	of	_	
109-11	18237-18248	large-scale	_	
109-12	18249-18256	network	_	
109-13	18257-18272	dysconnectivity	_	
109-14	18273-18283	associated	_	
109-15	18284-18288	with	_	
109-16	18289-18295	reward	_	
109-17	18296-18304	deficits	_	
109-18	18305-18311	across	_	
109-19	18312-18320	clinical	_	
109-20	18321-18331	diagnostic	_	
109-21	18332-18342	categories	_	
109-22	18342-18343	.	_	

#Text=MDMR allows full exploration of the connectome in relation to reward responsivity
#Text=To date, the majority of studies examining reward-related functional connectivity abnormalities in psychiatric disorders have utilized a priori defined seed-based approaches.
110-1	18344-18348	MDMR	_	
110-2	18349-18355	allows	_	
110-3	18356-18360	full	_	
110-4	18361-18372	exploration	_	
110-5	18373-18375	of	_	
110-6	18376-18379	the	_	
110-7	18380-18390	connectome	_	
110-8	18391-18393	in	_	
110-9	18394-18402	relation	_	
110-10	18403-18405	to	_	
110-11	18406-18412	reward	_	
110-12	18413-18425	responsivity	_	
110-13	18426-18428	To	_	
110-14	18429-18433	date	_	
110-15	18433-18434	,	_	
110-16	18435-18438	the	_	
110-17	18439-18447	majority	_	
110-18	18448-18450	of	_	
110-19	18451-18458	studies	_	
110-20	18459-18468	examining	_	
110-21	18469-18483	reward-related	_	
110-22	18484-18494	functional	_	
110-23	18495-18507	connectivity	_	
110-24	18508-18521	abnormalities	_	
110-25	18522-18524	in	_	
110-26	18525-18536	psychiatric	_	
110-27	18537-18546	disorders	_	
110-28	18547-18551	have	_	
110-29	18552-18560	utilized	_	
110-30	18561-18562	a	_	
110-31	18563-18569	priori	_	
110-32	18570-18577	defined	_	
110-33	18578-18588	seed-based	_	
110-34	18589-18599	approaches	_	
110-35	18599-18600	.	_	

#Text=In contrast, we used MDMR to conduct a data-driven analysis of the entire functional connectome in relation to reward responsiveness.
111-1	18601-18603	In	_	
111-2	18604-18612	contrast	_	
111-3	18612-18613	,	_	
111-4	18614-18616	we	_	
111-5	18617-18621	used	_	
111-6	18622-18626	MDMR	_	
111-7	18627-18629	to	_	
111-8	18630-18637	conduct	_	
111-9	18638-18639	a	_	
111-10	18640-18651	data-driven	_	
111-11	18652-18660	analysis	_	
111-12	18661-18663	of	_	
111-13	18664-18667	the	_	
111-14	18668-18674	entire	_	
111-15	18675-18685	functional	_	
111-16	18686-18696	connectome	_	
111-17	18697-18699	in	_	
111-18	18700-18708	relation	_	
111-19	18709-18711	to	_	
111-20	18712-18718	reward	_	
111-21	18719-18733	responsiveness	_	
111-22	18733-18734	.	_	

#Text=MDMR has the advantage of simultaneously assessing associations between reward responsiveness and each connection within the functional connectome, while controlling for the effects of potential confounds.
112-1	18735-18739	MDMR	_	
112-2	18740-18743	has	_	
112-3	18744-18747	the	_	
112-4	18748-18757	advantage	_	
112-5	18758-18760	of	_	
112-6	18761-18775	simultaneously	_	
112-7	18776-18785	assessing	_	
112-8	18786-18798	associations	_	
112-9	18799-18806	between	_	
112-10	18807-18813	reward	_	
112-11	18814-18828	responsiveness	_	
112-12	18829-18832	and	_	
112-13	18833-18837	each	_	
112-14	18838-18848	connection	_	
112-15	18849-18855	within	_	
112-16	18856-18859	the	_	
112-17	18860-18870	functional	_	
112-18	18871-18881	connectome	_	
112-19	18881-18882	,	_	
112-20	18883-18888	while	_	
112-21	18889-18900	controlling	_	
112-22	18901-18904	for	_	
112-23	18905-18908	the	_	
112-24	18909-18916	effects	_	
112-25	18917-18919	of	_	
112-26	18920-18929	potential	_	
112-27	18930-18939	confounds	_	
112-28	18939-18940	.	_	

#Text=MDMR thus eliminates the need for users to select specific brain regions of interest, minimizing bias in the experimental design.
113-1	18941-18945	MDMR	_	
113-2	18946-18950	thus	_	
113-3	18951-18961	eliminates	_	
113-4	18962-18965	the	_	
113-5	18966-18970	need	_	
113-6	18971-18974	for	_	
113-7	18975-18980	users	_	
113-8	18981-18983	to	_	
113-9	18984-18990	select	_	
113-10	18991-18999	specific	_	
113-11	19000-19005	brain	_	
113-12	19006-19013	regions	_	
113-13	19014-19016	of	_	
113-14	19017-19025	interest	_	
113-15	19025-19026	,	_	
113-16	19027-19037	minimizing	_	
113-17	19038-19042	bias	_	
113-18	19043-19045	in	_	
113-19	19046-19049	the	_	
113-20	19050-19062	experimental	_	
113-21	19063-19069	design	_	
113-22	19069-19070	.	_	

#Text=Remarkably, this exploratory multivariate analysis identified abnormalities in the nucleus accumbens, a region critical for reward processing.
114-1	19071-19081	Remarkably	_	
114-2	19081-19082	,	_	
114-3	19083-19087	this	_	
114-4	19088-19099	exploratory	_	
114-5	19100-19112	multivariate	_	
114-6	19113-19121	analysis	_	
114-7	19122-19132	identified	_	
114-8	19133-19146	abnormalities	_	
114-9	19147-19149	in	_	
114-10	19150-19153	the	_	
114-11	19154-19161	nucleus	_	
114-12	19162-19171	accumbens	_	
114-13	19171-19172	,	_	
114-14	19173-19174	a	_	
114-15	19175-19181	region	_	
114-16	19182-19190	critical	_	
114-17	19191-19194	for	_	
114-18	19195-19201	reward	_	
114-19	19202-19212	processing	_	
114-20	19212-19213	.	_	

#Text=Single-disorder case-control studies have consistently implicated the NAc in reward-related pathophysiology in mood and psychotic disorders.
115-1	19214-19229	Single-disorder	_	
115-2	19230-19242	case-control	_	
115-3	19243-19250	studies	_	
115-4	19251-19255	have	_	
115-5	19256-19268	consistently	_	
115-6	19269-19279	implicated	_	
115-7	19280-19283	the	_	
115-8	19284-19287	NAc	_	
115-9	19288-19290	in	_	
115-10	19291-19305	reward-related	_	
115-11	19306-19321	pathophysiology	_	
115-12	19322-19324	in	_	
115-13	19325-19329	mood	_	
115-14	19330-19333	and	_	
115-15	19334-19343	psychotic	_	
115-16	19344-19353	disorders	_	
115-17	19353-19354	.	_	

#Text=Furthermore, abnormalities involving the NAc have specifically been linked with symptoms of anhedonia.
116-1	19355-19366	Furthermore	_	
116-2	19366-19367	,	_	
116-3	19368-19381	abnormalities	_	
116-4	19382-19391	involving	_	
116-5	19392-19395	the	_	
116-6	19396-19399	NAc	_	
116-7	19400-19404	have	_	
116-8	19405-19417	specifically	_	
116-9	19418-19422	been	_	
116-10	19423-19429	linked	_	
116-11	19430-19434	with	_	
116-12	19435-19443	symptoms	_	
116-13	19444-19446	of	_	
116-14	19447-19456	anhedonia	_	
116-15	19456-19457	.	_	

#Text=However, whether circuit-level abnormalities involving the NAc can be identified across these disorders has not previously been evaluated.
117-1	19458-19465	However	_	
117-2	19465-19466	,	_	
117-3	19467-19474	whether	_	
117-4	19475-19488	circuit-level	_	
117-5	19489-19502	abnormalities	_	
117-6	19503-19512	involving	_	
117-7	19513-19516	the	_	
117-8	19517-19520	NAc	_	
117-9	19521-19524	can	_	
117-10	19525-19527	be	_	
117-11	19528-19538	identified	_	
117-12	19539-19545	across	_	
117-13	19546-19551	these	_	
117-14	19552-19561	disorders	_	
117-15	19562-19565	has	_	
117-16	19566-19569	not	_	
117-17	19570-19580	previously	_	
117-18	19581-19585	been	_	
117-19	19586-19595	evaluated	_	
117-20	19595-19596	.	_	

#Text=As discussed below, dimensional deficits of reward responsivity are associated with connectivity abnormalities between the NAc and major functional networks.
118-1	19597-19599	As	_	
118-2	19600-19609	discussed	_	
118-3	19610-19615	below	_	
118-4	19615-19616	,	_	
118-5	19617-19628	dimensional	_	
118-6	19629-19637	deficits	_	
118-7	19638-19640	of	_	
118-8	19641-19647	reward	_	
118-9	19648-19660	responsivity	_	
118-10	19661-19664	are	_	
118-11	19665-19675	associated	_	
118-12	19676-19680	with	_	
118-13	19681-19693	connectivity	_	
118-14	19694-19707	abnormalities	_	
118-15	19708-19715	between	_	
118-16	19716-19719	the	_	
118-17	19720-19723	NAc	_	
118-18	19724-19727	and	_	
118-19	19728-19733	major	_	
118-20	19734-19744	functional	_	
118-21	19745-19753	networks	_	
118-22	19753-19754	.	_	

#Text=Hyper-connectivity within a DMN subsystem scales with reward impairments
#Text=The DMN is comprised of brain regions which are important for internally-directed modes of cognition, including memory, prospection, theory of mind, and reward valuation.
119-1	19755-19773	Hyper-connectivity	_	
119-2	19774-19780	within	_	
119-3	19781-19782	a	_	
119-4	19783-19786	DMN	_	
119-5	19787-19796	subsystem	_	
119-6	19797-19803	scales	_	
119-7	19804-19808	with	_	
119-8	19809-19815	reward	_	
119-9	19816-19827	impairments	_	
119-10	19828-19831	The	_	
119-11	19832-19835	DMN	_	
119-12	19836-19838	is	_	
119-13	19839-19848	comprised	_	
119-14	19849-19851	of	_	
119-15	19852-19857	brain	_	
119-16	19858-19865	regions	_	
119-17	19866-19871	which	_	
119-18	19872-19875	are	_	
119-19	19876-19885	important	_	
119-20	19886-19889	for	_	
119-21	19890-19909	internally-directed	_	
119-22	19910-19915	modes	_	
119-23	19916-19918	of	_	
119-24	19919-19928	cognition	_	
119-25	19928-19929	,	_	
119-26	19930-19939	including	_	
119-27	19940-19946	memory	_	
119-28	19946-19947	,	_	
119-29	19948-19959	prospection	_	
119-30	19959-19960	,	_	
119-31	19961-19967	theory	_	
119-32	19968-19970	of	_	
119-33	19971-19975	mind	_	
119-34	19975-19976	,	_	
119-35	19977-19980	and	_	
119-36	19981-19987	reward	_	
119-37	19988-19997	valuation	_	
119-38	19997-19998	.	_	

#Text=Abnormally enhanced connectivity within the DMN has been reported in multiple psychiatric conditions where anhedonia is prominent.
120-1	19999-20009	Abnormally	_	
120-2	20010-20018	enhanced	_	
120-3	20019-20031	connectivity	_	
120-4	20032-20038	within	_	
120-5	20039-20042	the	_	
120-6	20043-20046	DMN	_	
120-7	20047-20050	has	_	
120-8	20051-20055	been	_	
120-9	20056-20064	reported	_	
120-10	20065-20067	in	_	
120-11	20068-20076	multiple	_	
120-12	20077-20088	psychiatric	_	
120-13	20089-20099	conditions	_	
120-14	20100-20105	where	_	
120-15	20106-20115	anhedonia	_	
120-16	20116-20118	is	_	
120-17	20119-20128	prominent	_	
120-18	20128-20129	.	_	

#Text=In our heterogeneous sample, MDMR identified DMN regions including the temporoparietal junction and lateral temporal cortex.
121-1	20130-20132	In	_	
121-2	20133-20136	our	_	
121-3	20137-20150	heterogeneous	_	
121-4	20151-20157	sample	_	
121-5	20157-20158	,	_	
121-6	20159-20163	MDMR	_	
121-7	20164-20174	identified	_	
121-8	20175-20178	DMN	_	
121-9	20179-20186	regions	_	
121-10	20187-20196	including	_	
121-11	20197-20200	the	_	
121-12	20201-20216	temporoparietal	_	
121-13	20217-20225	junction	_	
121-14	20226-20229	and	_	
121-15	20230-20237	lateral	_	
121-16	20238-20246	temporal	_	
121-17	20247-20253	cortex	_	
121-18	20253-20254	.	_	

#Text=Follow-up seed-based connectivity analyses identified additional DMN regions including the posterior cingulate cortex and anterior medial prefrontal cortex.
122-1	20255-20264	Follow-up	_	
122-2	20265-20275	seed-based	_	
122-3	20276-20288	connectivity	_	
122-4	20289-20297	analyses	_	
122-5	20298-20308	identified	_	
122-6	20309-20319	additional	_	
122-7	20320-20323	DMN	_	
122-8	20324-20331	regions	_	
122-9	20332-20341	including	_	
122-10	20342-20345	the	_	
122-11	20346-20355	posterior	_	
122-12	20356-20365	cingulate	_	
122-13	20366-20372	cortex	_	
122-14	20373-20376	and	_	
122-15	20377-20385	anterior	_	
122-16	20386-20392	medial	_	
122-17	20393-20403	prefrontal	_	
122-18	20404-20410	cortex	_	
122-19	20410-20411	.	_	

#Text=These regions map to a functionally-specific DMN subsystem (dorsomedial prefrontal subsystem) linked to present-state, self-referential and affective cognition.
123-1	20412-20417	These	_	
123-2	20418-20425	regions	_	
123-3	20426-20429	map	_	
123-4	20430-20432	to	_	
123-5	20433-20434	a	_	
123-6	20435-20456	functionally-specific	_	
123-7	20457-20460	DMN	_	
123-8	20461-20470	subsystem	_	
123-9	20471-20472	(	_	
123-10	20472-20483	dorsomedial	_	
123-11	20484-20494	prefrontal	_	
123-12	20495-20504	subsystem	_	
123-13	20504-20505	)	_	
123-14	20506-20512	linked	_	
123-15	20513-20515	to	_	
123-16	20516-20529	present-state	_	
123-17	20529-20530	,	_	
123-18	20531-20547	self-referential	_	
123-19	20548-20551	and	_	
123-20	20552-20561	affective	_	
123-21	20562-20571	cognition	_	
123-22	20571-20572	.	_	

#Text=Notably, regions belonging to another DMN subsystem  the medial temporal lobe system, which is preferentially active during memory rather than affective processing - were not identified by MDMR.
124-1	20573-20580	Notably	_	
124-2	20580-20581	,	_	
124-3	20582-20589	regions	_	
124-4	20590-20599	belonging	_	
124-5	20600-20602	to	_	
124-6	20603-20610	another	_	
124-7	20611-20614	DMN	_	
124-8	20615-20624	subsystem	_	
124-9	20625-20626		_	
124-10	20627-20630	the	_	
124-11	20631-20637	medial	_	
124-12	20638-20646	temporal	_	
124-13	20647-20651	lobe	_	
124-14	20652-20658	system	_	
124-15	20658-20659	,	_	
124-16	20660-20665	which	_	
124-17	20666-20668	is	_	
124-18	20669-20683	preferentially	_	
124-19	20684-20690	active	_	
124-20	20691-20697	during	_	
124-21	20698-20704	memory	_	
124-22	20705-20711	rather	_	
124-23	20712-20716	than	_	
124-24	20717-20726	affective	_	
124-25	20727-20737	processing	_	
124-26	20738-20739	-	_	
124-27	20740-20744	were	_	
124-28	20745-20748	not	_	
124-29	20749-20759	identified	_	
124-30	20760-20762	by	_	
124-31	20763-20767	MDMR	_	
124-32	20767-20768	.	_	

#Text=Hyper-connectivity within the dorsomedial prefrontal DMN subsystem scaled with impairments in reward responsivity.
125-1	20769-20787	Hyper-connectivity	_	
125-2	20788-20794	within	_	
125-3	20795-20798	the	_	
125-4	20799-20810	dorsomedial	_	
125-5	20811-20821	prefrontal	_	
125-6	20822-20825	DMN	_	
125-7	20826-20835	subsystem	_	
125-8	20836-20842	scaled	_	
125-9	20843-20847	with	_	
125-10	20848-20859	impairments	_	
125-11	20860-20862	in	_	
125-12	20863-20869	reward	_	
125-13	20870-20882	responsivity	_	
125-14	20882-20883	.	_	

#Text=Additionally, there was diminished connectivity between this DMN subsystem and the CON, a cognitive-control network involved in detecting salient external stimuli.
126-1	20884-20896	Additionally	_	
126-2	20896-20897	,	_	
126-3	20898-20903	there	_	
126-4	20904-20907	was	_	
126-5	20908-20918	diminished	_	
126-6	20919-20931	connectivity	_	
126-7	20932-20939	between	_	
126-8	20940-20944	this	_	
126-9	20945-20948	DMN	_	
126-10	20949-20958	subsystem	_	
126-11	20959-20962	and	_	
126-12	20963-20966	the	_	
126-13	20967-20970	CON	_	
126-14	20970-20971	,	_	
126-15	20972-20973	a	_	
126-16	20974-20991	cognitive-control	_	
126-17	20992-20999	network	_	
126-18	21000-21008	involved	_	
126-19	21009-21011	in	_	
126-20	21012-21021	detecting	_	
126-21	21022-21029	salient	_	
126-22	21030-21038	external	_	
126-23	21039-21046	stimuli	_	
126-24	21046-21047	.	_	

#Text=These findings were present in each clinical group, highlighting the relevance of these abnormalities across diagnostic categories.
127-1	21048-21053	These	_	
127-2	21054-21062	findings	_	
127-3	21063-21067	were	_	
127-4	21068-21075	present	_	
127-5	21076-21078	in	_	
127-6	21079-21083	each	_	
127-7	21084-21092	clinical	_	
127-8	21093-21098	group	_	
127-9	21098-21099	,	_	
127-10	21100-21112	highlighting	_	
127-11	21113-21116	the	_	
127-12	21117-21126	relevance	_	
127-13	21127-21129	of	_	
127-14	21130-21135	these	_	
127-15	21136-21149	abnormalities	_	
127-16	21150-21156	across	_	
127-17	21157-21167	diagnostic	_	
127-18	21168-21178	categories	_	
127-19	21178-21179	.	_	

#Text=Though speculative, DMN hyper-connectivity and diminished DMN connectivity with the CON may represent a deficit in network integration necessary for reward responsiveness.
128-1	21180-21186	Though	_	
128-2	21187-21198	speculative	_	
128-3	21198-21199	,	_	
128-4	21200-21203	DMN	_	
128-5	21204-21222	hyper-connectivity	_	
128-6	21223-21226	and	_	
128-7	21227-21237	diminished	_	
128-8	21238-21241	DMN	_	
128-9	21242-21254	connectivity	_	
128-10	21255-21259	with	_	
128-11	21260-21263	the	_	
128-12	21264-21267	CON	_	
128-13	21268-21271	may	_	
128-14	21272-21281	represent	_	
128-15	21282-21283	a	_	
128-16	21284-21291	deficit	_	
128-17	21292-21294	in	_	
128-18	21295-21302	network	_	
128-19	21303-21314	integration	_	
128-20	21315-21324	necessary	_	
128-21	21325-21328	for	_	
128-22	21329-21335	reward	_	
128-23	21336-21350	responsiveness	_	
128-24	21350-21351	.	_	

#Text=Symptoms of anhedonia may also be associated with increased rumination and ineffective transitioning from internal to external modes of cognition.
129-1	21352-21360	Symptoms	_	
129-2	21361-21363	of	_	
129-3	21364-21373	anhedonia	_	
129-4	21374-21377	may	_	
129-5	21378-21382	also	_	
129-6	21383-21385	be	_	
129-7	21386-21396	associated	_	
129-8	21397-21401	with	_	
129-9	21402-21411	increased	_	
129-10	21412-21422	rumination	_	
129-11	21423-21426	and	_	
129-12	21427-21438	ineffective	_	
129-13	21439-21452	transitioning	_	
129-14	21453-21457	from	_	
129-15	21458-21466	internal	_	
129-16	21467-21469	to	_	
129-17	21470-21478	external	_	
129-18	21479-21484	modes	_	
129-19	21485-21487	of	_	
129-20	21488-21497	cognition	_	
129-21	21497-21498	.	_	

#Text=Reduced connectivity between NAc and a DMN subsystem is associated with reward deficits
#Text=Corticostriatal abnormalities involving the NAc have been reported in diverse psychiatric disorders.
130-1	21499-21506	Reduced	_	
130-2	21507-21519	connectivity	_	
130-3	21520-21527	between	_	
130-4	21528-21531	NAc	_	
130-5	21532-21535	and	_	
130-6	21536-21537	a	_	
130-7	21538-21541	DMN	_	
130-8	21542-21551	subsystem	_	
130-9	21552-21554	is	_	
130-10	21555-21565	associated	_	
130-11	21566-21570	with	_	
130-12	21571-21577	reward	_	
130-13	21578-21586	deficits	_	
130-14	21587-21602	Corticostriatal	_	
130-15	21603-21616	abnormalities	_	
130-16	21617-21626	involving	_	
130-17	21627-21630	the	_	
130-18	21631-21634	NAc	_	
130-19	21635-21639	have	_	
130-20	21640-21644	been	_	
130-21	21645-21653	reported	_	
130-22	21654-21656	in	_	
130-23	21657-21664	diverse	_	
130-24	21665-21676	psychiatric	_	
130-25	21677-21686	disorders	_	
130-26	21686-21687	.	_	

#Text=In our study, reward deficits were related to dissociable patterns of NAc dysconnectivity, including decreased connectivity between the NAc and DMN and increased connectivity between NAc and CON.
131-1	21688-21690	In	_	
131-2	21691-21694	our	_	
131-3	21695-21700	study	_	
131-4	21700-21701	,	_	
131-5	21702-21708	reward	_	
131-6	21709-21717	deficits	_	
131-7	21718-21722	were	_	
131-8	21723-21730	related	_	
131-9	21731-21733	to	_	
131-10	21734-21745	dissociable	_	
131-11	21746-21754	patterns	_	
131-12	21755-21757	of	_	
131-13	21758-21761	NAc	_	
131-14	21762-21777	dysconnectivity	_	
131-15	21777-21778	,	_	
131-16	21779-21788	including	_	
131-17	21789-21798	decreased	_	
131-18	21799-21811	connectivity	_	
131-19	21812-21819	between	_	
131-20	21820-21823	the	_	
131-21	21824-21827	NAc	_	
131-22	21828-21831	and	_	
131-23	21832-21835	DMN	_	
131-24	21836-21839	and	_	
131-25	21840-21849	increased	_	
131-26	21850-21862	connectivity	_	
131-27	21863-21870	between	_	
131-28	21871-21874	NAc	_	
131-29	21875-21878	and	_	
131-30	21879-21882	CON	_	
131-31	21882-21883	.	_	

#Text=Together, these findings implicate a pattern of dysconnectivity between the NAc and major functional networks where dysconnectivity has commonly been reported in both mood and psychotic disorders.
132-1	21884-21892	Together	_	
132-2	21892-21893	,	_	
132-3	21894-21899	these	_	
132-4	21900-21908	findings	_	
132-5	21909-21918	implicate	_	
132-6	21919-21920	a	_	
132-7	21921-21928	pattern	_	
132-8	21929-21931	of	_	
132-9	21932-21947	dysconnectivity	_	
132-10	21948-21955	between	_	
132-11	21956-21959	the	_	
132-12	21960-21963	NAc	_	
132-13	21964-21967	and	_	
132-14	21968-21973	major	_	
132-15	21974-21984	functional	_	
132-16	21985-21993	networks	_	
132-17	21994-21999	where	_	
132-18	22000-22015	dysconnectivity	_	
132-19	22016-22019	has	_	
132-20	22020-22028	commonly	_	
132-21	22029-22033	been	_	
132-22	22034-22042	reported	_	
132-23	22043-22045	in	_	
132-24	22046-22050	both	_	
132-25	22051-22055	mood	_	
132-26	22056-22059	and	_	
132-27	22060-22069	psychotic	_	
132-28	22070-22079	disorders	_	
132-29	22079-22080	.	_	

#Text=Of note, these effects were consistent for subjects with MDD, BPD, SCZ, and psychosis risk groups.
133-1	22081-22083	Of	_	
133-2	22084-22088	note	_	
133-3	22088-22089	,	_	
133-4	22090-22095	these	_	
133-5	22096-22103	effects	_	
133-6	22104-22108	were	_	
133-7	22109-22119	consistent	_	
133-8	22120-22123	for	_	
133-9	22124-22132	subjects	_	
133-10	22133-22137	with	_	
133-11	22138-22141	MDD	_	
133-12	22141-22142	,	_	
133-13	22143-22146	BPD	_	
133-14	22146-22147	,	_	
133-15	22148-22151	SCZ	_	
133-16	22151-22152	,	_	
133-17	22153-22156	and	_	
133-18	22157-22166	psychosis	_	
133-19	22167-22171	risk	_	
133-20	22172-22178	groups	_	
133-21	22178-22179	.	_	

#Text=This raises the interesting possibility that NAc dysconnectivity is associated with reward responsiveness deficits, regardless of the clinical diagnostic category.
134-1	22180-22184	This	_	
134-2	22185-22191	raises	_	
134-3	22192-22195	the	_	
134-4	22196-22207	interesting	_	
134-5	22208-22219	possibility	_	
134-6	22220-22224	that	_	
134-7	22225-22228	NAc	_	
134-8	22229-22244	dysconnectivity	_	
134-9	22245-22247	is	_	
134-10	22248-22258	associated	_	
134-11	22259-22263	with	_	
134-12	22264-22270	reward	_	
134-13	22271-22285	responsiveness	_	
134-14	22286-22294	deficits	_	
134-15	22294-22295	,	_	
134-16	22296-22306	regardless	_	
134-17	22307-22309	of	_	
134-18	22310-22313	the	_	
134-19	22314-22322	clinical	_	
134-20	22323-22333	diagnostic	_	
134-21	22334-22342	category	_	
134-22	22342-22343	.	_	

#Text=Diminished integration between the NAc and the DMN may reflect a brain phenotype corresponding to impairments in reward-oriented internal cognition.
135-1	22344-22354	Diminished	_	
135-2	22355-22366	integration	_	
135-3	22367-22374	between	_	
135-4	22375-22378	the	_	
135-5	22379-22382	NAc	_	
135-6	22383-22386	and	_	
135-7	22387-22390	the	_	
135-8	22391-22394	DMN	_	
135-9	22395-22398	may	_	
135-10	22399-22406	reflect	_	
135-11	22407-22408	a	_	
135-12	22409-22414	brain	_	
135-13	22415-22424	phenotype	_	
135-14	22425-22438	corresponding	_	
135-15	22439-22441	to	_	
135-16	22442-22453	impairments	_	
135-17	22454-22456	in	_	
135-18	22457-22472	reward-oriented	_	
135-19	22473-22481	internal	_	
135-20	22482-22491	cognition	_	
135-21	22491-22492	.	_	

#Text=Increased integration seen between the NAc and the CON may relate to elevated cognitive control on reward system activity.
136-1	22493-22502	Increased	_	
136-2	22503-22514	integration	_	
136-3	22515-22519	seen	_	
136-4	22520-22527	between	_	
136-5	22528-22531	the	_	
136-6	22532-22535	NAc	_	
136-7	22536-22539	and	_	
136-8	22540-22543	the	_	
136-9	22544-22547	CON	_	
136-10	22548-22551	may	_	
136-11	22552-22558	relate	_	
136-12	22559-22561	to	_	
136-13	22562-22570	elevated	_	
136-14	22571-22580	cognitive	_	
136-15	22581-22588	control	_	
136-16	22589-22591	on	_	
136-17	22592-22598	reward	_	
136-18	22599-22605	system	_	
136-19	22606-22614	activity	_	
136-20	22614-22615	.	_	

#Text=Strengths and limitations of examining dimensions in heterogeneous populations
#Text=Establishing common patterns of brain dysconnectivity across clinical diagnostic category is a central aim of the NIMH RDoC.
137-1	22616-22625	Strengths	_	
137-2	22626-22629	and	_	
137-3	22630-22641	limitations	_	
137-4	22642-22644	of	_	
137-5	22645-22654	examining	_	
137-6	22655-22665	dimensions	_	
137-7	22666-22668	in	_	
137-8	22669-22682	heterogeneous	_	
137-9	22683-22694	populations	_	
137-10	22695-22707	Establishing	_	
137-11	22708-22714	common	_	
137-12	22715-22723	patterns	_	
137-13	22724-22726	of	_	
137-14	22727-22732	brain	_	
137-15	22733-22748	dysconnectivity	_	
137-16	22749-22755	across	_	
137-17	22756-22764	clinical	_	
137-18	22765-22775	diagnostic	_	
137-19	22776-22784	category	_	
137-20	22785-22787	is	_	
137-21	22788-22789	a	_	
137-22	22790-22797	central	_	
137-23	22798-22801	aim	_	
137-24	22802-22804	of	_	
137-25	22805-22808	the	_	
137-26	22809-22813	NIMH	_	
137-27	22814-22818	RDoC	_	
137-28	22818-22819	.	_	

#Text=In the present study, inclusion of a heterogeneous population of adults with diverse psychopathology allowed identification of common dimensional patterns of dysconnectivity related to reward functioning.
138-1	22820-22822	In	_	
138-2	22823-22826	the	_	
138-3	22827-22834	present	_	
138-4	22835-22840	study	_	
138-5	22840-22841	,	_	
138-6	22842-22851	inclusion	_	
138-7	22852-22854	of	_	
138-8	22855-22856	a	_	
138-9	22857-22870	heterogeneous	_	
138-10	22871-22881	population	_	
138-11	22882-22884	of	_	
138-12	22885-22891	adults	_	
138-13	22892-22896	with	_	
138-14	22897-22904	diverse	_	
138-15	22905-22920	psychopathology	_	
138-16	22921-22928	allowed	_	
138-17	22929-22943	identification	_	
138-18	22944-22946	of	_	
138-19	22947-22953	common	_	
138-20	22954-22965	dimensional	_	
138-21	22966-22974	patterns	_	
138-22	22975-22977	of	_	
138-23	22978-22993	dysconnectivity	_	
138-24	22994-23001	related	_	
138-25	23002-23004	to	_	
138-26	23005-23011	reward	_	
138-27	23012-23023	functioning	_	
138-28	23023-23024	.	_	

#Text=However, certain limitations of our approach should be noted.
139-1	23025-23032	However	_	
139-2	23032-23033	,	_	
139-3	23034-23041	certain	_	
139-4	23042-23053	limitations	_	
139-5	23054-23056	of	_	
139-6	23057-23060	our	_	
139-7	23061-23069	approach	_	
139-8	23070-23076	should	_	
139-9	23077-23079	be	_	
139-10	23080-23085	noted	_	
139-11	23085-23086	.	_	

#Text=First, the cross-sectional analyses here do not allow determination of causation or the temporal pattern of changes.
140-1	23087-23092	First	_	
140-2	23092-23093	,	_	
140-3	23094-23097	the	_	
140-4	23098-23113	cross-sectional	_	
140-5	23114-23122	analyses	_	
140-6	23123-23127	here	_	
140-7	23128-23130	do	_	
140-8	23131-23134	not	_	
140-9	23135-23140	allow	_	
140-10	23141-23154	determination	_	
140-11	23155-23157	of	_	
140-12	23158-23167	causation	_	
140-13	23168-23170	or	_	
140-14	23171-23174	the	_	
140-15	23175-23183	temporal	_	
140-16	23184-23191	pattern	_	
140-17	23192-23194	of	_	
140-18	23195-23202	changes	_	
140-19	23202-23203	.	_	

#Text=Second, evaluating whole-brain connectivity using MDMR may have decreased sensitivity to localized patterns of dysconnectivity related to reward functioning.
141-1	23204-23210	Second	_	
141-2	23210-23211	,	_	
141-3	23212-23222	evaluating	_	
141-4	23223-23234	whole-brain	_	
141-5	23235-23247	connectivity	_	
141-6	23248-23253	using	_	
141-7	23254-23258	MDMR	_	
141-8	23259-23262	may	_	
141-9	23263-23267	have	_	
141-10	23268-23277	decreased	_	
141-11	23278-23289	sensitivity	_	
141-12	23290-23292	to	_	
141-13	23293-23302	localized	_	
141-14	23303-23311	patterns	_	
141-15	23312-23314	of	_	
141-16	23315-23330	dysconnectivity	_	
141-17	23331-23338	related	_	
141-18	23339-23341	to	_	
141-19	23342-23348	reward	_	
141-20	23349-23360	functioning	_	
141-21	23360-23361	.	_	

#Text=While comparisons of different MDMR distance measures have generally yielded similar findings, it remains unclear whether there is an optimal metric depending on the question of interest.
142-1	23362-23367	While	_	
142-2	23368-23379	comparisons	_	
142-3	23380-23382	of	_	
142-4	23383-23392	different	_	
142-5	23393-23397	MDMR	_	
142-6	23398-23406	distance	_	
142-7	23407-23415	measures	_	
142-8	23416-23420	have	_	
142-9	23421-23430	generally	_	
142-10	23431-23438	yielded	_	
142-11	23439-23446	similar	_	
142-12	23447-23455	findings	_	
142-13	23455-23456	,	_	
142-14	23457-23459	it	_	
142-15	23460-23467	remains	_	
142-16	23468-23475	unclear	_	
142-17	23476-23483	whether	_	
142-18	23484-23489	there	_	
142-19	23490-23492	is	_	
142-20	23493-23495	an	_	
142-21	23496-23503	optimal	_	
142-22	23504-23510	metric	_	
142-23	23511-23520	depending	_	
142-24	23521-23523	on	_	
142-25	23524-23527	the	_	
142-26	23528-23536	question	_	
142-27	23537-23539	of	_	
142-28	23540-23548	interest	_	
142-29	23548-23549	.	_	

#Text=Third, while this study characterizes anhedonia in terms of diminished self-reported reward responsivity, this may be distinct from other elements of anhedonia, including reward anticipation, effort and satiety.
143-1	23550-23555	Third	_	
143-2	23555-23556	,	_	
143-3	23557-23562	while	_	
143-4	23563-23567	this	_	
143-5	23568-23573	study	_	
143-6	23574-23587	characterizes	_	
143-7	23588-23597	anhedonia	_	
143-8	23598-23600	in	_	
143-9	23601-23606	terms	_	
143-10	23607-23609	of	_	
143-11	23610-23620	diminished	_	
143-12	23621-23634	self-reported	_	
143-13	23635-23641	reward	_	
143-14	23642-23654	responsivity	_	
143-15	23654-23655	,	_	
143-16	23656-23660	this	_	
143-17	23661-23664	may	_	
143-18	23665-23667	be	_	
143-19	23668-23676	distinct	_	
143-20	23677-23681	from	_	
143-21	23682-23687	other	_	
143-22	23688-23696	elements	_	
143-23	23697-23699	of	_	
143-24	23700-23709	anhedonia	_	
143-25	23709-23710	,	_	
143-26	23711-23720	including	_	
143-27	23721-23727	reward	_	
143-28	23728-23740	anticipation	_	
143-29	23740-23741	,	_	
143-30	23742-23748	effort	_	
143-31	23749-23752	and	_	
143-32	23753-23760	satiety	_	
143-33	23760-23761	.	_	

#Text=Fourth, while our findings suggest no significant impact of composite medication load upon neural activity and were similar for psychosis risk groups with few medicated subjects, future studies should confirm these findings in un-medicated populations.
144-1	23762-23768	Fourth	_	
144-2	23768-23769	,	_	
144-3	23770-23775	while	_	
144-4	23776-23779	our	_	
144-5	23780-23788	findings	_	
144-6	23789-23796	suggest	_	
144-7	23797-23799	no	_	
144-8	23800-23811	significant	_	
144-9	23812-23818	impact	_	
144-10	23819-23821	of	_	
144-11	23822-23831	composite	_	
144-12	23832-23842	medication	_	
144-13	23843-23847	load	_	
144-14	23848-23852	upon	_	
144-15	23853-23859	neural	_	
144-16	23860-23868	activity	_	
144-17	23869-23872	and	_	
144-18	23873-23877	were	_	
144-19	23878-23885	similar	_	
144-20	23886-23889	for	_	
144-21	23890-23899	psychosis	_	
144-22	23900-23904	risk	_	
144-23	23905-23911	groups	_	
144-24	23912-23916	with	_	
144-25	23917-23920	few	_	
144-26	23921-23930	medicated	_	
144-27	23931-23939	subjects	_	
144-28	23939-23940	,	_	
144-29	23941-23947	future	_	
144-30	23948-23955	studies	_	
144-31	23956-23962	should	_	
144-32	23963-23970	confirm	_	
144-33	23971-23976	these	_	
144-34	23977-23985	findings	_	
144-35	23986-23988	in	_	
144-36	23989-24001	un-medicated	_	
144-37	24002-24013	populations	_	
144-38	24013-24014	.	_	

#Text=Finally, the dimensional analysis of a heterogeneous sample may not identify important disorder-specific brain phenotypes related to reward dysfunction, and results may not extend to other psychiatric disorders with reward dysfunction, such as addiction and ADHD.
145-1	24015-24022	Finally	_	
145-2	24022-24023	,	_	
145-3	24024-24027	the	_	
145-4	24028-24039	dimensional	_	
145-5	24040-24048	analysis	_	
145-6	24049-24051	of	_	
145-7	24052-24053	a	_	
145-8	24054-24067	heterogeneous	_	
145-9	24068-24074	sample	_	
145-10	24075-24078	may	_	
145-11	24079-24082	not	_	
145-12	24083-24091	identify	_	
145-13	24092-24101	important	_	
145-14	24102-24119	disorder-specific	_	
145-15	24120-24125	brain	_	
145-16	24126-24136	phenotypes	_	
145-17	24137-24144	related	_	
145-18	24145-24147	to	_	
145-19	24148-24154	reward	_	
145-20	24155-24166	dysfunction	_	
145-21	24166-24167	,	_	
145-22	24168-24171	and	_	
145-23	24172-24179	results	_	
145-24	24180-24183	may	_	
145-25	24184-24187	not	_	
145-26	24188-24194	extend	_	
145-27	24195-24197	to	_	
145-28	24198-24203	other	_	
145-29	24204-24215	psychiatric	_	
145-30	24216-24225	disorders	_	
145-31	24226-24230	with	_	
145-32	24231-24237	reward	_	
145-33	24238-24249	dysfunction	_	
145-34	24249-24250	,	_	
145-35	24251-24255	such	_	
145-36	24256-24258	as	_	
145-37	24259-24268	addiction	_	
145-38	24269-24272	and	_	
145-39	24273-24277	ADHD	_	
145-40	24277-24278	.	_	

#Text=Consideration of Findings Within the Framework of Traditional Diagnostic Categories
#Text=Neuroimaging studies in different psychiatric disorders have previously reported corticostriatal abnormalities involving the reward system.
146-1	24279-24292	Consideration	_	
146-2	24293-24295	of	_	
146-3	24296-24304	Findings	_	
146-4	24305-24311	Within	_	
146-5	24312-24315	the	_	
146-6	24316-24325	Framework	_	
146-7	24326-24328	of	_	
146-8	24329-24340	Traditional	_	
146-9	24341-24351	Diagnostic	_	
146-10	24352-24362	Categories	_	
146-11	24363-24375	Neuroimaging	_	
146-12	24376-24383	studies	_	
146-13	24384-24386	in	_	
146-14	24387-24396	different	_	
146-15	24397-24408	psychiatric	_	
146-16	24409-24418	disorders	_	
146-17	24419-24423	have	_	
146-18	24424-24434	previously	_	
146-19	24435-24443	reported	_	
146-20	24444-24459	corticostriatal	_	
146-21	24460-24473	abnormalities	_	
146-22	24474-24483	involving	_	
146-23	24484-24487	the	_	
146-24	24488-24494	reward	_	
146-25	24495-24501	system	_	
146-26	24501-24502	.	_	

#Text=In our study, dissociable patterns of dysconnectivity among large-scale cortical networks and the NAc were identified across the dimension of reward responsiveness.
147-1	24503-24505	In	_	
147-2	24506-24509	our	_	
147-3	24510-24515	study	_	
147-4	24515-24516	,	_	
147-5	24517-24528	dissociable	_	
147-6	24529-24537	patterns	_	
147-7	24538-24540	of	_	
147-8	24541-24556	dysconnectivity	_	
147-9	24557-24562	among	_	
147-10	24563-24574	large-scale	_	
147-11	24575-24583	cortical	_	
147-12	24584-24592	networks	_	
147-13	24593-24596	and	_	
147-14	24597-24600	the	_	
147-15	24601-24604	NAc	_	
147-16	24605-24609	were	_	
147-17	24610-24620	identified	_	
147-18	24621-24627	across	_	
147-19	24628-24631	the	_	
147-20	24632-24641	dimension	_	
147-21	24642-24644	of	_	
147-22	24645-24651	reward	_	
147-23	24652-24666	responsiveness	_	
147-24	24666-24667	.	_	

#Text=These neurobiological patterns were found in subjects with both mood and psychotic disorders.
148-1	24668-24673	These	_	
148-2	24674-24689	neurobiological	_	
148-3	24690-24698	patterns	_	
148-4	24699-24703	were	_	
148-5	24704-24709	found	_	
148-6	24710-24712	in	_	
148-7	24713-24721	subjects	_	
148-8	24722-24726	with	_	
148-9	24727-24731	both	_	
148-10	24732-24736	mood	_	
148-11	24737-24740	and	_	
148-12	24741-24750	psychotic	_	
148-13	24751-24760	disorders	_	
148-14	24760-24761	.	_	

#Text=This suggests common pathophysiological mechanisms may underlie the development of anhedonia in different psychiatric disorders.
149-1	24762-24766	This	_	
149-2	24767-24775	suggests	_	
149-3	24776-24782	common	_	
149-4	24783-24801	pathophysiological	_	
149-5	24802-24812	mechanisms	_	
149-6	24813-24816	may	_	
149-7	24817-24825	underlie	_	
149-8	24826-24829	the	_	
149-9	24830-24841	development	_	
149-10	24842-24844	of	_	
149-11	24845-24854	anhedonia	_	
149-12	24855-24857	in	_	
149-13	24858-24867	different	_	
149-14	24868-24879	psychiatric	_	
149-15	24880-24889	disorders	_	
149-16	24889-24890	.	_	

#Text=However, distinct pathological mechanisms have also been shown to underlie aspects of anhedonia seen in these disorders.
150-1	24891-24898	However	_	
150-2	24898-24899	,	_	
150-3	24900-24908	distinct	_	
150-4	24909-24921	pathological	_	
150-5	24922-24932	mechanisms	_	
150-6	24933-24937	have	_	
150-7	24938-24942	also	_	
150-8	24943-24947	been	_	
150-9	24948-24953	shown	_	
150-10	24954-24956	to	_	
150-11	24957-24965	underlie	_	
150-12	24966-24973	aspects	_	
150-13	24974-24976	of	_	
150-14	24977-24986	anhedonia	_	
150-15	24987-24991	seen	_	
150-16	24992-24994	in	_	
150-17	24995-25000	these	_	
150-18	25001-25010	disorders	_	
150-19	25010-25011	.	_	

#Text=Consequently, a focus on the etiologic and neurodevelopmental aspects of reward-related dysfunction is needed to clarify common and dissociable mechanisms.
151-1	25012-25024	Consequently	_	
151-2	25024-25025	,	_	
151-3	25026-25027	a	_	
151-4	25028-25033	focus	_	
151-5	25034-25036	on	_	
151-6	25037-25040	the	_	
151-7	25041-25050	etiologic	_	
151-8	25051-25054	and	_	
151-9	25055-25073	neurodevelopmental	_	
151-10	25074-25081	aspects	_	
151-11	25082-25084	of	_	
151-12	25085-25099	reward-related	_	
151-13	25100-25111	dysfunction	_	
151-14	25112-25114	is	_	
151-15	25115-25121	needed	_	
151-16	25122-25124	to	_	
151-17	25125-25132	clarify	_	
151-18	25133-25139	common	_	
151-19	25140-25143	and	_	
151-20	25144-25155	dissociable	_	
151-21	25156-25166	mechanisms	_	
151-22	25166-25167	.	_	

#Text=This will be important for developing interventions that target shared and unique processes underlying anhedonia in these disorders.
152-1	25168-25172	This	_	
152-2	25173-25177	will	_	
152-3	25178-25180	be	_	
152-4	25181-25190	important	_	
152-5	25191-25194	for	_	
152-6	25195-25205	developing	_	
152-7	25206-25219	interventions	_	
152-8	25220-25224	that	_	
152-9	25225-25231	target	_	
152-10	25232-25238	shared	_	
152-11	25239-25242	and	_	
152-12	25243-25249	unique	_	
152-13	25250-25259	processes	_	
152-14	25260-25270	underlying	_	
152-15	25271-25280	anhedonia	_	
152-16	25281-25283	in	_	
152-17	25284-25289	these	_	
152-18	25290-25299	disorders	_	
152-19	25299-25300	.	_	

#Text=Conclusions
#Text=In summary, the present data corroborates prior research using case-control designs, and emphasizes that corticostriatal dysconnectivity is implicated in reward-related abnormalities across clinical diagnostic categories and those at risk for these disorders.
153-1	25301-25312	Conclusions	_	
153-2	25313-25315	In	_	
153-3	25316-25323	summary	_	
153-4	25323-25324	,	_	
153-5	25325-25328	the	_	
153-6	25329-25336	present	_	
153-7	25337-25341	data	_	
153-8	25342-25354	corroborates	_	
153-9	25355-25360	prior	_	
153-10	25361-25369	research	_	
153-11	25370-25375	using	_	
153-12	25376-25388	case-control	_	
153-13	25389-25396	designs	_	
153-14	25396-25397	,	_	
153-15	25398-25401	and	_	
153-16	25402-25412	emphasizes	_	
153-17	25413-25417	that	_	
153-18	25418-25433	corticostriatal	_	
153-19	25434-25449	dysconnectivity	_	
153-20	25450-25452	is	_	
153-21	25453-25463	implicated	_	
153-22	25464-25466	in	_	
153-23	25467-25481	reward-related	_	
153-24	25482-25495	abnormalities	_	
153-25	25496-25502	across	_	
153-26	25503-25511	clinical	_	
153-27	25512-25522	diagnostic	_	
153-28	25523-25533	categories	_	
153-29	25534-25537	and	_	
153-30	25538-25543	those	_	
153-31	25544-25546	at	_	
153-32	25547-25551	risk	_	
153-33	25552-25555	for	_	
153-34	25556-25561	these	_	
153-35	25562-25571	disorders	_	
153-36	25571-25572	.	_	

#Text=Specifically, common abnormalities among large-scale cortical networks and the NAc may underlie reward deficits.
154-1	25573-25585	Specifically	_	
154-2	25585-25586	,	_	
154-3	25587-25593	common	_	
154-4	25594-25607	abnormalities	_	
154-5	25608-25613	among	_	
154-6	25614-25625	large-scale	_	
154-7	25626-25634	cortical	_	
154-8	25635-25643	networks	_	
154-9	25644-25647	and	_	
154-10	25648-25651	the	_	
154-11	25652-25655	NAc	_	
154-12	25656-25659	may	_	
154-13	25660-25668	underlie	_	
154-14	25669-25675	reward	_	
154-15	25676-25684	deficits	_	
154-16	25684-25685	.	_	

#Text=These results suggest that development of interventions to treat anhedonia in different psychiatric disorders may effectively target shared neural abnormalities in critical functional networks.
155-1	25686-25691	These	_	
155-2	25692-25699	results	_	
155-3	25700-25707	suggest	_	
155-4	25708-25712	that	_	
155-5	25713-25724	development	_	
155-6	25725-25727	of	_	
155-7	25728-25741	interventions	_	
155-8	25742-25744	to	_	
155-9	25745-25750	treat	_	
155-10	25751-25760	anhedonia	_	
155-11	25761-25763	in	_	
155-12	25764-25773	different	_	
155-13	25774-25785	psychiatric	_	
155-14	25786-25795	disorders	_	
155-15	25796-25799	may	_	
155-16	25800-25811	effectively	_	
155-17	25812-25818	target	_	
155-18	25819-25825	shared	_	
155-19	25826-25832	neural	_	
155-20	25833-25846	abnormalities	_	
155-21	25847-25849	in	_	
155-22	25850-25858	critical	_	
155-23	25859-25869	functional	_	
155-24	25870-25878	networks	_	
155-25	25878-25879	.	_	

#Text=Future research employing longitudinal designs may allow for evaluation of early interventions that promote resilience against shared reward-related psychopathology prior to the development of disabling symptoms.
156-1	25880-25886	Future	_	
156-2	25887-25895	research	_	
156-3	25896-25905	employing	_	
156-4	25906-25918	longitudinal	_	
156-5	25919-25926	designs	_	
156-6	25927-25930	may	_	
156-7	25931-25936	allow	_	
156-8	25937-25940	for	_	
156-9	25941-25951	evaluation	_	
156-10	25952-25954	of	_	
156-11	25955-25960	early	_	
156-12	25961-25974	interventions	_	
156-13	25975-25979	that	_	
156-14	25980-25987	promote	_	
156-15	25988-25998	resilience	_	
156-16	25999-26006	against	_	
156-17	26007-26013	shared	_	
156-18	26014-26028	reward-related	_	
156-19	26029-26044	psychopathology	_	
156-20	26045-26050	prior	_	
156-21	26051-26053	to	_	
156-22	26054-26057	the	_	
156-23	26058-26069	development	_	
156-24	26070-26072	of	_	
156-25	26073-26082	disabling	_	
156-26	26083-26091	symptoms	_	
156-27	26091-26092	.	_	

#Text=Supplementary Material
#Text=Previous Presentation: Presented at the 2016 annual meeting of the Society of Biological Psychiatry.
157-1	26093-26106	Supplementary	_	
157-2	26107-26115	Material	_	
157-3	26116-26124	Previous	_	
157-4	26125-26137	Presentation	_	
157-5	26137-26138	:	_	
157-6	26139-26148	Presented	_	
157-7	26149-26151	at	_	
157-8	26152-26155	the	_	
157-9	26156-26160	2016	_	
157-10	26161-26167	annual	_	
157-11	26168-26175	meeting	_	
157-12	26176-26178	of	_	
157-13	26179-26182	the	_	
157-14	26183-26190	Society	_	
157-15	26191-26193	of	_	
157-16	26194-26204	Biological	_	
157-17	26205-26215	Psychiatry	_	
157-18	26215-26216	.	_	

#Text=Atlanta, Georgia.
158-1	26217-26224	Atlanta	_	
158-2	26224-26225	,	_	
158-3	26226-26233	Georgia	_	
158-4	26233-26234	.	_	

#Text=May 12-15, 2016.
159-1	26235-26238	May	_	
159-2	26239-26241	12	_	
159-3	26241-26242	-	_	
159-4	26242-26244	15	_	
159-5	26244-26245	,	_	
159-6	26246-26250	2016	_	
159-7	26250-26251	.	_	

#Text=Location of work and address for reprints: From the Departments of Psychiatry, Psychology, Biostatistics and Epidemiology, Radiology, Bioengineering; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
160-1	26252-26260	Location	_	
160-2	26261-26263	of	_	
160-3	26264-26268	work	_	
160-4	26269-26272	and	_	
160-5	26273-26280	address	_	
160-6	26281-26284	for	_	
160-7	26285-26293	reprints	_	
160-8	26293-26294	:	_	
160-9	26295-26299	From	_	
160-10	26300-26303	the	_	
160-11	26304-26315	Departments	_	
160-12	26316-26318	of	_	
160-13	26319-26329	Psychiatry	_	
160-14	26329-26330	,	_	
160-15	26331-26341	Psychology	_	
160-16	26341-26342	,	_	
160-17	26343-26356	Biostatistics	_	
160-18	26357-26360	and	_	
160-19	26361-26373	Epidemiology	_	
160-20	26373-26374	,	_	
160-21	26375-26384	Radiology	_	
160-22	26384-26385	,	_	
160-23	26386-26400	Bioengineering	_	
160-24	26400-26401	;	_	
160-25	26402-26410	Perelman	_	
160-26	26411-26417	School	_	
160-27	26418-26420	of	_	
160-28	26421-26429	Medicine	_	
160-29	26429-26430	,	_	
160-30	26431-26441	University	_	
160-31	26442-26444	of	_	
160-32	26445-26457	Pennsylvania	_	
160-33	26457-26458	,	_	
160-34	26459-26471	Philadelphia	_	
160-35	26471-26472	,	_	
160-36	26473-26475	PA	_	
160-37	26475-26476	.	_	

#Text=Disclosures: Dr.
161-1	26477-26488	Disclosures	_	
161-2	26488-26489	:	_	
161-3	26490-26492	Dr	_	
161-4	26492-26493	.	_	

#Text=Shinohara has received consulting fees from Hoffman-La Roche.
162-1	26494-26503	Shinohara	_	
162-2	26504-26507	has	_	
162-3	26508-26516	received	_	
162-4	26517-26527	consulting	_	
162-5	26528-26532	fees	_	
162-6	26533-26537	from	_	
162-7	26538-26548	Hoffman-La	_	
162-8	26549-26554	Roche	_	
162-9	26554-26555	.	_	

#Text=All others report no financial relationships with commercial interests.
163-1	26556-26559	All	_	
163-2	26560-26566	others	_	
163-3	26567-26573	report	_	
163-4	26574-26576	no	_	
163-5	26577-26586	financial	_	
163-6	26587-26600	relationships	_	
163-7	26601-26605	with	_	
163-8	26606-26616	commercial	_	
163-9	26617-26626	interests	_	
163-10	26626-26627	.	_	

#Text=Long-term morbidity in bipolar-i, bipolar-ii, and unipolar major depressive disorders
#Text=Anhedonia in schizophrenia
#Text=Research domain criteria (rdoc): Toward a new classification framework for research on mental disorders
#Text=The valuation system: A coordinate-based meta-analysis of BOLD fmri experiments examining neural correlates of subjective value
#Text=Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder
#Text=Common and dissociable dysfunction of the reward system in bipolar and unipolar depression
#Text=Amotivation in schizophrenia: Integrated assessment with behavioral, clinical, and imaging measures
#Text=Striatal response to reward anticipation: Evidence for a systems-level intermediate phenotype for schizophrenia
#Text=Reduction in ventral striatal activity when anticipating a reward in depression and schizophrenia: A replicated cross-diagnostic finding
#Text=Dimensional psychiatry: Reward dysfunction and depressive mood across psychiatric disorders
#Text=Diminished effort on a progressive ratio task in both unipolar and bipolar depression
#Text=A systematic literature review of resting state network-functional MRI in bipolar disorder
#Text=Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia
#Text=A critical appraisal of neuroimaging studies of bipolar disorder: Toward a new conceptualization of underlying neural circuitry and a road map for future research
#Text=Altered corticostriatal functional connectivity in individuals with high social anhedonia
#Text=A multivariate distance-based analytic framework for connectome-wide association studies
#Text=
#Text=Behavioral inhibition, behavioral activation, and affective responses to impending reward and punishment: The BIS/BAS scales
#Text=Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure
#Text=An improved framework for confound regression and filtering for control of motion artifact in the preprocessing of resting-state functional connectivity data
#Text=Impact of in-scanner head motion on multiple measures of functional connectivity: relevance for studies of neurodevelopment in youth
#Text=AFNI: Software for analysis and visualization of functional magnetic resonance neuroimages
#Text=An integrated software suite for surface-based analyses of cerebral cortex
#Text=Dimensional depression severity in women with major depression and post-traumatic stress disorder correlates with fronto-amygdalar hypoconnectivity
#Text=Connectome-wide network analysis of youth with Psychosis-Spectrum symptoms
#Text=Generation and evaluation of a cortical area parcellation from resting-state correlations
#Text=Emergence of system roles in normative neurodevelopment
#Text=Elevated striatal and decreased dorsolateral prefrontal cortical activity in response to emotional stimuli in euthymic bipolar disorder: no associations with psychotropic medication load
#Text=Default-mode and task-positive network activity in major depressive disorder: Implications for adaptive and maladaptive rumination
#Text=Aberrant default mode functional connectivity in early onset schizophrenia
#Text=Functional-Anatomic fractionation of the brains default network
#Text=Links among resting-state default-mode network, salience network, and symptomatology in schizophrenia
#Text=Frontal cortex and reward-guided learning and decision-making
#Text=Motivation and cognitive control: from behavior to neural mechanism
#Text=Assessing anhedonia in depression: Potentials and pitfalls
#Text=A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction
#Text=Reward processing dysfunction in major depression, bipolar disorder and schizophrenia
#Text=Connectome-wide analysis using multivariate distance-based matrix regression (MDMR).
164-1	26628-26637	Long-term	_	
164-2	26638-26647	morbidity	_	
164-3	26648-26650	in	_	
164-4	26651-26660	bipolar-i	_	
164-5	26660-26661	,	_	
164-6	26662-26672	bipolar-ii	_	
164-7	26672-26673	,	_	
164-8	26674-26677	and	_	
164-9	26678-26686	unipolar	_	
164-10	26687-26692	major	_	
164-11	26693-26703	depressive	_	
164-12	26704-26713	disorders	_	
164-13	26714-26723	Anhedonia	_	
164-14	26724-26726	in	_	
164-15	26727-26740	schizophrenia	_	
164-16	26741-26749	Research	_	
164-17	26750-26756	domain	_	
164-18	26757-26765	criteria	_	
164-19	26766-26767	(	_	
164-20	26767-26771	rdoc	_	
164-21	26771-26772	)	_	
164-22	26772-26773	:	_	
164-23	26774-26780	Toward	_	
164-24	26781-26782	a	_	
164-25	26783-26786	new	_	
164-26	26787-26801	classification	_	
164-27	26802-26811	framework	_	
164-28	26812-26815	for	_	
164-29	26816-26824	research	_	
164-30	26825-26827	on	_	
164-31	26828-26834	mental	_	
164-32	26835-26844	disorders	_	
164-33	26845-26848	The	_	
164-34	26849-26858	valuation	_	
164-35	26859-26865	system	_	
164-36	26865-26866	:	_	
164-37	26867-26868	A	_	
164-38	26869-26885	coordinate-based	_	
164-39	26886-26899	meta-analysis	_	
164-40	26900-26902	of	_	
164-41	26903-26907	BOLD	_	
164-42	26908-26912	fmri	_	
164-43	26913-26924	experiments	_	
164-44	26925-26934	examining	_	
164-45	26935-26941	neural	_	
164-46	26942-26952	correlates	_	
164-47	26953-26955	of	_	
164-48	26956-26966	subjective	_	
164-49	26967-26972	value	_	
164-50	26973-26980	Reduced	_	
164-51	26981-26988	caudate	_	
164-52	26989-26992	and	_	
164-53	26993-27000	nucleus	_	
164-54	27001-27010	accumbens	_	
164-55	27011-27019	response	_	
164-56	27020-27022	to	_	
164-57	27023-27030	rewards	_	
164-58	27031-27033	in	_	
164-59	27034-27045	unmedicated	_	
164-60	27046-27057	individuals	_	
164-61	27058-27062	with	_	
164-62	27063-27068	major	_	
164-63	27069-27079	depressive	_	
164-64	27080-27088	disorder	_	
164-65	27089-27095	Common	_	
164-66	27096-27099	and	_	
164-67	27100-27111	dissociable	_	
164-68	27112-27123	dysfunction	_	
164-69	27124-27126	of	_	
164-70	27127-27130	the	_	
164-71	27131-27137	reward	_	
164-72	27138-27144	system	_	
164-73	27145-27147	in	_	
164-74	27148-27155	bipolar	_	
164-75	27156-27159	and	_	
164-76	27160-27168	unipolar	_	
164-77	27169-27179	depression	_	
164-78	27180-27191	Amotivation	_	
164-79	27192-27194	in	_	
164-80	27195-27208	schizophrenia	_	
164-81	27208-27209	:	_	
164-82	27210-27220	Integrated	_	
164-83	27221-27231	assessment	_	
164-84	27232-27236	with	_	
164-85	27237-27247	behavioral	_	
164-86	27247-27248	,	_	
164-87	27249-27257	clinical	_	
164-88	27257-27258	,	_	
164-89	27259-27262	and	_	
164-90	27263-27270	imaging	_	
164-91	27271-27279	measures	_	
164-92	27280-27288	Striatal	_	
164-93	27289-27297	response	_	
164-94	27298-27300	to	_	
164-95	27301-27307	reward	_	
164-96	27308-27320	anticipation	_	
164-97	27320-27321	:	_	
164-98	27322-27330	Evidence	_	
164-99	27331-27334	for	_	
164-100	27335-27336	a	_	
164-101	27337-27350	systems-level	_	
164-102	27351-27363	intermediate	_	
164-103	27364-27373	phenotype	_	
164-104	27374-27377	for	_	
164-105	27378-27391	schizophrenia	_	
164-106	27392-27401	Reduction	_	
164-107	27402-27404	in	_	
164-108	27405-27412	ventral	_	
164-109	27413-27421	striatal	_	
164-110	27422-27430	activity	_	
164-111	27431-27435	when	_	
164-112	27436-27448	anticipating	_	
164-113	27449-27450	a	_	
164-114	27451-27457	reward	_	
164-115	27458-27460	in	_	
164-116	27461-27471	depression	_	
164-117	27472-27475	and	_	
164-118	27476-27489	schizophrenia	_	
164-119	27489-27490	:	_	
164-120	27491-27492	A	_	
164-121	27493-27503	replicated	_	
164-122	27504-27520	cross-diagnostic	_	
164-123	27521-27528	finding	_	
164-124	27529-27540	Dimensional	_	
164-125	27541-27551	psychiatry	_	
164-126	27551-27552	:	_	
164-127	27553-27559	Reward	_	
164-128	27560-27571	dysfunction	_	
164-129	27572-27575	and	_	
164-130	27576-27586	depressive	_	
164-131	27587-27591	mood	_	
164-132	27592-27598	across	_	
164-133	27599-27610	psychiatric	_	
164-134	27611-27620	disorders	_	
164-135	27621-27631	Diminished	_	
164-136	27632-27638	effort	_	
164-137	27639-27641	on	_	
164-138	27642-27643	a	_	
164-139	27644-27655	progressive	_	
164-140	27656-27661	ratio	_	
164-141	27662-27666	task	_	
164-142	27667-27669	in	_	
164-143	27670-27674	both	_	
164-144	27675-27683	unipolar	_	
164-145	27684-27687	and	_	
164-146	27688-27695	bipolar	_	
164-147	27696-27706	depression	_	
164-148	27707-27708	A	_	
164-149	27709-27719	systematic	_	
164-150	27720-27730	literature	_	
164-151	27731-27737	review	_	
164-152	27738-27740	of	_	
164-153	27741-27748	resting	_	
164-154	27749-27754	state	_	
164-155	27755-27773	network-functional	_	
164-156	27774-27777	MRI	_	
164-157	27778-27780	in	_	
164-158	27781-27788	bipolar	_	
164-159	27789-27797	disorder	_	
164-160	27798-27811	Hyperactivity	_	
164-161	27812-27815	and	_	
164-162	27816-27833	hyperconnectivity	_	
164-163	27834-27836	of	_	
164-164	27837-27840	the	_	
164-165	27841-27848	default	_	
164-166	27849-27856	network	_	
164-167	27857-27859	in	_	
164-168	27860-27873	schizophrenia	_	
164-169	27874-27877	and	_	
164-170	27878-27880	in	_	
164-171	27881-27893	first-degree	_	
164-172	27894-27903	relatives	_	
164-173	27904-27906	of	_	
164-174	27907-27914	persons	_	
164-175	27915-27919	with	_	
164-176	27920-27933	schizophrenia	_	
164-177	27934-27935	A	_	
164-178	27936-27944	critical	_	
164-179	27945-27954	appraisal	_	
164-180	27955-27957	of	_	
164-181	27958-27970	neuroimaging	_	
164-182	27971-27978	studies	_	
164-183	27979-27981	of	_	
164-184	27982-27989	bipolar	_	
164-185	27990-27998	disorder	_	
164-186	27998-27999	:	_	
164-187	28000-28006	Toward	_	
164-188	28007-28008	a	_	
164-189	28009-28012	new	_	
164-190	28013-28030	conceptualization	_	
164-191	28031-28033	of	_	
164-192	28034-28044	underlying	_	
164-193	28045-28051	neural	_	
164-194	28052-28061	circuitry	_	
164-195	28062-28065	and	_	
164-196	28066-28067	a	_	
164-197	28068-28072	road	_	
164-198	28073-28076	map	_	
164-199	28077-28080	for	_	
164-200	28081-28087	future	_	
164-201	28088-28096	research	_	
164-202	28097-28104	Altered	_	
164-203	28105-28120	corticostriatal	_	
164-204	28121-28131	functional	_	
164-205	28132-28144	connectivity	_	
164-206	28145-28147	in	_	
164-207	28148-28159	individuals	_	
164-208	28160-28164	with	_	
164-209	28165-28169	high	_	
164-210	28170-28176	social	_	
164-211	28177-28186	anhedonia	_	
164-212	28187-28188	A	_	
164-213	28189-28201	multivariate	_	
164-214	28202-28216	distance-based	_	
164-215	28217-28225	analytic	_	
164-216	28226-28235	framework	_	
164-217	28236-28239	for	_	
164-218	28240-28255	connectome-wide	_	
164-219	28256-28267	association	_	
164-220	28268-28275	studies	_	
164-221	28277-28287	Behavioral	_	
164-222	28288-28298	inhibition	_	
164-223	28298-28299	,	_	
164-224	28300-28310	behavioral	_	
164-225	28311-28321	activation	_	
164-226	28321-28322	,	_	
164-227	28323-28326	and	_	
164-228	28327-28336	affective	_	
164-229	28337-28346	responses	_	
164-230	28347-28349	to	_	
164-231	28350-28359	impending	_	
164-232	28360-28366	reward	_	
164-233	28367-28370	and	_	
164-234	28371-28381	punishment	_	
164-235	28381-28382	:	_	
164-236	28383-28386	The	_	
164-237	28387-28390	BIS	_	
164-238	28390-28391	/	_	
164-239	28391-28394	BAS	_	
164-240	28395-28401	scales	_	
164-241	28402-28411	Anhedonia	_	
164-242	28412-28414	in	_	
164-243	28415-28428	schizophrenia	_	
164-244	28428-28429	:	_	
164-245	28430-28442	distinctions	_	
164-246	28443-28450	between	_	
164-247	28451-28463	anticipatory	_	
164-248	28464-28467	and	_	
164-249	28468-28480	consummatory	_	
164-250	28481-28489	pleasure	_	
164-251	28490-28492	An	_	
164-252	28493-28501	improved	_	
164-253	28502-28511	framework	_	
164-254	28512-28515	for	_	
164-255	28516-28524	confound	_	
164-256	28525-28535	regression	_	
164-257	28536-28539	and	_	
164-258	28540-28549	filtering	_	
164-259	28550-28553	for	_	
164-260	28554-28561	control	_	
164-261	28562-28564	of	_	
164-262	28565-28571	motion	_	
164-263	28572-28580	artifact	_	
164-264	28581-28583	in	_	
164-265	28584-28587	the	_	
164-266	28588-28601	preprocessing	_	
164-267	28602-28604	of	_	
164-268	28605-28618	resting-state	_	
164-269	28619-28629	functional	_	
164-270	28630-28642	connectivity	_	
164-271	28643-28647	data	_	
164-272	28648-28654	Impact	_	
164-273	28655-28657	of	_	
164-274	28658-28668	in-scanner	_	
164-275	28669-28673	head	_	
164-276	28674-28680	motion	_	
164-277	28681-28683	on	_	
164-278	28684-28692	multiple	_	
164-279	28693-28701	measures	_	
164-280	28702-28704	of	_	
164-281	28705-28715	functional	_	
164-282	28716-28728	connectivity	_	
164-283	28728-28729	:	_	
164-284	28730-28739	relevance	_	
164-285	28740-28743	for	_	
164-286	28744-28751	studies	_	
164-287	28752-28754	of	_	
164-288	28755-28771	neurodevelopment	_	
164-289	28772-28774	in	_	
164-290	28775-28780	youth	_	
164-291	28781-28785	AFNI	_	
164-292	28785-28786	:	_	
164-293	28787-28795	Software	_	
164-294	28796-28799	for	_	
164-295	28800-28808	analysis	_	
164-296	28809-28812	and	_	
164-297	28813-28826	visualization	_	
164-298	28827-28829	of	_	
164-299	28830-28840	functional	_	
164-300	28841-28849	magnetic	_	
164-301	28850-28859	resonance	_	
164-302	28860-28871	neuroimages	_	
164-303	28872-28874	An	_	
164-304	28875-28885	integrated	_	
164-305	28886-28894	software	_	
164-306	28895-28900	suite	_	
164-307	28901-28904	for	_	
164-308	28905-28918	surface-based	_	
164-309	28919-28927	analyses	_	
164-310	28928-28930	of	_	
164-311	28931-28939	cerebral	_	
164-312	28940-28946	cortex	_	
164-313	28947-28958	Dimensional	_	
164-314	28959-28969	depression	_	
164-315	28970-28978	severity	_	
164-316	28979-28981	in	_	
164-317	28982-28987	women	_	
164-318	28988-28992	with	_	
164-319	28993-28998	major	_	
164-320	28999-29009	depression	_	
164-321	29010-29013	and	_	
164-322	29014-29028	post-traumatic	_	
164-323	29029-29035	stress	_	
164-324	29036-29044	disorder	_	
164-325	29045-29055	correlates	_	
164-326	29056-29060	with	_	
164-327	29061-29077	fronto-amygdalar	_	
164-328	29078-29094	hypoconnectivity	_	
164-329	29095-29110	Connectome-wide	_	
164-330	29111-29118	network	_	
164-331	29119-29127	analysis	_	
164-332	29128-29130	of	_	
164-333	29131-29136	youth	_	
164-334	29137-29141	with	_	
164-335	29142-29160	Psychosis-Spectrum	_	
164-336	29161-29169	symptoms	_	
164-337	29170-29180	Generation	_	
164-338	29181-29184	and	_	
164-339	29185-29195	evaluation	_	
164-340	29196-29198	of	_	
164-341	29199-29200	a	_	
164-342	29201-29209	cortical	_	
164-343	29210-29214	area	_	
164-344	29215-29227	parcellation	_	
164-345	29228-29232	from	_	
164-346	29233-29246	resting-state	_	
164-347	29247-29259	correlations	_	
164-348	29260-29269	Emergence	_	
164-349	29270-29272	of	_	
164-350	29273-29279	system	_	
164-351	29280-29285	roles	_	
164-352	29286-29288	in	_	
164-353	29289-29298	normative	_	
164-354	29299-29315	neurodevelopment	_	
164-355	29316-29324	Elevated	_	
164-356	29325-29333	striatal	_	
164-357	29334-29337	and	_	
164-358	29338-29347	decreased	_	
164-359	29348-29360	dorsolateral	_	
164-360	29361-29371	prefrontal	_	
164-361	29372-29380	cortical	_	
164-362	29381-29389	activity	_	
164-363	29390-29392	in	_	
164-364	29393-29401	response	_	
164-365	29402-29404	to	_	
164-366	29405-29414	emotional	_	
164-367	29415-29422	stimuli	_	
164-368	29423-29425	in	_	
164-369	29426-29434	euthymic	_	
164-370	29435-29442	bipolar	_	
164-371	29443-29451	disorder	_	
164-372	29451-29452	:	_	
164-373	29453-29455	no	_	
164-374	29456-29468	associations	_	
164-375	29469-29473	with	_	
164-376	29474-29486	psychotropic	_	
164-377	29487-29497	medication	_	
164-378	29498-29502	load	_	
164-379	29503-29515	Default-mode	_	
164-380	29516-29519	and	_	
164-381	29520-29533	task-positive	_	
164-382	29534-29541	network	_	
164-383	29542-29550	activity	_	
164-384	29551-29553	in	_	
164-385	29554-29559	major	_	
164-386	29560-29570	depressive	_	
164-387	29571-29579	disorder	_	
164-388	29579-29580	:	_	
164-389	29581-29593	Implications	_	
164-390	29594-29597	for	_	
164-391	29598-29606	adaptive	_	
164-392	29607-29610	and	_	
164-393	29611-29622	maladaptive	_	
164-394	29623-29633	rumination	_	
164-395	29634-29642	Aberrant	_	
164-396	29643-29650	default	_	
164-397	29651-29655	mode	_	
164-398	29656-29666	functional	_	
164-399	29667-29679	connectivity	_	
164-400	29680-29682	in	_	
164-401	29683-29688	early	_	
164-402	29689-29694	onset	_	
164-403	29695-29708	schizophrenia	_	
164-404	29709-29728	Functional-Anatomic	_	
164-405	29729-29742	fractionation	_	
164-406	29743-29745	of	_	
164-407	29746-29749	the	_	
164-408	29750-29755	brain	_	
164-409	29755-29756		_	
164-410	29756-29757	s	_	
164-411	29758-29765	default	_	
164-412	29766-29773	network	_	
164-413	29774-29779	Links	_	
164-414	29780-29785	among	_	
164-415	29786-29799	resting-state	_	
164-416	29800-29812	default-mode	_	
164-417	29813-29820	network	_	
164-418	29820-29821	,	_	
164-419	29822-29830	salience	_	
164-420	29831-29838	network	_	
164-421	29838-29839	,	_	
164-422	29840-29843	and	_	
164-423	29844-29858	symptomatology	_	
164-424	29859-29861	in	_	
164-425	29862-29875	schizophrenia	_	
164-426	29876-29883	Frontal	_	
164-427	29884-29890	cortex	_	
164-428	29891-29894	and	_	
164-429	29895-29908	reward-guided	_	
164-430	29909-29917	learning	_	
164-431	29918-29921	and	_	
164-432	29922-29937	decision-making	_	
164-433	29938-29948	Motivation	_	
164-434	29949-29952	and	_	
164-435	29953-29962	cognitive	_	
164-436	29963-29970	control	_	
164-437	29970-29971	:	_	
164-438	29972-29976	from	_	
164-439	29977-29985	behavior	_	
164-440	29986-29988	to	_	
164-441	29989-29995	neural	_	
164-442	29996-30005	mechanism	_	
164-443	30006-30015	Assessing	_	
164-444	30016-30025	anhedonia	_	
164-445	30026-30028	in	_	
164-446	30029-30039	depression	_	
164-447	30039-30040	:	_	
164-448	30041-30051	Potentials	_	
164-449	30052-30055	and	_	
164-450	30056-30064	pitfalls	_	
164-451	30065-30066	A	_	
164-452	30067-30078	genetically	_	
164-453	30079-30088	modulated	_	
164-454	30088-30089	,	_	
164-455	30090-30099	intrinsic	_	
164-456	30100-30109	cingulate	_	
164-457	30110-30117	circuit	_	
164-458	30118-30126	supports	_	
164-459	30127-30132	human	_	
164-460	30133-30141	nicotine	_	
164-461	30142-30151	addiction	_	
164-462	30152-30158	Reward	_	
164-463	30159-30169	processing	_	
164-464	30170-30181	dysfunction	_	
164-465	30182-30184	in	_	
164-466	30185-30190	major	_	
164-467	30191-30201	depression	_	
164-468	30201-30202	,	_	
164-469	30203-30210	bipolar	_	
164-470	30211-30219	disorder	_	
164-471	30220-30223	and	_	
164-472	30224-30237	schizophrenia	_	
164-473	30238-30253	Connectome-wide	_	
164-474	30254-30262	analysis	_	
164-475	30263-30268	using	_	
164-476	30269-30281	multivariate	_	
164-477	30282-30296	distance-based	_	
164-478	30297-30303	matrix	_	
164-479	30304-30314	regression	_	
164-480	30315-30316	(	_	
164-481	30316-30320	MDMR	_	
164-482	30320-30321	)	_	
164-483	30321-30322	.	_	

#Text=Template-space functional time series were resampled at 4mm3 for computational feasibility.
165-1	30323-30337	Template-space	_	
165-2	30338-30348	functional	_	
165-3	30349-30353	time	_	
165-4	30354-30360	series	_	
165-5	30361-30365	were	_	
165-6	30366-30375	resampled	_	
165-7	30376-30378	at	_	
165-8	30379-30383	4mm3	_	
165-9	30384-30387	for	_	
165-10	30388-30401	computational	_	
165-11	30402-30413	feasibility	_	
165-12	30413-30414	.	_	

#Text=For each gray matter voxel a connectivity map was created for each subject, which were compared in a pairwise manner to create a distance matrix.
166-1	30415-30418	For	_	
166-2	30419-30423	each	_	
166-3	30424-30428	gray	_	
166-4	30429-30435	matter	_	
166-5	30436-30441	voxel	_	
166-6	30442-30443	a	_	
166-7	30444-30456	connectivity	_	
166-8	30457-30460	map	_	
166-9	30461-30464	was	_	
166-10	30465-30472	created	_	
166-11	30473-30476	for	_	
166-12	30477-30481	each	_	
166-13	30482-30489	subject	_	
166-14	30489-30490	,	_	
166-15	30491-30496	which	_	
166-16	30497-30501	were	_	
166-17	30502-30510	compared	_	
166-18	30511-30513	in	_	
166-19	30514-30515	a	_	
166-20	30516-30524	pairwise	_	
166-21	30525-30531	manner	_	
166-22	30532-30534	to	_	
166-23	30535-30541	create	_	
166-24	30542-30543	a	_	
166-25	30544-30552	distance	_	
166-26	30553-30559	matrix	_	
166-27	30559-30560	.	_	

#Text=MDMR used these distance matrices to evaluate the complex multivariate pattern of connectivity in association with reward responsivity (BAS Reward) across subjects while controlling for clinical group, age, sex and in-scanner motion.
167-1	30561-30565	MDMR	_	
167-2	30566-30570	used	_	
167-3	30571-30576	these	_	
167-4	30577-30585	distance	_	
167-5	30586-30594	matrices	_	
167-6	30595-30597	to	_	
167-7	30598-30606	evaluate	_	
167-8	30607-30610	the	_	
167-9	30611-30618	complex	_	
167-10	30619-30631	multivariate	_	
167-11	30632-30639	pattern	_	
167-12	30640-30642	of	_	
167-13	30643-30655	connectivity	_	
167-14	30656-30658	in	_	
167-15	30659-30670	association	_	
167-16	30671-30675	with	_	
167-17	30676-30682	reward	_	
167-18	30683-30695	responsivity	_	
167-19	30696-30697	(	_	
167-20	30697-30700	BAS	_	
167-21	30701-30707	Reward	_	
167-22	30707-30708	)	_	
167-23	30709-30715	across	_	
167-24	30716-30724	subjects	_	
167-25	30725-30730	while	_	
167-26	30731-30742	controlling	_	
167-27	30743-30746	for	_	
167-28	30747-30755	clinical	_	
167-29	30756-30761	group	_	
167-30	30761-30762	,	_	
167-31	30763-30766	age	_	
167-32	30766-30767	,	_	
167-33	30768-30771	sex	_	
167-34	30772-30775	and	_	
167-35	30776-30786	in-scanner	_	
167-36	30787-30793	motion	_	
167-37	30793-30794	.	_	

#Text=This yielded a pseudo-F statistic and a corresponding P value through permutation testing.
168-1	30795-30799	This	_	
168-2	30800-30807	yielded	_	
168-3	30808-30809	a	_	
168-4	30810-30818	pseudo-F	_	
168-5	30819-30828	statistic	_	
168-6	30829-30832	and	_	
168-7	30833-30834	a	_	
168-8	30835-30848	corresponding	_	
168-9	30849-30850	P	_	
168-10	30851-30856	value	_	
168-11	30857-30864	through	_	
168-12	30865-30876	permutation	_	
168-13	30877-30884	testing	_	
168-14	30884-30885	.	_	

#Text=This procedure was repeated for each gray matter voxel, yielding a voxel-wise significance map.
169-1	30886-30890	This	_	
169-2	30891-30900	procedure	_	
169-3	30901-30904	was	_	
169-4	30905-30913	repeated	_	
169-5	30914-30917	for	_	
169-6	30918-30922	each	_	
169-7	30923-30927	gray	_	
169-8	30928-30934	matter	_	
169-9	30935-30940	voxel	_	
169-10	30940-30941	,	_	
169-11	30942-30950	yielding	_	
169-12	30951-30952	a	_	
169-13	30953-30963	voxel-wise	_	
169-14	30964-30976	significance	_	
169-15	30977-30980	map	_	
169-16	30980-30981	.	_	

#Text=Modified with permission from Shehzad et al..
170-1	30982-30990	Modified	_	
170-2	30991-30995	with	_	
170-3	30996-31006	permission	_	
170-4	31007-31011	from	_	
170-5	31012-31019	Shehzad	_	
170-6	31020-31022	et	_	
170-7	31023-31025	al	_	
170-8	31025-31026	.	_	
170-9	31026-31027	.	_	

#Text=MDMR identified multiple foci of connectivity related to reward responsivity.
171-1	31028-31032	MDMR	_	
171-2	31033-31043	identified	_	
171-3	31044-31052	multiple	_	
171-4	31053-31057	foci	_	
171-5	31058-31060	of	_	
171-6	31061-31073	connectivity	_	
171-7	31074-31081	related	_	
171-8	31082-31084	to	_	
171-9	31085-31091	reward	_	
171-10	31092-31104	responsivity	_	
171-11	31104-31105	.	_	

#Text=Cortical projection displaying clusters identified by multivariate distance-based matrix regression (MDMR) where BAS Reward affected the overall multivariate pattern of functional connectivity.
172-1	31106-31114	Cortical	_	
172-2	31115-31125	projection	_	
172-3	31126-31136	displaying	_	
172-4	31137-31145	clusters	_	
172-5	31146-31156	identified	_	
172-6	31157-31159	by	_	
172-7	31160-31172	multivariate	_	
172-8	31173-31187	distance-based	_	
172-9	31188-31194	matrix	_	
172-10	31195-31205	regression	_	
172-11	31206-31207	(	_	
172-12	31207-31211	MDMR	_	
172-13	31211-31212	)	_	
172-14	31213-31218	where	_	
172-15	31219-31222	BAS	_	
172-16	31223-31229	Reward	_	
172-17	31230-31238	affected	_	
172-18	31239-31242	the	_	
172-19	31243-31250	overall	_	
172-20	31251-31263	multivariate	_	
172-21	31264-31271	pattern	_	
172-22	31272-31274	of	_	
172-23	31275-31285	functional	_	
172-24	31286-31298	connectivity	_	
172-25	31298-31299	.	_	

#Text=All clusters corrected for multiple comparisons at z>1.64, P<0.01.
173-1	31300-31303	All	_	
173-2	31304-31312	clusters	_	
173-3	31313-31322	corrected	_	
173-4	31323-31326	for	_	
173-5	31327-31335	multiple	_	
173-6	31336-31347	comparisons	_	
173-7	31348-31350	at	_	
173-8	31351-31352	z	_	
173-9	31352-31353	>	_	
173-10	31353-31357	1.64	_	
173-11	31357-31358	,	_	
173-12	31359-31360	P	_	
173-13	31360-31361	<	_	
173-14	31361-31365	0.01	_	
173-15	31365-31366	.	_	

#Text=Follow-up seed-based connectivity analyses explain patterns of connectivity that drive MDMR results.
174-1	31367-31376	Follow-up	_	
174-2	31377-31387	seed-based	_	
174-3	31388-31400	connectivity	_	
174-4	31401-31409	analyses	_	
174-5	31410-31417	explain	_	
174-6	31418-31426	patterns	_	
174-7	31427-31429	of	_	
174-8	31430-31442	connectivity	_	
174-9	31443-31447	that	_	
174-10	31448-31453	drive	_	
174-11	31454-31458	MDMR	_	
174-12	31459-31466	results	_	
174-13	31466-31467	.	_	

#Text=The multivariate results of the connectome-wide association study (CWAS) identified the nucleus accumbens (A), default mode regions (B) and cingulo-opercular regions (C) where the overall pattern of connectivity is related to reward responsivity, but did not delineate the nature of those patterns.
175-1	31468-31471	The	_	
175-2	31472-31484	multivariate	_	
175-3	31485-31492	results	_	
175-4	31493-31495	of	_	
175-5	31496-31499	the	_	
175-6	31500-31515	connectome-wide	_	
175-7	31516-31527	association	_	
175-8	31528-31533	study	_	
175-9	31534-31535	(	_	
175-10	31535-31539	CWAS	_	
175-11	31539-31540	)	_	
175-12	31541-31551	identified	_	
175-13	31552-31555	the	_	
175-14	31556-31563	nucleus	_	
175-15	31564-31573	accumbens	_	
175-16	31574-31575	(	_	
175-17	31575-31576	A	_	
175-18	31576-31577	)	_	
175-19	31577-31578	,	_	
175-20	31579-31586	default	_	
175-21	31587-31591	mode	_	
175-22	31592-31599	regions	_	
175-23	31600-31601	(	_	
175-24	31601-31602	B	_	
175-25	31602-31603	)	_	
175-26	31604-31607	and	_	
175-27	31608-31625	cingulo-opercular	_	
175-28	31626-31633	regions	_	
175-29	31634-31635	(	_	
175-30	31635-31636	C	_	
175-31	31636-31637	)	_	
175-32	31638-31643	where	_	
175-33	31644-31647	the	_	
175-34	31648-31655	overall	_	
175-35	31656-31663	pattern	_	
175-36	31664-31666	of	_	
175-37	31667-31679	connectivity	_	
175-38	31680-31682	is	_	
175-39	31683-31690	related	_	
175-40	31691-31693	to	_	
175-41	31694-31700	reward	_	
175-42	31701-31713	responsivity	_	
175-43	31713-31714	,	_	
175-44	31715-31718	but	_	
175-45	31719-31722	did	_	
175-46	31723-31726	not	_	
175-47	31727-31736	delineate	_	
175-48	31737-31740	the	_	
175-49	31741-31747	nature	_	
175-50	31748-31750	of	_	
175-51	31751-31756	those	_	
175-52	31757-31765	patterns	_	
175-53	31765-31766	.	_	

#Text=Accordingly, each cluster identified by CWAS (left column) was used as a seed to identify what changes in connectivity led to the significant finding.
176-1	31767-31778	Accordingly	_	
176-2	31778-31779	,	_	
176-3	31780-31784	each	_	
176-4	31785-31792	cluster	_	
176-5	31793-31803	identified	_	
176-6	31804-31806	by	_	
176-7	31807-31811	CWAS	_	
176-8	31812-31813	(	_	
176-9	31813-31817	left	_	
176-10	31818-31824	column	_	
176-11	31824-31825	)	_	
176-12	31826-31829	was	_	
176-13	31830-31834	used	_	
176-14	31835-31837	as	_	
176-15	31838-31839	a	_	
176-16	31840-31844	seed	_	
176-17	31845-31847	to	_	
176-18	31848-31856	identify	_	
176-19	31857-31861	what	_	
176-20	31862-31869	changes	_	
176-21	31870-31872	in	_	
176-22	31873-31885	connectivity	_	
176-23	31886-31889	led	_	
176-24	31890-31892	to	_	
176-25	31893-31896	the	_	
176-26	31897-31908	significant	_	
176-27	31909-31916	finding	_	
176-28	31916-31917	.	_	

#Text=The middle column displays the mean connectivity across all subjects from each seed.
177-1	31918-31921	The	_	
177-2	31922-31928	middle	_	
177-3	31929-31935	column	_	
177-4	31936-31944	displays	_	
177-5	31945-31948	the	_	
177-6	31949-31953	mean	_	
177-7	31954-31966	connectivity	_	
177-8	31967-31973	across	_	
177-9	31974-31977	all	_	
177-10	31978-31986	subjects	_	
177-11	31987-31991	from	_	
177-12	31992-31996	each	_	
177-13	31997-32001	seed	_	
177-14	32001-32002	.	_	

#Text=The right column displays the association with BAS Reward for each seed.
178-1	32003-32006	The	_	
178-2	32007-32012	right	_	
178-3	32013-32019	column	_	
178-4	32020-32028	displays	_	
178-5	32029-32032	the	_	
178-6	32033-32044	association	_	
178-7	32045-32049	with	_	
178-8	32050-32053	BAS	_	
178-9	32054-32060	Reward	_	
178-10	32061-32064	for	_	
178-11	32065-32069	each	_	
178-12	32070-32074	seed	_	
178-13	32074-32075	.	_	

#Text=Dissociable patterns of within and between-network connectivity dimensionally relate to reward deficits across psychiatric disorders.
179-1	32076-32087	Dissociable	_	
179-2	32088-32096	patterns	_	
179-3	32097-32099	of	_	
179-4	32100-32106	within	_	
179-5	32107-32110	and	_	
179-6	32111-32126	between-network	_	
179-7	32127-32139	connectivity	_	
179-8	32140-32153	dimensionally	_	
179-9	32154-32160	relate	_	
179-10	32161-32163	to	_	
179-11	32164-32170	reward	_	
179-12	32171-32179	deficits	_	
179-13	32180-32186	across	_	
179-14	32187-32198	psychiatric	_	
179-15	32199-32208	disorders	_	
179-16	32208-32209	.	_	

#Text=Layout of mean connectivity within a network of nodes defined by multivariate distance-based matrix regression (MDMR) (Panel A).
180-1	32210-32216	Layout	_	
180-2	32217-32219	of	_	
180-3	32220-32224	mean	_	
180-4	32225-32237	connectivity	_	
180-5	32238-32244	within	_	
180-6	32245-32246	a	_	
180-7	32247-32254	network	_	
180-8	32255-32257	of	_	
180-9	32258-32263	nodes	_	
180-10	32264-32271	defined	_	
180-11	32272-32274	by	_	
180-12	32275-32287	multivariate	_	
180-13	32288-32302	distance-based	_	
180-14	32303-32309	matrix	_	
180-15	32310-32320	regression	_	
180-16	32321-32322	(	_	
180-17	32322-32326	MDMR	_	
180-18	32326-32327	)	_	
180-19	32328-32329	(	_	
180-20	32329-32334	Panel	_	
180-21	32335-32336	A	_	
180-22	32336-32337	)	_	
180-23	32337-32338	.	_	

#Text=DMN hyperconnectivity and decreased connectivity between DMN and CON regions scales with reward deficits (Panel B).
181-1	32339-32342	DMN	_	
181-2	32343-32360	hyperconnectivity	_	
181-3	32361-32364	and	_	
181-4	32365-32374	decreased	_	
181-5	32375-32387	connectivity	_	
181-6	32388-32395	between	_	
181-7	32396-32399	DMN	_	
181-8	32400-32403	and	_	
181-9	32404-32407	CON	_	
181-10	32408-32415	regions	_	
181-11	32416-32422	scales	_	
181-12	32423-32427	with	_	
181-13	32428-32434	reward	_	
181-14	32435-32443	deficits	_	
181-15	32444-32445	(	_	
181-16	32445-32450	Panel	_	
181-17	32451-32452	B	_	
181-18	32452-32453	)	_	
181-19	32453-32454	.	_	

#Text=Cortical projection displaying the NAc (green) along with DMN (blue) and CON regions (red) (Panel C).
182-1	32455-32463	Cortical	_	
182-2	32464-32474	projection	_	
182-3	32475-32485	displaying	_	
182-4	32486-32489	the	_	
182-5	32490-32493	NAc	_	
182-6	32494-32495	(	_	
182-7	32495-32500	green	_	
182-8	32500-32501	)	_	
182-9	32502-32507	along	_	
182-10	32508-32512	with	_	
182-11	32513-32516	DMN	_	
182-12	32517-32518	(	_	
182-13	32518-32522	blue	_	
182-14	32522-32523	)	_	
182-15	32524-32527	and	_	
182-16	32528-32531	CON	_	
182-17	32532-32539	regions	_	
182-18	32540-32541	(	_	
182-19	32541-32544	red	_	
182-20	32544-32545	)	_	
182-21	32546-32547	(	_	
182-22	32547-32552	Panel	_	
182-23	32553-32554	C	_	
182-24	32554-32555	)	_	
182-25	32555-32556	.	_	

#Text=Reward deficits are related to dissociable patterns of NAc dysconnectivity, including diminished connectivity with the DMN and increased connectivity with the CON (Panel D).
183-1	32557-32563	Reward	_	
183-2	32564-32572	deficits	_	
183-3	32573-32576	are	_	
183-4	32577-32584	related	_	
183-5	32585-32587	to	_	
183-6	32588-32599	dissociable	_	
183-7	32600-32608	patterns	_	
183-8	32609-32611	of	_	
183-9	32612-32615	NAc	_	
183-10	32616-32631	dysconnectivity	_	
183-11	32631-32632	,	_	
183-12	32633-32642	including	_	
183-13	32643-32653	diminished	_	
183-14	32654-32666	connectivity	_	
183-15	32667-32671	with	_	
183-16	32672-32675	the	_	
183-17	32676-32679	DMN	_	
183-18	32680-32683	and	_	
183-19	32684-32693	increased	_	
183-20	32694-32706	connectivity	_	
183-21	32707-32711	with	_	
183-22	32712-32715	the	_	
183-23	32716-32719	CON	_	
183-24	32720-32721	(	_	
183-25	32721-32726	Panel	_	
183-26	32727-32728	D	_	
183-27	32728-32729	)	_	
183-28	32729-32730	.	_	

#Text=DMN=default mode network; CON=cingulo-opercular network; NAc= nucleus accumbens.
184-1	32731-32734	DMN	_	
184-2	32734-32735	=	_	
184-3	32735-32742	default	_	
184-4	32743-32747	mode	_	
184-5	32748-32755	network	_	
184-6	32755-32756	;	_	
184-7	32757-32760	CON	_	
184-8	32760-32761	=	_	
184-9	32761-32778	cingulo-opercular	_	
184-10	32779-32786	network	_	
184-11	32786-32787	;	_	
184-12	32788-32791	NAc	_	
184-13	32791-32792	=	_	
184-14	32793-32800	nucleus	_	
184-15	32801-32810	accumbens	_	
184-16	32810-32811	.	_	

#Text=Demographics of the study participants
#Text=\tNC\tBPD\tMDD\tSCZ\tPR\tP value\t \tn\t53\t50\t32\t51\t39\tNA\t \tGender (% Female)\t53%\t62%\t50%\t47%\t41%\t0.36\t \tAge (mean, sd in years)\t32.52 (13.0)\t30.58 (10.6)\t40.13 (13.0)\t37.54 (12.0)\t32.84 (16.2)\t< 0.01\t \tEducation (mean, sd in years)\t14.86 (2.3)\t14.47 (2.2)\t14.10 (2.8)\t13.65 (2.2)\t14.34 (2.4)\t0.12\t \tBAS Reward (mean, sd)\t17.72 (1.8)\t17.06 (2.5)\t16.09 (2.8)\t16.74 (2.6)\t17.44 (1.9)\t< 0.05\t \t% taking psychotropic medication\t0%\t92%\t66%\t96%\t15%\t< 0.001\t \tIn-scanner motion (mean, sd in mm)\t0.08 (0.03)\t0.07 (0.04)\t0.09 (0.05)\t0.09 (0.06)\t0.09 (0.06)\t0.18\t \t
#Text=Abbreviations: BAS reward; Behavioral Activation Scale, reward sensitivity subscale; NA, not applicable; NC, normal controls; BPD, bipolar disorder; MDD, major depressive disorder; SCZ, schizophrenia; PR, psychosis risk
185-1	32812-32824	Demographics	_	
185-2	32825-32827	of	_	
185-3	32828-32831	the	_	
185-4	32832-32837	study	_	
185-5	32838-32850	participants	_	
185-6	32852-32854	NC	_	
185-7	32855-32858	BPD	_	
185-8	32859-32862	MDD	_	
185-9	32863-32866	SCZ	_	
185-10	32867-32869	PR	_	
185-11	32870-32871	P	_	
185-12	32872-32877	value	_	
185-13	32880-32881	n	_	
185-14	32882-32884	53	_	
185-15	32885-32887	50	_	
185-16	32888-32890	32	_	
185-17	32891-32893	51	_	
185-18	32894-32896	39	_	
185-19	32897-32899	NA	_	
185-20	32902-32908	Gender	_	
185-21	32909-32910	(	_	
185-22	32910-32911	%	_	
185-23	32912-32918	Female	_	
185-24	32918-32919	)	_	
185-25	32920-32923	53%	_	
185-26	32924-32927	62%	_	
185-27	32928-32931	50%	_	
185-28	32932-32935	47%	_	
185-29	32936-32939	41%	_	
185-30	32940-32944	0.36	_	
185-31	32947-32950	Age	_	
185-32	32951-32952	(	_	
185-33	32952-32956	mean	_	
185-34	32956-32957	,	_	
185-35	32958-32960	sd	_	
185-36	32961-32963	in	_	
185-37	32964-32969	years	_	
185-38	32969-32970	)	_	
185-39	32971-32976	32.52	_	
185-40	32977-32978	(	_	
185-41	32978-32982	13.0	_	
185-42	32982-32983	)	_	
185-43	32984-32989	30.58	_	
185-44	32990-32991	(	_	
185-45	32991-32995	10.6	_	
185-46	32995-32996	)	_	
185-47	32997-33002	40.13	_	
185-48	33003-33004	(	_	
185-49	33004-33008	13.0	_	
185-50	33008-33009	)	_	
185-51	33010-33015	37.54	_	
185-52	33016-33017	(	_	
185-53	33017-33021	12.0	_	
185-54	33021-33022	)	_	
185-55	33023-33028	32.84	_	
185-56	33029-33030	(	_	
185-57	33030-33034	16.2	_	
185-58	33034-33035	)	_	
185-59	33036-33037	<	_	
185-60	33038-33042	0.01	_	
185-61	33045-33054	Education	_	
185-62	33055-33056	(	_	
185-63	33056-33060	mean	_	
185-64	33060-33061	,	_	
185-65	33062-33064	sd	_	
185-66	33065-33067	in	_	
185-67	33068-33073	years	_	
185-68	33073-33074	)	_	
185-69	33075-33080	14.86	_	
185-70	33081-33082	(	_	
185-71	33082-33085	2.3	_	
185-72	33085-33086	)	_	
185-73	33087-33092	14.47	_	
185-74	33093-33094	(	_	
185-75	33094-33097	2.2	_	
185-76	33097-33098	)	_	
185-77	33099-33104	14.10	_	
185-78	33105-33106	(	_	
185-79	33106-33109	2.8	_	
185-80	33109-33110	)	_	
185-81	33111-33116	13.65	_	
185-82	33117-33118	(	_	
185-83	33118-33121	2.2	_	
185-84	33121-33122	)	_	
185-85	33123-33128	14.34	_	
185-86	33129-33130	(	_	
185-87	33130-33133	2.4	_	
185-88	33133-33134	)	_	
185-89	33135-33139	0.12	_	
185-90	33142-33145	BAS	_	
185-91	33146-33152	Reward	_	
185-92	33153-33154	(	_	
185-93	33154-33158	mean	_	
185-94	33158-33159	,	_	
185-95	33160-33162	sd	_	
185-96	33162-33163	)	_	
185-97	33164-33169	17.72	_	
185-98	33170-33171	(	_	
185-99	33171-33174	1.8	_	
185-100	33174-33175	)	_	
185-101	33176-33181	17.06	_	
185-102	33182-33183	(	_	
185-103	33183-33186	2.5	_	
185-104	33186-33187	)	_	
185-105	33188-33193	16.09	_	
185-106	33194-33195	(	_	
185-107	33195-33198	2.8	_	
185-108	33198-33199	)	_	
185-109	33200-33205	16.74	_	
185-110	33206-33207	(	_	
185-111	33207-33210	2.6	_	
185-112	33210-33211	)	_	
185-113	33212-33217	17.44	_	
185-114	33218-33219	(	_	
185-115	33219-33222	1.9	_	
185-116	33222-33223	)	_	
185-117	33224-33225	<	_	
185-118	33226-33230	0.05	_	
185-119	33233-33234	%	_	
185-120	33235-33241	taking	_	
185-121	33242-33254	psychotropic	_	
185-122	33255-33265	medication	_	
185-123	33266-33268	0%	_	
185-124	33269-33272	92%	_	
185-125	33273-33276	66%	_	
185-126	33277-33280	96%	_	
185-127	33281-33284	15%	_	
185-128	33285-33286	<	_	
185-129	33287-33292	0.001	_	
185-130	33295-33305	In-scanner	_	
185-131	33306-33312	motion	_	
185-132	33313-33314	(	_	
185-133	33314-33318	mean	_	
185-134	33318-33319	,	_	
185-135	33320-33322	sd	_	
185-136	33323-33325	in	_	
185-137	33326-33328	mm	_	
185-138	33328-33329	)	_	
185-139	33330-33334	0.08	_	
185-140	33335-33336	(	_	
185-141	33336-33340	0.03	_	
185-142	33340-33341	)	_	
185-143	33342-33346	0.07	_	
185-144	33347-33348	(	_	
185-145	33348-33352	0.04	_	
185-146	33352-33353	)	_	
185-147	33354-33358	0.09	_	
185-148	33359-33360	(	_	
185-149	33360-33364	0.05	_	
185-150	33364-33365	)	_	
185-151	33366-33370	0.09	_	
185-152	33371-33372	(	_	
185-153	33372-33376	0.06	_	
185-154	33376-33377	)	_	
185-155	33378-33382	0.09	_	
185-156	33383-33384	(	_	
185-157	33384-33388	0.06	_	
185-158	33388-33389	)	_	
185-159	33390-33394	0.18	_	
185-160	33398-33411	Abbreviations	_	
185-161	33411-33412	:	_	
185-162	33413-33416	BAS	_	
185-163	33417-33423	reward	_	
185-164	33423-33424	;	_	
185-165	33425-33435	Behavioral	_	
185-166	33436-33446	Activation	_	
185-167	33447-33452	Scale	_	
185-168	33452-33453	,	_	
185-169	33454-33460	reward	_	
185-170	33461-33472	sensitivity	_	
185-171	33473-33481	subscale	_	
185-172	33481-33482	;	_	
185-173	33483-33485	NA	_	
185-174	33485-33486	,	_	
185-175	33487-33490	not	_	
185-176	33491-33501	applicable	_	
185-177	33501-33502	;	_	
185-178	33503-33505	NC	_	
185-179	33505-33506	,	_	
185-180	33507-33513	normal	_	
185-181	33514-33522	controls	_	
185-182	33522-33523	;	_	
185-183	33524-33527	BPD	_	
185-184	33527-33528	,	_	
185-185	33529-33536	bipolar	_	
185-186	33537-33545	disorder	_	
185-187	33545-33546	;	_	
185-188	33547-33550	MDD	_	
185-189	33550-33551	,	_	
185-190	33552-33557	major	_	
185-191	33558-33568	depressive	_	
185-192	33569-33577	disorder	_	
185-193	33577-33578	;	_	
185-194	33579-33582	SCZ	_	
185-195	33582-33583	,	_	
185-196	33584-33597	schizophrenia	_	
185-197	33597-33598	;	_	
185-198	33599-33601	PR	_	
185-199	33601-33602	,	_	
185-200	33603-33612	psychosis	_	
185-201	33613-33617	risk	_	
